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ABSTRACT
Intracellular pH (pH*) is one of the most important factors which influence 
metabolic processes in cells and affects the sensitivity of tumour cells to drugs. 
Measurement of pH* is important in biochemistry and drug design. The 
potential of acidic and basic trifluoromethylheterocycles to act as pH sensors, 
through change of 19F chemical shift with state of ionisation, has been studied.
Intracellular pH is currently estimated (i) by microelectrodes, (ii) by pH- 
sensitive fluorescent compounds, (Hi) by 31P NMR of endogenous "inorganic" 
phosphate. The 19F nucleus has many NMR properties which are particularly 
suitable for biological NMR studies. It has nuclear spin /  = V2 and high 
sensitivity (0.833 x *H; 12.6 x 31P). Fluorine chemical shifts are very sensitive 
to changes in its environment and it has a wide chemical shift range (0-960 
ppm), allowing fluorinated compounds to be clearly recognised in spite of the 
line-broadening which is associated with biological studies.
Several series of trifluoromethylheterocycles have been synthesised, including
3.5-bis(trifluoromethyl)pyrazoles, co-(trifluoromethylpyrazolyl)- and co-(tri- 
fluoromethyl-l,2,4-triazolyl)-alkanols, 2-(trifluoromethyl)benzimidazoles, 2- 
(trifluoromethyl)imidazopyridines and a 5-(trifluoromethyl)oxazole. Several 
synthetic routes towards 4-substituted 3,5-bis(trifluoromethyl)pyrazoles were 
investigated but none were successful. Studies of the condensation reactions of
1.1.1.5.5.5-hexafluoropentane-2,4-dione with aryl- and acylhydrazines have 
lead to revision of published structures of the products.
Measurements of 19F chemical shift against pH in aqueous solution have been 
made to establish the pKa values of the acid-base equilibria for the above 
compounds and other trifluoromethylheterocycles. Two pyrazoles and two 
imidazopyridines have pKa close to physiological pH; ionisation causes a 
change in 19F chemical shift of up to 2.0 ppm.
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Almost exactly 110 years ago T. H. Huxley, in his anniversary address as 
President of the Royal Society, said "What an enormous revolution would be 
made in biology, if physics or chemistry could supply the physiologist with a 
means of making out the molecular structure of living tissues comparable to 
that which the spectroscope affords to the inquirer into the nature of the 
heavenly bodies1". By the discovery of nuclear magnetic resonance (NMR), 
physics has provided the basic method and chemistry has provided the 
extensive background for exploration in biological systems.
The opening chapter of this report describes research areas where the 
measurement of intracellular pH (pH*) has become important. Chapter Two is 
concerned with the mechanisms of pHi regulation thought to be used by a cell. 
Chapter Three discusses the methods currently available for the determination 
of pHj. Chapter Four describes the design requirements of a 19F NMR sensor 
of pHi and discusses the aims of the project. Chapters Five, Six and Seven 
discuss the design and synthesis of some fluorine containing compounds. 
Chapter Eight describes the method of evaluating the potential of the fluorine 
containing heterocycles to act as sensors of pH and reports the results of these 
tests.
1. The Study of Intracellular pH.
In clinical practice today, there is much information about suspected lesions 
available which is gained from imaging methods. However, for differential 
diagnosis it is important to have functional or physiological information. The 
pHj and extracellular pH (pHe) of the tissue are two interesting parameters in 
this regard.
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Myocardial ischaemia commonly arises from a partial restriction of coronary 
blood flow. This results in both a decrease in the supply of oxygen to the 
tissues and a reduction in the removal of metabolites, such as lactic acid. 
Depending on the severity of the restriction of coronary blood flow, the pHi 
has been reported2,3 to drop from the normal value of around 7.24 to values as 
low as 6.0 to 6.2 or even 5.7, while pHe was somewhat higher. Similar 
reductions in pH* have been reported5,6 in cases of cerebral ischaemia.
NMR information about ischaemic tissues regarding the levels of biogenetic 
metabolites shows a decrease in phosphocreatine and nucleoside triphosphate 
and a corresponding increase in inorganic phosphate7. These changes often 
resemble those observed during the untreated growth of experimental tumours. 
Over 60 years ago, studies of glucose consumption in tumour slices incubated 
aerobically showed a high rate of lactic acid production8. Some normal tissues, 
for example exercising muscle, also produce large amounts of lactic acid which 
is rapidly removed. However, in the case of tumours with poorly organised 
vasculature, there is inadequate elimination of protons from the interstitial 
space9,10. This copious production of lactic acid was for many years thought to 
result in a decrease in the pHi11. It has been confirmed12,13,14,15,16 that the pH; 
(pH = 7.2 - 7.7) of several rodent tumours is higher than that of the pHc (pH = 
5.9 - 7.4). This is in contrast to normal tissues in which the pH* (pH = 7.0 - 
7.4) is lower than the pHe (pH = 7.3 - 7.8). That is, the proton gradient is 
reversed and is invariably12 a major difference between tumour and normal 
tissue.
It appears that tumour cells are able to regulate their pH* under the acidic 
conditions encountered interstitially within solid tumours. There are three 
major mechanisms which allow cells to regulate their pHi under acidic 
conditions (these mechanisms are discussed in more detail later): (i) The 
buffering capacity of the cytosolic and organellar contents; (ii) the sodium / 
proton exchanger; (iii) the sodium-dependent chloride ion / bicarbonate
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exchanger. In cells surrounded by an acidic environment in which the 
concentration of bicarbonate is reduced, the role of the sodium / proton 
exchanger may be particularly important in controlling pH*10 Agents that 
inhibit the operation of this exchanger show considerable potential for causing 
pHe-dependent cytotoxicity, selectively killing cells in the acidic regions of 
solid tumours. Rational development of these agents requires greater 
understanding of tumour pH and its regulation.
Tissue oxygenation is also a major factor in the sensitivity of many non- 
surgical treatments of malignancies. Hypoxic cells are relatively resistant to 
radiotherapy and certain types of chemotherapy. In the mechanism of 
radiotherapy, oxygen is thought to play an important role in the production of 
cytotoxic DNA species17. Tissue oxygenation depends principally on the 
oxygen availability and the respiration rate of cells. When the percentage 
oxygen saturation of the blood is plotted against the partial pressure of blood, 
the curve obtained is called the oxygen dissociation curve. Release of oxygen 
into the tissues is mostly dependent on the shape of this curve, which can be 
shifted through changes in pH. Other forms of chemotherapy have been able to 
exploit hypoxia in tumours, for example the bioreductively activated 2- 
nitroimidazole drugs18’19. There can, therefore, be an advantage in selectively 
increasing the level of hypoxia in tumours20. There are various measures which 
can be taken to increase the level of hypoxia in tumours. These include the 
administration of a vasodilator such as hydralazine, a drug which binds to 
oxyhaemoglobin and shifts the dissociation curve to the left.
Data on parameters such as pH in tumours have mostly been derived from 
rodent tumours. This may not adequately represent the multitude of neoplastic 
tumours encountered in humans13. Also the data available on human tumours 
are sparse and often contain significant errors associated with the techniques 
currently used for measurement13.
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In many NMR studies on small rodents, a factor affecting experimental results 
is stress. It has been demonstrated quantitatively21 that the stress of alignment 
of the rodent within a vertical magnet is superimposed on the stress of hypoxia. 
This parameter was rarely addressed in early studies and one should, therefore, 
be cautious about interpretations of NMR data obtained from such experiments 
because of potential complications.
Problems encounted in the literature are often a consequence of the difficulties 
in the accurate measurement of pH. It is possible that tumour pH may be a 
characteristic property of tumour lines rather than individual lesions. Larger 
tumours may achieve more acid pH values than smaller, better vasculated 
tumours. Some may maintain a higher glycolytic rate than others under hypoxic 
conditions, thus leading to the production of more lactic acid17,22.
Spontaneous cell death has been observed within regions of solid tumours23. 
The deficiency of nutrients and acidic conditions maiy contribute to this cell 
death and necrosis24. However, as already discussed, many cells are known to 
survive these conditions and are an important cause for the failure of 
conventional therapies. Acidity may be a factor that could be exploited 
therapeutically to destroy such cells.
It is now an established fact that an acidic environment greatly increases the 
thermosensitivity of tissue, inhibits the recovery of tissue from thermal damage 
and perhaps inhibits the development of thermotoleraJice24,25,26,27. Response to 
hyperthermia appears to be a function of pHj rather than pH*28. Thus an 
increase in the thermosensitivity of tumour cells may be achieved by lowering 
pHi. The inhibition of the sodium / proton antiporter has already been 
mentioned briefly and hyperthermia represents a further exploitation.
Potent and specific inhibitors of sodium / proton exchange have been 
developed28. Using such compounds, it has been demonstrated that blocking
extrusion of protons from cells produces a lowering of the pH* and an increase 
in thermosensitisation28. Importantly, this increase in thermosensitisation was 
found to be greater in an acidic environment than in a neutral environment. 
This suggests that the acidic pHe of tumours may be exploited to increase 
preferentially the thermal damage in tumours relative to normal tissue.
The use of agents which cause acute acidification of cells in the presence of a 
low pHe reduces the development of thermotolerance. Without these agents, 
heat treatment would be expected to be selectively toxic only to cells which 
have become acutely acidic within solid tumours. The mechanisms by which 
heat treatment kills cells is not fully understood, although increased fluidity in 
cell membranes and protein denaturation are believed to play a primary role24. 
Further, heat treatment leads to rapid fall in pH* in many solid tumours. This 
effect appears to be the due to vasoconstriction and coagulation necrosis which 
results in a marked decrease in blood flow and thus further reduces the 
accumulation of metabolites.
Any improvements to be made on the selectivity of anti-cancer drugs must be 
based on differences distinguishing tumours cells from normal tissue. Many of 
these differences can be detected by the studying the interaction of a drug with 
its active site. Measurements of the pHi of tumours have allowed greater 
understanding of the activity or lack of activity of many drugs. For example, 
the mechanism underlying the cytotoxicity of 5-fluorouracil is 
controversial29,30. 5-Fluorouracil and its derivatives are known to be 
incorporated into DNA. However their adopted geometry when bound to 
guanine is pH-dependent and is the basis of much of this controversy. 
Determination of the physiological pH was vital for the binding studies which 
highlighted a discrepancy in results29,30.
Anti-cancer drugs must be transported into the cells either by active transport 
or by passive diffusion and frequently undergo intracellular metabolism. Since
5
all these processes are dependent on the pHi, the cytotoxicity of the drugs will 
also be dependent on the pH; and pHe. If a drug contains either acidic or basic 
functionalities and its uptake mechanism is passive difliision, then transport will 
be enhanced by values of pHe that favour the non-ionised form of that 
compound.
During chemotherapy, tumour cells often lose their sensitivity to drugs. This is 
often due to an acquired multidrug resistance (MDR) and can occur over a 
broad range of drug classes and targets. MDR is often, but not always, 
associated with increased expression of the MDR protein or P- 
glycoprotein31,32,33. The most widely accepted hypothesis for the mode of 
action of MDR suggests that the protein actively expels drugs out of the cell. 
Also supported33 is the idea that the MDR protein can change the pHi, thus 
altering the transmembrane partitioning or intracellular sequestration of drugs. 
Further studies to address this hypothesis will be helped by the accurate 
determination of the pHi of cells experiencing MDR relative to both non-MDR 
tumour cells and normal cells.
The measurement of pHi may provide valuable information on the metabolic 
state of a tissue and could assist in elucidating the chronology and extent of the 
effects observed following treatment of malignancies34. The absolute 
determination of pH* may be a significant marker of response to therapy35. 
Furthermore, pHi may give indirect information about the metabolic state of a 
tissue. An alkaline shift in pH* following treatment is coincident with increased 
blood flow and an increased cell proliferation rate36. It is likely that this 
improved blood flow to the tumour results in an increased lactic acid 
clearance17. An alkaline shift in tumour pH could also be the result of a 
decreased lactic acid production, indicating an improved oxygenation of the 
tissue.
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It has also been observed that the pHj is positively correlated with the ratio of 
phosphocreatine to inorganic phosphate. That is, changes in pHi may be 
indicative of changes in metabolism of phosphate. However, in contrast to the 
detection of phosphate metabolites, changes in pHi have been detected at lower 
drug doses36. Using non-invasive methods, it should be possible to monitor 
tumour response to therapy following a low, relatively non-toxic "test-dose" of 
chemotherapy17. This would allow patients to avoid the systemic toxicities 
associated with a full course of therapy and would aid the clinician in selecting 
treatment protocols for the cancer patient37,38. However, it is important to 
consider the possiblity of drug resistance being acquired by the cells.
The intracellular acidosis which has been reported2,3 during ischaemia of the 
heart muscle has already been mentioned. The effect of pH on contractile 
elements is of interest for studies of the other muscles in the human body. 
Measurement of pH* during and following periods of muscle exercise provides 
information about the health of the muscle5,39. Muscle contraction can occur 
under aerobic and / or anaerobic conditions. Even among healthy individuals, 
there will be large variations in the way they respond metabolically to the same 
work. Although there is diversity in normal individuals, there are still criteria 
available by which to identify disease conditions. A decrease in pHi is observed 
during dynamic exercise. This occurrence does not depend on the individual 
muscle or the type of exercise performed. The metabolic switch from aerobic 
to anaerobic energy supply is invariant and can be used to define normal 
response39. Additionally, the rate of recovery from this temporary acidosis 
following exercise provides characteristic indices for healthy muscle. Studies of 
pHi provide biochemical information about known muscle diseases and help to 
elucidate and characterise new diseases. Extensive studies on animals have 
aided this research and have allowed the design of models for human disease39.
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pHj is an important factor in cellular homeostasis. Many cellular processes, 
such as enzyme activity, ion channel conductivities, membrane permeability and 
cell growth and development are sensitive to changes in pHi10,14,40,41.
The activities of a large number of enzymes, including those used in cellular 
metabolism, are pHi-sensitive. A popular example is phosphofiuctokinase, the 
rate-limiting enzyme of glycolysis40,42. It is commonly known that insulin is 
responsible for the stimulation of this enzyme. It does so by interacting with 
the sodium / proton antiporter in the plasma membrane, resulting in a rise in 
pHi which activates the enzyme40. The production of urea by hepatocytes is 
also pHj-dependent, although somewhat less so than the synthesis of glucose. 
Both of these processes are inhibited by intracellular acidification which would 
have important physiological consequences to the body43. It should be noted 
that, although insulin resulted in an increase in pHi under these conditions, this 
response is not general for all cell types. In fact, the observed response to the 
administration of insulin into skeletal muscle was a slight decrease in pHj44.
In addition to the effects of pHi on the permeability of a drug through a cell 
membrane discussed earlier, the conductivities of many ion-channels are also 
pHj-dependent. Interesting examples are the potassium channels in many 
excitable cells. A reduction of pHi in these cells blocks the potassium ion 
conductance and depolarises the membrane producing an action potential. pHi- 
sensitive potassium channels have been found in crayfish slow muscle fibres 
and in the squid giant axon40.
Changes in pHi have been shown to be important in cell growth and 
development10,14,41. Quiescent or dormant cells can be stimulated to reinitiate 
DNA synthesis and cell division by the addition of certain growth 
factors43,46,47,48. The effect of insulin on the sodium / proton antiporter in the 
stimulation of glycolysis in certain cell types has already been discussed. Insulin 
is known to act synergistically with many growth factors. It is not surprising,
g
therefore, to find that the stimulation of cells by growth factors is accompanied 
by a rise in pHi which is blocked by amiloride, an inhibitor of the sodium / 
proton antiporter46.
The suggestion that the activation of the sodium / proton antiporter and the 
resulting elevation of pHi may play a role in the stimulation of cell proliferation 
originated from the pioneering work of Johnson et al.49 on sea urchin eggs. It 
was discovered that fertilisation by sperm causes a rapid increase in the 
concentration of free cytoplasmic Ca2+, followed by a sustained increase in 
pH47. Interestingly, the stimulation of respiration and motility in the sperm of 
the sea urchin also appears to be associated with a rise in pHj50. Conversely, at 
decreased pH*, sperm respiration and motility are inhibited. In fact, intracellular 
alkalisation has been associated with the activation of the cell cycle in a wide 
range of organisms. This spans from the initiation of cell differentiation in slime 
mould51 to the mitogenic-stimulation of mouse quiescent fibroblasts47. There is 
increasing reason to believe that research into the role of pHi in the lower 
organisms may have an important significance to studies of cell proliferation in 
higher animals. A greater understanding of the involvement of the sodium / 
proton antiporter and pHi in the initiation of cell growth and proliferation may 
be important in the study of tumour growth. Human tumour cells lacking the 
sodium / proton antiporter have lost or severely reduced their ability to grow 
tumours10. The importance of these mechanisms in the design of anti-cancer 
agents once again becomes apparent.
Estimations of pHi generally represent the pH of the cytoplasm. Also of 
interest is the estimation of the pH in subcellular compartments, which has 
been shown to be feasible52.This may be carried out using 15N NMR of amino 
acids but experiments with 31P NMR have also identified two intracellular 
components with pHs of 7.1 - 7.3 and >6.0 which probably represent 
cytoplasm and vacuole, respectively. Both of these experiments have provided 
evidence for the intracellular localisation of various amino acids in acidic
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organelles. In addition, the acidity of the vacuole relative to the cytoplasm is 
consistent with its lysosomal nature and the acidic pH optima of many enzymes 
associated with these organelles52.
There have been indications that exposure to sunlight may lead to an 
improvement of acne53. To investigate the possible reasons for the beneficial 
effect of sunlight, photobiological studies have been carried out on the 
bacterium held responsible for this skin disease53. Results indicate that 
exposure to near-uv light causes membrane damage, notably to the proton 
gradient generating system. Further investigations of the possible uv-induced 
effects on pHi would be of interest and are currently in progress53.
Described above, is a brief account of the research areas where pH* has 
become an important consideration. There is clearly a need for an accurate, 
non-invasive technique for the measurement of pH; in biological systems.
CHAPTER TWO
2. The Regulation of Intracellular pH in Cells.
2.1 Buffering of pH.
It was once believed that the pHi of mammalian cells depended only on the pHe 
and the membrane potential54. In this belief, it was assumed that protons, 
hydroxy ions and bicarbonate ions were passively distributed across the cell 
membrane. We now know this to be wrong. In reality, the level of pHi in 
mammalian cells is regulated within a narrow range that is compatible with 
cellular functions.
Normal plasma of the blood has a pH of 7.4 and is maintained under limits 
±0.04-0.05 pH units55. In fact, the concentration of protons is regulated within 
narrower limits than that of any other electrolyte in the blood. The pH is 
regulated by the bicarbonate-carbon dioxide buffer system and is defended by 
the ratio of the dominant acid-base pair in the blood, bicarbonate : carbonic 
acid, as shown in Figure 1.
H+ + HCO" R.CO,
Figure 1. Equilibrium of bicarbonate and carbonic acid in the blood plasma.
Carbonic acid is, in turn, in equilibrium with carbon dioxide, in a process 
catalysed by the enzyme carbonic anhydrase, as shown in Figure 2.
H+ + HC03'  * ■ HJCO, * C02 + H .0
Figure 2. Carbonic anhydrase catalysed equilibrium of carbonic acid with 
carbon dioxide in blood plasma.
This relationship can be summarised by the Henderson equation (Equation 1).
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where, a  = solubility coefficient of C 0 2
K = carbonic acid dissociation costant
Equation 1
More familiar is the negative logarithmic transformation of this equation to the 
Henderson-Hasselbalch equation (Equation 2) with the appropriate numeric 
equivalents of K and a.
In practical terms, the kidneys regulate the concentration of bicarbonate, while 
the lungs sensitively control the carbon dioxide tension (Pco2).
The values of pHi commonly observed fall between the range 7.0-7.4, which is 
higher than would be expected if protons were passively distributed across the 
cell membrane. For a typical membrane potential of -59 mV, pHi should be 6.4. 
This value for pHi is far too low for normal cellular function, clearly showing 
that protons are actively extruded from the cell.
An elaborate array of buffers are known to exist in the cell, principally 
haemoglobin, other proteins and dibasic phosphate (HPO42’). The combined 
buffering capacity of cells has been determined to be between 10 and 50 mM 
per pH unit, depending on the cell type40. However, buffering alone cannot 
account for the well maintained pHi observed. There have been four 
membrane-bound ion-transport mechanisms reported56 to play a role in the 
regulation of pHj.
2.2 The Sodium / Proton Antiporter.
The sodium / proton antiporter is ubiquitous in mammalian cells and is the
pH = 6.1 + log




most widely studied56 membrane mechanism that is involved in the regulation
of pHj. The importance of this antiporter has already been stressed in the 
preceding chapter and it is clearly worthy of explanation in some detail It is 
responsible for the reversible and electroneutral exchange of sodium ions (or 
lithium) for protons. Under physiological conditions, where protons are formed 
continuously intracellularly during metabolism, the antiporter operates to 
export protons from the cell, as illustrated in Figure 3.
Figure 3 A schematic representation of the sodium / proton antiporter.
sodium ions back out of the cell by the sodium / potassium-ATPase. This can 
be demonstrated by the inhibition of the ATPase with ouabain, which 
eventually leads to a shut down of the antiporter. Much of the work carried out 
on the sodium / proton antiporter has been helped by highly potent inhibitors, 
such as ethylisopropylamiloride, which are derived from the diuretic drug, 





The driving force for the extrusion of protons from the cell is produced by a 






N ^^N H ;
Amiloride Ethylisopropylamiloride (EIPA)
Figure 4. Structures of amiloride and ethylisopropylamiloride.
Amiloride and EIPA inhibit by competitively binding to the extracellular site 
which accommodates sodium ions.
The activity of the antiporter is known to be dependent on the external 
concentrations of both sodium ions and protons. If the external concentration 
of sodium ions or protons is increased, the rate of sodium / proton exchange 
increases. There have been various binding sites proposed for these cations, 
including a shared site in the kidney brush border membranes57 and distinct 
binding sites in many non-renal cells108.
The influence of pH* on the activity of the antiporter has been extensively 
studied. However, the interactions of internal sodium ions with the antiporter 
have received less attention. The activity of the antiporter may be measured as 
sodium ion influx or proton efflux, and ranges from maximum activity at acid 
pHi values to no activity at pHi values >7.5. This activity profile is 
characteristic of the sodium / proton antiporter and, therefore, its main function 
is to prevent intracellular acidification.
The shape of this pHi-dependent activity profile varies between cell types. 
Figure 5 shows two extreme cases between which most other cell types lie56. 
From the shape of the curve it is possible to predict that in the heart, a small 
variation in pHi would result in a large change in sodium / proton antiporter
14















Figure 5. The pH; dependence of the activity of the sodium / proton 
antiporter (redrawn from a report by Frelin et al.56).
Many suggestions have been made for the way in which the sodium / proton 
antiporter is regulated The effects of some hormones and growth factors have 
already been mentioned. However, it should be noted that all of these 
observations were carried out in the absence of bicarbonate / chloride ion 
exchange. In mutant cells which lack sodium / proton antiporters this 
alkalinisation does not occur and cells do not proliferate without artificial 
elevation of pH;59 In the presence of bicarbonate / chloride ion exchange 
growth factors fail to raise pH* in many cell types. The mode of action of these 
growth factors in the regulation of pH* is therefore complex and probably 
involves the stimulation of three acid-base transporters59. The list of effectors 
of sodium / proton exchange is very long and varied. There have also been
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proposed various mechanisms to achieve the activation of the antiporter, which 
can act simultaneously in the same cell60. Of the many activation pathways 
proposed, the three most widely accepted are:
(i) The C kinase pathway.
This is thought to account for the effect of many mitogens. The binding of the 
effector to specific membrane receptors activates phospholipase C via a 
pertussis-toxin-sensitive G protein. Inositol phospholipids are hydrolysed to 
release diacylglycerol which activates protein kinase C. This then may 
phosphorylate the antiporter protein56. The result is a shift of the pHj-activity 
profile to the right, leading to an increased activity of the sodium / proton 
antiporter in the alkaline range and thus a reduction in pHi.
(ii) The calcium-dependent pathway.
It has been observed in some cells, that an increase in intracellular 
concentration of calcium activates the sodium / proton antiporter. It has been 
suggested that a calcium-calmodulin protein kinase could mediate the calcium 
ion effect, although many other mechanisms involving calcium ions have been 
proposed56.
(iii) cAMP-dependent regulation.
Increased levels of cAMP lead to a decrease in the activity of the sodium / 
proton antiporter. The inhibitory effect is produced by a shift in the pHj-activity 
profile to the left. That is, an inverse of the mechanism of C kinase activation56.
2.3 Bicarbonate Transport Systems
2.3.1 Introduction
Anion exchange is also essential for the regulation of pHi and, at levels of pHi 
close to neutrality, may be more active than the sodium / proton antiporter in
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some cell lines61. The understanding of the role of bicarbonate transport 
systems in the regulation of pHi is less advanced than that of the sodium / 
proton antiporter. This is because (i) there are several transport systems 
involved, (ii) until recently, there were no selective potent inhibitors of these 
systems available, and (iii) bicarbonate equilibrates with carbon dioxide which 
is volatile and is also able to modify pHi. Three major bicarbonate-dependent 
mechanisms of regulating pHi have been suggested. Not all of these systems 
are present in all cell types and the significance of each combination is not fully 
understood. They all appear to be under hormonal control, similar to 
mechanisms described for the sodium / proton antiporter62,63,64.
2.3.2 The Sodium-Dependent Bicarbonate / Chloride Ion Antiporter
The purpose of the sodium-dependent bicarbonate / chloride ion antiporter is 
to increase the pH* of the cell following an acid load. Its activity is dependent 
on intracellular chloride ions and extracellular bicarbonate and sodium ions 
(not lithium). It is electroneutral, meaning that one sodium ion and two 
bicarbonate ions are exchanged for chloride ions, or that one sodium ion and 
one bicarbonate ion are exchanged for a proton and a chloride ion. That is, the 
bicarbonate influx associated with the functioning of the system is accompanied 
by an influx of sodium ions. A schematic representation of this mechanism is 
given in Figure 6.
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H P  «■ COa * CO,
h c o ;
Na+
V
Figure 6 A schematic representation of the sodium-dependent bicarbonate / 
chloride ion antiporter.
2.3.3 The Sodium-Independent Bicarbonate / Chloride Ion Antiporter
it is often necessary for a system to catalyse the efflux of bicarbonate. One such 
system is the sodium-independent bicarbonate / chloride ion antiporter which 
under these conditions acts as a cell acidifying mechanism following an alkaline 
load. However, if the extracellular concentration of chloride ions is decreased 
the system then reverses and acts to increase the pH of the cell. The system is 
electroneutral and a schematic representation of this mechanism is given in 
Figure 7.
The inward gradient for chloride ions usually exceeds that for bicarbonate and
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crCl" 4
Figure 7. A schematic representation of the sodium-independent bicarbonate / 
chloride ion antiporter.
2.3.4 The Bicarbonate / Chloride Ion Symporter
This bicarbonate transport system is sodium-selective, independent of chloride 
ions and electrogenic65 It was reported66 to act as a bicarbonate influx 
mechanism in bovine corneal endothelium leading to an increase in pH; 
Conversely, it has been claimed to mediate reabsorption of bicarbonate and 
sodium ions into the blood in the basolateral membrane of the renal proximal 
convoluted tubule66.
2.3.5 Inhibition of Bicarbonate / Chloride Ion exchange.
Inhibition of the sodium / proton antiporter has been shown to increase the 
thermosensitivity of tumour cells, as discussed earlier. This thermosensitisation 
has been reported to be further enhanced by the inhibition of bicarbonate / 
chloride ion exchange28. One of the most potent and specific inhibitors of 
bicarbonate / chloride ion exchange available is /?(+)-[(5,6-dichloro-2,3,9,9a- 
tetrahydro-3-oxo-9#-propyl- l//-fluoren-7-yl)oxy]acetic acid (B-3(+)), 
illustrated in Figure 8
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a B-3(+)
Figure 8 Structure of JK(+)-[(5,6-dichloro-2,3,9,9a-tetrahydro-3-oxo-9a- 
propyl-l//-fluoren-7-yl)oxy]acetic acid (B-3(+)).
When B-3(+) is used alone there is little change in the thermosensitivity of the 
tumour, suggesting that the role of bicarbonate / chloride ion exchange in the 
regulation of pH, is relatively small The use of bicarbonate / chloride ion 
exchange inhibitors in therapy should be considered with caution as they may 
even reduce the therapeutic index due their toxicity effects.
2.4 Proton Pumps
There have been various proton pumps described which may play a role in the 
regulation of pHj. Electrogenic proton-translocating ATPase pumps have been 
found in the mammalian distal nephron67 and in the turtle urinary bladder68. 
Also, electroneutral potassium / proton exchange ATPase pumps are thought 
to be involved in gastric acid secretion56. The energy for these proton pumps is 
provided by the hydrolysis of ATP. The examples given are all located in the 
cell membrane and are all efficient in the expulsion of protons from the cytosol. 
However, their role in the regulation of pHj is not yet clear.
2.5 Proton Channels
Proton conductive pathways have been observed, for example in renal brush 
border membrane vesicles69 and in neurons70. These channels will have a 
limited role in the regulation of pHj under physiological conditions and under 
the extreme circumstances relative to the major systems of regulation.
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Therefore, studies of these channels have received less attention.
The above account has described a large array of mechanisms at a cells 
disposal for the strict regulation of pHj. Much of this knowledge has required 
the measurement of pHj. Furthermore, the very existence of these mechanism 
illustrates the importance of pHi to a cell. Therefore, the measurement of pHi 
may provide important information about the metabolic state of a tissue and 
may also highlight areas for possible therapeutic exploitation of pH;.
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CHAPTER THREE
3. Measurement of pH in Biological Systems.
3.1 Measurement of Homogenates.
One of the oldest methods for estimating pHi, the measurement of the pH of 
cell lysate or homogenate, was first employed in 1912 by Michaelis and 
Davidoflf71. The potentially serious problems of this technique were recognised 
early on. For example, production of lactic acid and carbon dioxide continue 
after cellular destruction and lead to a fall in pH. In addition, the mixing of 
intra- and extracellular fluids can lead to changes in pH because the solutions 
are of different pH and because the intra- and extracellular buffers become 
diluted. Finally, disruption of intracellular organelles makes it impossible to 
calculate the pH of the bulk intracellular fluid4.
3.2 Radiolabelled Weak Acids / Bases.
Twenty years ago the most popular method of estimating the pHi was to 
measure the distribution of a weak acid or base across the cell membrane. This 
relies on the observation that for some weak acids or bases, the permeability of 
a biological membrane to the non-ionised form is very much greater than the 
ionised form42. Weak acids will occur in higher concentrations in more alkaline 
compartments; for weak bases the opposite is true. There are several 
assumptions made for this method, including:
(i) It is based on a two compartment system representing intra- and 
extracellular spaces.
(ii) The dissociation constant is the same in both compartments.
(iii) No binding, active transport or metabolism of the indicator occurs.
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Problems often associated with this method include:
(i) The preparation must be biopsied, causing damage to cells and a limit of 
one measurement per preparation.
(ii) To measure the intracellular concentration of the non-ionised form of the 
indicator, a correlation must be applied for contamination with extracellular 
fluid. For this purpose, markers of extracellular space must be used, for 
example [14C] inulin, [14C] sorbitol, 36C1‘ and total tissue water (3HHO). This 
can be carried out on parallel samples to those being used for pH determination 
but it is sometimes preferred to determine the extracellular space in the same 
samples49.
(iii) Binding to intracellular proteins means that measured intracellular 
concentrations are often higher than free concentrations. An underestimate of 
pH; occurs if a weak base binds and an overestimate if a weak acid binds42.
(iv) Only slow changes in pH* can be monitored due to the time it often takes 
the indicator to equilibrate between the intra- and extracellular 
compartments72.
(v) The method is sensitive to changes in cellular volume4.
(vi) Intracellular compartmentation may occur. For example, a weak acid will 
be excluded from acidic compartments (e.g. lysosomes) and will accumulate in 
relatively alkaline compartments (e.g. mitochondria). The proportion of the 
intracellular volume that these compartments occupy in different cell types 
could have important implications on the value of pH* measured.
(vii) Measurements usually have to be carried out in suspension. If the cells are 
attached to a solid surface, which is a condition often required45, then the 
remaining volume of extracellular fluid can be 20-30 times greater than the 
intracellular volume. This in itself poses a problem, but in addition, washing of 
the extracellular fluid results in leakage of the indicator.
These limitations mean that absolute values of pHi cannot be determined with 
certainty using this method. The major advantage of this method is cheapness 
and, despite the many uncertainties, it has found much use in the estimation of
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pHi45,49 The most popular commercially available indicator is the radioactive 
weak acid, 5,5-dimethyloxazolidine-2,4-dione (DMO)49. Here, an increase in 
pHi results in an increased accumulation of DMO anion intracellularly.
3.3 Positron Emission Tomography of Weak Acids.
The principle of this method is the same as for radiolabelled weak acids. DMO 
is once again the compound of choice, but the [nC] DMO isotope is used and 
detection is by positron emission tomography. The major application of this 
technique has been in the measurement of brain tissue pH, that is a composite 
value of pH; and pHe13. These measurements do not use extracellular markers 
as required for the calculation of pHi. The main limitation associated with this 
technique is the short half life of the isotope (20.3 minutes).
3.4 Luminescence.
When a molecule undergoes electronic excitation, it can also be taken to a 
higher vibrational state. In this excited state, the molecule is subjected to 
collisions with surrounding molecules and gives up energy as it steps down the 
vibrational levels. If the molecule is able to retain the large energy difference 
between the excited electronic state and ground electronic state, then it may 
undergo spontaneous emission of fluorescent radiation. The characteristic 
fluorescent spectrum produced by many compounds has been exploited in the 
measurement of pH. There are three types of fluorescent pH probes; those 
which work on the same principle as radioactive weak acids/bases but use 
fluorescence as the method of detection, those which exhibit pH-dependent 
fluorescence absorption and/or excitation spectra, and those which have a 
proton-controlled fluorescence.
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3.4.1 Fluorescent Weak Acids/Bases.
The weak base, 9-aminoacridine (9-AA) is the most popular fluorescent 
compound which partitions across the cell membrane according to the 
transmembrane pH gradient73. It was reported50 that uptake of 9-AA by sea 
urchin sperm cells results in a quenching of its fluorescence. This appears to be 
related to intracellular binding. In this example, the fluorescence served as a 
measure of the extracellular 9-AA and therefore simplified calculations of pH*.
3.4.2 pH-Dependent Fluorescence Absorption/Excitation Spectra.
quin 2
quene 1
Figure 9. Structures of quin 2 and quene 1.
One of the first fluorescent compounds to be used as a pHj probe was 
fluorescein This exhibits a pH-dependent absorption spectrum between pH 3.0 
and 8.0 with maxima at 435 and 495 nm, respectively42. Fluorescein found 
much use in the measurement of pHj until new improved fluorescent probes
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were introduced42. The design of the first alternative to fluorescein was based 
on the fluorescent indicator of calcium ion concentration, quin 247
The new probe47, 8-|flis(ethoxycarbonyhnethyl)amino]-6-methoxy-2-[*r<ms-2- 
[bis(ethoxycarbonylmethyl)amino]styryl]quinoline, was named quene 1 and is 
illustrated in Figure 9. Quene 1 has excitation and emission maxima at 390 and 
530 nm respectively, and shows a 30-fold increase in fluorescence between pH 
5 and 9 with a pK. of 7.3. It is claimed that the fluorescence is insensitive to 
concentrations of calcium and magnesium ions up to 10"4 M and to 
concentrations of sodium and potassium ions up to 100-200 nM74. The 
indicator is loaded into the cells as its tetra(acetoxymethyl) ester derivative 
which is hydrolysed in the cells to give the tetracarboxylate anion. The main 
limitation of this compound is its affinity for cations and a correction factor is 
often required for the pHj value. Also, some leakage of the probe has been 
reported74.
A fluorescent probe which has found considerable use in recent years is 2,7- 
bis(carboxyethyl)-5(6)-carboxyfluorescein (BCECF). Excitation and emission 
wavelengths are 495 and 525 nm, respectively, and the pK« is 6.9810,53. The 
compound is loaded into cells as its membrane-permeable acetoxymethyl ester, 
BCECF-AM. As with the previous esters of probes, hydrolysis by intracellular 
esterases releases the BCECF, which will be charged and therefore trapped. 
Unfortunately, this method of administration is not applicable to bacteria due 
to a very slow rate of absorption53. Once in the cell, the probe can give a good 
estimation of pHi. Calibration of pHi is required and is usually carried out with 
the potassium/proton ionophore, nigericin75. Nigericin sets pHi equal to pHe 
and fluorescence is measured at varying pHe.
Recently, carboxy seminaphthorhodafluor-1 (SNARF-1) has emerged as a new 
pH-sensitive fluorescent probe. This has so far found use in pHj determination 
of multidrug resistant cells31,32,33. The potential of this probe requires further
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investigation, but the initial reports appear promising.
The advantages of pH-sensitive fluorescent probes include:
(i) They can be used to detect rapid, transient changes in pH*.
(ii) Variations in pHi can be detected in cell populations using 
spectrofluorimetry, but also in single cells using fluorescence microscopy15, or 
using flow cytometry23.
(iii) BCECF appears to have a relatively low toxicity towards most cell types53. 
Problems often encountered with this method include:
(i) Leakage is a major limitation32,53. This will particularly affect the results of 
long term monitoring experiments. To avoid significant errors, appropriate 
countermeasures need to be taken. Due to the leakage into the supernatant, 
each sample needs to be resuspended immediately prior to investigation, 
however a 5% error in the pH* value can be obtained after only 10 minutes53. 
Also, these measures reduce the time resolution of observations and can be 
inconvenient when studying rapid changes. Leakage of these probes could 
occur by passive diffusion or active transport. In the case of BCECF, the 
presence of 4/5 negative charges at physiological pH means that passive 
diffusion is unlikely. Evidence of an ATP-driven transport system involved in 
BCECF efflux has been suggested for many bacteria53.
(ii) Fluorescence can respond to changes other than in pH, such as altered 
partitioning between soluble and membrane phases, and changes in cell volume 
and organelles.
(iii) Fluorescence can be quenched by intracellular binding50.
(iv) It has been reported76 that a lipophillic fluorescent probe can catalyse 
photo-oxidation reactions.
The free acid form of BCECF has been used for the measurement of pH* by 
fluorescent ratio imaging microscopy (FRIM)15. Under these conditions the 
maximum of the emission spectrum was found to be pH-sensitive while the
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excitation spectrum was pH-insensitive below 440 nm. Thus, pH* was 
determined from the ratio of the two values. The in vivo application of this 
technique shows particular promise, for example in showing the difference 
between normal and tumour pHe.
3.4.3 Proton-Controlled ”on-off” Switching of Fluorescence.
(i) Aminomethyltetraphenylporphyrin-Tin(iv) Derivatives77.
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Figure 10. Fluorescence quantum yield vs pH (redrawn from a report 
by Grigg et al.11)
For certain complexes, its degree of protonation can determine how important 
fluorescence will be as a pathway by which to lose excess energy following an 
electronic transition to an excited state. This can be considered as a proton- 
controlled "on-off' switching of fluorescence. Grigg and Norbert77,78,79 have
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synthesised a series of complexes which show luminescent pH sensor activity.
These have fluorescence quantum yield-pH profiles which are composed of 
two sigmoidal curves of opposite gradients. A typical curve shape is illustrated 
in Figure 10. Each of the gradients represents a different process of 
fluorescence quenching. The negative gradient is assignable to a photoinduced 
electron transfer (PIET) process which takes place between the amino group 
and the porphyrin moiety when the amino group is not protonated. Examples 
of these porphyrin-tin(iv) derivatives (I) are shown in Figure 11. The positive 
gradient is attributed to an axial ligand exchange process across the tin(iv) 
centre.
For these particular complexes, the proton-controlled changes in the quantum 
yield (<j>) occur without alteration of fluorescence band position or vibrational 
fine structure of fluorescence
As would be expected for the corresponding parent compound (II) where the 
amino group is absent, the (j)-pH profile does not contain the negative gradient 
of the PIET process.
R = alkvl, aryl
X,Y = Cl, OH,
Figure 11. Structures of aminomethyltetraphenylporphyrin-tin(iv) derivatives.
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(ii) Aminomethylbipyridyl-Ruthenium(n) Complexes78.
The complexes illustrated in Figure 12 show proton-controlled quenching of 




(a) R = NMePh
(b)R = NMeQH40Me4
(c) R = NMeQH3(OMe)2-3,4
(d)R = NB2
(e)R = N (012CH2C)H)2
Figure 12. Structures of aminomethylbipyridyl-ruthenium(ii) complexes.
For complex (a), the unprotonated form experiences quenching of 
luminescence by PIET Conversely, the protonated forms of complexes (b) and 
(c) have a quenched luminescence by PIET. The protonated and unprotonated 
forms of complexes (d) and (e) show a negligible quenching of luminescence 
by PIET, but a substantial quenching arises on protonation due to the 
generation of a positive charge close to the [Run(bpy)3]2" luminophore. As 
before, a <|>-pH profile can be constructed for each of these complexes. 
However, unlike the tin(iv) complexes, the emission maxima of the ruthenium
( ii)  complexes also show pH-dependence. Therefore, two pKa values can be 
calculated for each compound corresponding to two different pH profiles.
(iii) p-ter/-Butylcalix[4]arene-Linked Ruthenium(ii) Trisbipyridyl Complexes79.
These complexes are composed of a trisbipyridylruthenium(n) moiety acting as
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the luminophore and free phenolic units of a calix[4]arene as the acid-base site 
and are illustrated in Figure 13.
ROOH OH
where R = H or
v
Figure 13. Structure of /?-ter/-butylcalix[4]arene-linked ruthenium(n) 
trisbipyridyl complexes.
Formation of the phenolate anion(s) causes PIET between the ion(s) and the 
ruthenium (n) moiety with a quenching of luminescence. A single step <|>-pH 
profile can be constructed for each of these complexes and there is no pH- 
dependent shift in the wavelengths of the maxima in the spectra.
The potential for these complexes to act as pH probes has been demonstrated 
by Grigg and Norbert77 78-79. However, their application to biological studies 
has not been evaluated
3.5 Colourimetry, Using pH-Sensitive Dyes.
It is well established that many compounds undergo a colour change in 
response to changes in pH. The most widely used colourimetric pH indicator is 
Neutral Red, as illustrated in Figure 14. This is a relatively non-toxic dye and
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has a useful pH range of pH 6.0 (red) to pH 8.0 (yellow). It has the advantages 
that continuous recording can be made, and rapid changes in pH may be 
followed as the response of the dye to pH is almost instantaneous, and biopsy 
of the tissue is not normally required. However, a potential source of error, 
which affects quantitation of pHj, is dye-protein binding, since this can affect 
the activity coefficient of the dye. Additionally, although Neutral Red is 
reported by most to be non-toxic, effects on glucose metabolism, oxygen 
consumption, aggregation by the formation of ATP-dye complexes, and 
systemic cardiovascular changes when the dye has been administered iv. at high 
concentrations have been reported80. Further, the dye has shown a light- 
activated mutagenic effect through DNA binding, which has become the basis 
for using the dye in the treatment of recurrent herpes infection80 This avid 





Figure 14. Structure of Neutral Red.
3.6 Microelectrodes.
The principle of microelectrodes is identical to that governing "macro” pH- 
sensitive glass electrodes. The Hinke-type electrode was the initial 
breakthrough in microelectrode technology and was first described in 196754. 
Unfortunately the exposed length of pH-sensitive glass (several hundred 
micrometres) was too long for most types of cells72. Thomas81 described in 
1974 the 1 pm recessed-tip type, but this responds rather slowly and is tedious 
to make.
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In Zurich in 1981, a third type was developed, which depends on a pH- 
sensitive cocktail56. This cocktail is an organic solution sensitive to pH which is 
held into the tip of a micropipette made hydrophobic by treatment with silanes. 
However, when the tip of the microelectrode is inserted into a cell, it is 
separated from the exterior by the cell membrane and hence the potential of the 
electrode will be determined not only by the pH, but also by the membrane 
potential. Therefore, a second electrode is needed to measure membrane 
potential alone and a "double-barrelled" version was developed72 in 1983. This 
electrode is very similar to the single-barrelled recessed tip electrode, except 
that the simultaneous measurement of the membrane potential and the pHi 
gives a better indication of the intracellular location of the electrode tip.
This method is obviously rather destructive in nature and an inherent problem 
is that the measurements of pHi provide a composite value of pH with 
contributions from the interstitial and intravascular pH which are expected to 
be at least 50% of the measured value13,27. Although microelectrodes can 
sometimes give an estimate of pHj (provided that damage to the cell by the 
probe is minimised), they tend to have a short and rather unreliable life54.
3.7 Electron Paramagnetic Resonance.
It has been observed that the electroparamagnetic resonance (EPR) spectra of 
many radicals are sensitive to the pH of the medium82. pH-sensitive nitroxyl 
radicals have been put forward as the most promising for pH studies in 
biological systems. The EPR spectra of dihydro-imidazole and imidazolidine 
radicals appears to be particularly sensitive to pH, due to protonation of the N- 
3 atom of the radical heterocycle.
Berezina et al,82 investigated the potential of dihydroimidazoles for use as pH- 
sensitive probes. It was revealed that compounds such as the paramagnetic 
aldonitrane (I), shown in Figure 15, are limited to the pH range 2 to 5.
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However, attachment of amine substituents into the 4-position allowed 
successful manipulation of the pKa to allow measurement in the pH range 3 .3 
to 7.8 Examples of the modified compounds (II, III) are shown in Figure 15.
Little biological work has been carried out on these compounds, therefore their 
suitability as pH; indicators has yet to be determined.
BuHN
(I) (II) pKa = 6.6 ( m ) p K a =5.9
Figure 15 Structures of aldonitrane and related compounds
3.8 Nuclear Magnetic Resonance.
3.8.1 Introduction.
NMR spectroscopy is non-destructive, non-invasive, relatively non-perturbing 
and a fairly painless technique for patients It has the advantage that a 
particular tissue can be monitored over a period of time This can be useful for 
studying changes of pH in disease states before, during and after therapy. Its 
major limitation is expense. A variety of nuclei have been reported in the
QO Q 4 or Qdi
literature ’ ’ ’ to show pH-dependent chemical shifts in the physiological 
range. These include, 31P, *H, 15N and 19F.
3.8.2 31P NMR.
The naturally abundant 31P nucleus has a fairly wide chemical shift range and
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although it is only 0.066 fold as sensitive as *H, it has proved to be particularly 
useful for biological NMR studies. Many phosphorus containing compounds 
occupy a central role in the bioenergetics of living cell39. In 1975, Moon and 
Richards83 were the first to demonstrate that the pH-sensitive 31P  chemical shift 
of "inorganic phosphate" (P i) could serve as a useful probe of pHj in biological 
systems.
Measurement of pHi is generally carried out by determining the difference in 
chemical shift between the endogenous Pi resonance, which is regulated by the 
phosphate buffer system, and the resonance of endogenous phosphocreatine 
(PCr), which is insensitive to pH over the biological range52.
Initially, Moon and Richards used 2,3-diphosphoglycerate as the internal 
standard, but discovered that its chemical shift is influenced by other factors 
and that most systems do not contain significant concentrations. They 
suggested the use of PCr and ATP, although since then, ATP has also been 
proved unsuitable because of its dependence on the Mg2+ concentration and the 
presence of other resonances which result in peak broadening.
In the phosphate buffer system, illustrated in Figure 16, the H2PO4' conjugate 
acid and the HPOV conjugate base are in rapid exchange4 in the range pH 6.1 
to pH 7.7. Hence, the corresponding 31P NMR signal appears as a single line at 
a chemical shift determined by the weighted mean of the relative 
concentrations of the two species, thus, by the pH of the solution.
I^PO; * HPOj" + H+
Figure 16. The phosphate buffer system.
An in vitro calibration curve is constructed by simple titration and, assuming 
that such an in vitro standardisation curve is applicable to intracellular fluid, 
pHi can be obtained from the chemical shift of Pi.
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Limitations of this method include:
(i) For the accurate assignment of the Pi chemical shift, a reference signal is 
required. External standards should be avoided for biological studies because 
they may lie in a different field due to B0 (strength of the applied magnetic 
field) inhomogeneity and local susceptibility effects35. PCr is the usual choice, 
but the concentrations of PCr are generally so low as to make the 31P signal 
undetectable in most tumours26,34 and in the kidney87. It has been suggested 
that PCr resonances recorded in many tumour spectra are caused by adjacent 
muscle tissue, overlying skin or infiltrating lymphocytes and endothelial cells 
rather than the tumour itself22. If this is the case, then the position of the PCr 
peak is not "tumour specific" and may be experiencing a different B0 field due 
to local susceptibility effects35. Therefore, the H20  peak from the proton 
spectrum used for shimming is often the reference of choice. This is generally 
satisfactory provided that the reference signal is derived from the same region 
of tissue as the Pi signal. Unfortunately, this technique of referencing is not 
well understood by many research groups22. Alternative methods for reference 
include the glycerophosphorylcholine resonance but this requires the proton 
decoupling to resolve the peak. Decoupling requires energy which can be 
damaging to tissue.
(ii) The Pj peak is often not clearly visible. Low levels of Pi have been reported
for many cell types88,89 and often in well perfused tissues90. The Pi may also be 
masked by phosphodiester (PDE) signals90. The peak is often broad and not 
resolved into intra- and extracellular compartments. This means that most 
measurements of pHi by 31P NMR give a composite pH value with
contributions from pHi expected to be at least 85% of the total13, resulting in a 
large standard error16,91. When multiple P* peaks do occur, assignment is 
usually unsuccessful26.
36
(iii) The Pi resonance can be influenced by factors other than the pH. The 
concentration of Mg2+ in some cell types is high enough to affect the chemical 
shift. The ionic strength, protein solvation and temperature can also have an 
influence90. Uncertainty about the effects of substances on the chemical shift of 
P i introduce errors between 0.1 and 0.5 pH units85,92,93.
(iv) The cellular pH may extend beyond the pH range of Pi. For example, under 
severe hypoxia90.
(v) Poor signal to noise ratio (SNR). This can be due to low concentrations of 
phosphorus and, to some extent, the relatively low sensitivity of 31P. It 
introduces two major problems35. Firstly, recognition of peaks becomes 
difficult and statistical methods are usually applied. Secondly, there is an 
uncertainty in the position of identified peaks. Poor line shapes and SNR's 
often mean that mathematical fitting of the data is necessary to measure the 
peak position35. The broad base line introduced by the presence of the peaks 
from the phosphomonoesters (PME), PDE and phospholipids may result in an 
apparent shift in the Pi resonance. Additionally, the magnitude of this shift is 
expected to vary in different patients, in different tissues and also during 
tumour therapy where the contribution from PME and PDE will change with 
regression of the tumour35.
pHe can also be measured using 31P NMR if an extracellular marker is used. 
This marker must have a distinct spectral peak position, be non-cytotoxic, have 
an appropriate pKa and be largely excluded from the cell. Phosphonic acids, 
such as phenylphosphonic acid (PPA), have been proposed as extracellular 
markers in the study of perfused skeletal muscle94. However, proof of their 
confinement in the extracellular fluid over prolonged perfusion periods has not 
been provided. Further, effects of PPA concentrations and exposure time on 
muscle contractability, for example, have not been assessed. In order to 
distinguish the pH of intra- and extracellular compartments using 31P NMR, a
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difference of at least 0.3 - 0.4 pH units is normally required. Another method 
used to distinguish pHi and pHe is by comparing spin-lattice relaxation times 
(TO for Pi.
3.8.3 JH NMR.
Although *H NMR has the advantage of high sensitivity, it is technically more 
difficult than less abundant nuclei because of the need to suppress the water 
and fat signals, and also because of the multiple overlapping of metabolite 
resonances5,90. Surprisingly, despite its obvious drawbacks, *H NMR has been 
used for pHi determination.
*H NMR studies of human erythrocytes have been carried out, where pHj was 
estimated from the chemical shift of histidine resonances in haemoglobin95. 
However, this method was not straightforward because of the acid dependence 
of the histidine chemical shifts on the oxy-deoxy status of the haemoglobin96.
The first *H NMR ’’probe" to be used for pHi determination was based on the 
pH-dependent chemical shifts of imidazole protons84. In the initial study84, 
imidazole was introduced into erythrocytes by incubation. Calibration was 
carried out by *H NMR measurements on cell lysates at pH values varied by 
the addition of aqueous hydrochloric acid or sodium hydroxide solutions and 
measured directly with a glass electrode. To select the peaks required, *H 
NMR spectra were measured by either a spin-echo method or by a transfer of 
saturation technique. A single pulse technique is not suitable due to a large 
number of haemoglobin imidazole resonances which are also visible by this 
method. The resonances for imidazole 2-H and 4,5-H protons are all pH- 
dependent with the pK* values determined to be 7.10 and 7.06 at 37°C 
respectively. The difference between these two values shows an error in the 
technique. This early study with erythrocytes highlighted a number of 
limitations associated with this method. Interactions with cellular substituents
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were encountered which affected the imidazole 2-H and 4,5-H proton 
resonances differently. Also, initially there were two signals for the 2-H proton 
representing intra- and extracellular compartments. However, these signals 
coalesced with time into a single resonance peak, indicating that the membrane 
was sufficiently permeable to both ionised and non-ionised forms of the 
imidazole to eventually lead to an equilibrium between compartments.
The only other !H NMR probe for pHi, so far, is that developed by Ballesteros 
et al.91. This was based on imidazole, with modifications to decrease the 
membrane permeability of the ionised form and improve its performance as an 
extrinsic pH; probe. Acetate, malonate or succinate esters were introduced at 
the 1-position of imidazole, followed by cleavage to the corresponding acids to 
increase further the charge of the ionised compound at physiological pH. 
Examples of these imidazole derivatives are illustrated in Figure 17.
[20p2Me CH2CQ2H
BOzCCH/ OOzEt EtQjCCH/ CX^H 
2-H pKa = 7.10 7.23 6.02 6.86
Figure 17. N-Substituted derivatives of imidazole and their corresponding pKa 
values.
It can be seen that some of these compounds still contain still contain ester 
groups. These will generally be cleaved to the corresponding acids once inside 
the cell, however, not all cells are able to cleave methyl esters. Once again, the 
chemical shift of the imidazole 2-H proton showed pH-dependence with the 
pKa values shown in Figure 17.
It has been demonstrated97 that *H NMR can be used for the measurement of 
pHi. However, the technical expertise required and the large errors introduced
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by using such an abundant nucleus, mean that accurate determination of pHi in 
biological systems is not feasible by this technique.
3.8.4 15N NMR
15N labelled compounds have been used for the measurement of pH using 1SN 
NMR spectroscopy. 15N has the advantage that it shows very substantial 
chemical shift changes in response to pH85. For example, in the measurement 
of cytoplasmic and vascular pH in Neurospora*5, using the N3- and N l- 
nitrogen chemical shifts of histidine, which are very sensitive to pH in the range 
pH 5 to pH 7.
Another NMR parameter that has been used for pH* estimation is the line width 
of proton-coupled 15N resonances of a-amino acids and the guanidine group of 
arginine. In aqueous solution, the protons attached to these nitrogens undergo 
base-catalysed exchange with water protons and the rates of exchange increase 
with pH.
Unfortunately, the N1-nitrogen chemical shift is also dependent on ionic 
strength, and large quantities of polyphosphates may associate with basic 
amino acids, introducing an uncertainty of the order of 0.4 pH units85. 15N 
labelled compounds are also very expensive.
3.8.5 19FNM R
The naturally occurring 19F nucleus has many NMR properties which make it 
particularly suitable for biological NMR studies. It has a spin Vz and relatively 
high sensitivity (0.833 x *H; 12.6 x 31P). Its chemical shifts and relaxation 
times are very sensitive to changes in its environment and has a wide chemical 
shift range (0-960 ppm), allowing various fluorinated compounds to be clearly 
recognised in spite of the line broadening which is often associated with
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biological studies. Fluorine is virtually absent from endogenous components of 
tissue, cells and biological media.
The suitability of 19F NMR for biological work has been shown by its 
considerable use in metabolism and disposition studies of fluorinated 
xenobiotics both in vitro and in v/vo94,98,99,100
The ease of detecting fluorine in biological systems may be illustrated with an 
example. The tumour selective retention of fluorinated 2-nitroimidazole probes 
was demonstrated by 19F NMR in v/vo1837 Consider the two compounds 
shown in Figure 18
Ro 07-0741 CCI-103F
Figure 18. Structures of Ro 07-0741 and CCI-103F.
Both the peak for the six fluorine atoms of CCI-103F and the peak for the 
single fluorine atom of Ro 07-0741 could be clearly identified in the in vivo 19F 
NMR spectra. The estimated practical limits for 19F detection in these studies 
was in the order of 107 atoms of 19F per gram of tissue or 2 x KT4 molar 
equivalents of 19F Moreover, the magnetic field used in the experiments was 
similar to those routinely used for whole body imaging instruments.
19F NMR chemical shifts are highly sensitive to changes in environment. These 
include pH, temperature, solvent and ionic strength100 in addition to the 
chemical and magnetic environment within the molecule itself.
In Chapter One the sensitivity of the 19F NMR spectrum of 5-fluorouracil to its
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adopted geometry once incorporated into DNA was discussed29,30. 19F NMR 
has become an important probe of base pairing within DNA101 and for the 
labelling of mRNA102 and tRNA103.
Another exploitation of the sensitivity of 19F chemical shifts has been for the 
probing of various ions in biological systems. Difluoro-derivatives of l,2-bis(o- 
aminophenoxvl)ethane-N,N,N’,N'-tetraacetic acid (wFBAPTA), shown in 
Figure 19, have chemical shifts which are highly sensitive to chelation by 
divalent cations (M2+)86.
wFBAPTA (The position of the fluorine atom on each ring is denoted by n)
Figure 19 Structure of difluoro-derivatives of 1,2-bis(o-amino 
phenoxyl)ethane-N,N,N’,N’-tetraacetic acid.
An increased understanding of the sensitivity of 19F chemical shifts has allowed 
the design of more specific ion probes. Indicators for intracellular Mg2+ have 
been developed, based on the chelator o-aminophenol-N,N,0-triacetic acid 
(APTRA)104. Examples of these fluorinated derivatives are illustrated in 
Figure 20 These probes have been designed in such a way that chelation of 
magnesium leads to observation of separate resonances corresponding to 
complexed and free chelator. However, in most cases chelation of calcium only 






Figure 20. Structures of fluorinated derivatives of the chelator o-aminophenol- 
N,N,0-triacetic acid.
These chelators have the advantage of providing a direct identification of the 
bound ions. Other methods for the measurement of divalent cations in 
biological systems include indirect calculations based on equilibrium systems, 
ion-sensitive microelectrodes and null point measurements using 
metallochromic dyes that are micro-injected into cells or placed into the 
extracellular space, with frequent lysis of cells Virtually all of these methods 
are invasive in nature and require sample destruction prior to analysis. In 
contrast, NMR has considerable advantage as a non-invasive tool. 
Furthermore, the ability to carry out studies on opaque cell suspensions and 
tissues, inaccessible to fluorescent measurements, was highlighted by these 
cation probes
The suitability of fluorinated compounds for use as biological probes can, 
therefore, be easily supported
The 19F chemical shift can also be sensitive to pH, particularly if the fluorine 
atom is located near an acidic or basic functional group in a molecule86. This 
phenomenon was first successfully exploited by Deutsch and Taylor in 1981, 
who have since developed a number of pH probes105.
They initially used the 19F resonance of trifluoroethylamine for the
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measurement of transmembrane pH gradients105. At 25°C a single broad peak 
was observed due to rapid exchange of CF3CH2NH2 across the membrane. It 
was necessary for the temperature to be lowered to 4°C before two separate 
signals could be observed. At this temperature, the pK® was 6.0, which was far 
from optimal. However, this early experiment showed that the development of 
fluorinated probes with pH-dependent chemical shifts is a worthwhile goal.
The next series of experiments investigated the 19F NMR resonances of 
fluorinated a-methylamino acids14. In studies on human peripheral blood 
lymphocytes, (±)-2-amino-3,3 -difluoro-2-methylpropanoic acid was used for 
the estimation of pH*. The methyl ester of this compound was taken up readily 
by the cells and cleaved to release the free acid inside the cell. The amino acid 
was present at concentrations as high as 4-5 mM and pHi determination was 
possible following relatively short measurement times (1-5 minutes). 
Unfortunately, leakage of the probe and interactions with intracellular 
potassium ions lead to complications. However, the results reported were 
comparable to those obtained using the distribution of radiolabelled DMO in 
parallel experiments14.
In later work, a series of such probes were evaluated43,52,76. The reported76 pK« 
values of these compounds are given in Table 1. As can be seen, these probes 
cover a large range of pK» values. In addition, they were specifically designed 
to be non-metabolisable and non-toxic. The measurements of pHi with an 
accuracy of ±0.06 pH units required the simultaneous use of two of these 
probes.
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methyl ester 5.1 0.14
a-difluoromethylalanine 7.3 0.09
a-monofluoromethylalanine 
methyl ester 6.4 0.08
a-monofluoromethylalanine 8.5 0.11
Table 1
The major limitation of these probes is the use of methyl esters. As mentioned 
earlier, not all cells are able to hydrolyse methyl esters76'106 Deutsch and 
Taylor realised this problem and examined the 4-chlorophenyl esters of 
fluorinated a-methylamino acids106. An example is illustrated in Figure 21, 
which was cleaved rapidly in cells which lack methyl esterases to generate high 
intracellular levels of the probe. No stereochemical information was provided 
in these reports76 106 Different diastereoisomers will have different sensitivities 
of the 19F chemical shift to pH.
CH
Figure 21. Structure of the 4-chlorophenyl ester of 2-amino-4,4-difluoro-3- 
methylbutanoic acid.
The next development by Deutsch and Taylor was the use of fluoroanilines as 
19F NMR pH indicators107. Probes were designed such that the fluorine atoms 
were directly attached to the aromatic ring. This class of compounds has pKa
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values ranging from pH 1 to 6 and total shifts of the 19F resonance from 5 to 
15 ppm between the conjugate acid and base. Therefore, a series of probes was 
investigated with various functional groups attached for the modulation of the 
pKa. Figure 22 illustrates the two main strategies used to shift the pKa of 
compound (I).
As shown in compound (H), the addition of an electron donating group into 
the aromatic ring had little appreciable effect on the pKa and was in the wrong 
direction. An electron withdrawing group such as a trifluoromethyl group 
would have been more appropriate. However, N-alkylation, as with compound 
(HI) produced a pKa slightly closer to physiological pH. The fluoroanilines are 
very sensitive to pH, with changes in chemical shift of up to 5 ppm per pH unit 
near the pKa This clearly demonstrates the great sensitivity of 19F chemical 
shift to pH. These examples of fluoroanilines are purely model compounds and 
have not yet been evaluated in situ
H
I pKa 6.0
n  pKa 5.8 m  pKa 6.8
Figure 22. Structures of 4-fluoroaniline derivatives.
Deutsch and Taylor virtually dominated all published research into 19F NMR 
pH probes in the 1980s but, lately, new probes have begun to appear from 
other research groups.
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Recently demonstrated was the attachment of fluorinated pH indicators to 
carrier polymers as a means to targetting a probe90. This has the advantage that 
the biological toxicity associated with the pH marker may be masked or altered 
upon coupling to non-toxic carrier polymers.
Macromolecules such as albumins, globulins, dextrans, and synthetic polymers 
(for example, polylysine) accumulate in tumour tissue because these tissues 
have a vascular network characterised by both enhanced permeability of the 
neovasculature and a lack of lymphatic recovery system. For example, Mehta 
et al.90 attached 19F NMR indicators, such as 3-fluorosalicylaldehyde (3-FSA), 
to various macromolecules, mainly dextrans. The polymer 3-FSA conjugates 
had chemical shift sensitivities of 1.36 to 1.41 ppm over a pH range of pH 5.5 
to pH 8.5 and a physiological pR* (ca pH 7.0 to pH 7.2). Unfortunately, this 
response was not as good as that for the parent probe, 3-FSA which had a 
chemical shift sensitivity of 2.05 ppm over the pH range
The same research group have recently reported108 another possible pH; 
indicator based on the vitamin B6 analogue, 6-fluoropyridoxol (6-FPOL), 
shown in Figure 23
Figure 23. Structure of 6-FPOL
The 19F resonance of 6-FPOL was shown to be highly sensitive to pH, with a 
shift of 9.76 ppm between conjugate acid and base, and a pKa of approximately
8.2 at 37°C. This shift appears to be independent of metal ion concentrations. 




blood cells, with an exchange rate sufficiently slow to provide separate 
resonances for intra- and extracellular compartments. A sharp signal is 
observed for each compartment These measurements on red blood cells 
compared favourably with those obtained from 31P NMR (pH,) and pH 
electrodes (pHe). Studies in vivo are currently in progress, however it would be 
expected that the sensitivity of detection may be hindered due to there only 
being one fluorine atom per molecule.
Frenzel et al.9 have recently suggested that 3-(N-(4-fluoro-2- 
trifluoromethylphenyl)sulphamoyl)propanoic acid could be a useful 19F NMR 
pH probe in biological systems. This compound, shown in Figure 24, contains 
a fluorine atom directly attached to the aromatic ring, which is very sensitive to 
changes in pH; 5.3 ppm per pH unit close to the pKa. Also attached to the ring 
is a trifluoromethyl group which was reported to be "almost” unaffected by 
changes in pH, and was used as an internal standard. The pK* was found to be 
7.16 (this is worth comparing with the attempt by Deutsch and Taylor107 to 
modulate the pR* of fluoroanilines, in Figure 22).
CĈ H
Figure 24. Structure of 3-(N-(4-fluoro-2-trifluoromethylphenyl)- 
sulphamoyl)propanoic acid.
As may be appreciated from Figure 24, this compound will be ionised at 
physiological pH. Consequently, the probe was reported to be distributed 
mainly in the extracellular space and thus provides a measurement of pHe. The 
probe was tested by a study of tumour pHe. Both the fluorine signals were 
clearly visible in vivo and provided values which were in good agreement to 
those provided by microelectrodes.
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Finally, Plenio et al.109 reported that the 19F resonance of l-fluoro-2,6- 
bis(methylene-iminodiacetate)benzene, shown in Figure 25, is highly sensitive 
to changes in pH. They suggested that this compound could be used as a pH 
probe. Unfortunately, this compound was originally designed as an indicator 
for metal ions with direct fluorine-metal interactions and is clearly not suitable 
for accurate pH determination in biological systems. However, this does 
highlight an important design consideration for 19F NMR pH probes. That is, 
the pH sensitive fluorine atoms must not be in close proximity to metal 
chelating functionalities. Further, the acid-base functional group must have 
limited interactions with cations other than protons.
Figure 25. Structure of 1 -fluoro-2,6-bis(methylene-iminodiacetate)benzene.
Most of the studies discussed above have been limited to compounds 
possessing only one pH-sensitive atom. This can lead to relatively poor 
sensitivity of detection of the signal Also, many of the examples contained 
fluorine atoms with neighbouring protons. H-F coupling constants are 
generally very large and can be observed as far as five bonds away. Coupling 
will result in splitting of peaks in the 19F NMR spectra and hence, poor SNR102 
Also the use of an internal 19F chemical shift standard directly attached to the 
probe has only recently been investigated9. However, the chemical shifts of 
fluorine atoms in different chemical and magnetic environments will not be 
affected by pH by the same magnitude. Therefore, it is advisable to incorporate 
the reference fluorine atom(s) away from the acid-base centre to ensure pH-
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insensitivity.
There is definitely a need for an accurate and non-invasive method for the 
determination of pHi. The potential of fluorinated compounds to act as pH 
sensors in biological systems has been demonstrated. However, there is clearly 
a lack of understanding of the requirements necessary for the development of a 
pH probe suitable for biological studies. These requirements will be addressed 
in the next chapter.
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CHAPTER FOUR
4. Aims of the Study
The purpose of this study was to design and synthesise fluorine containing 
compounds and to evaluate their potential as 19F NMR pHi sensors for 
biological systems. In order to design a probe of this type, a number of 
requirements must be considered. The following section examines these 
requirements and assesses how they can be met.
(i) Easily detectable in biological systems.
This requires a strong signal in the 19F NMR spectrum with a good signal to 
noise ratio (SNR). The compound must, therefore, have a large number of 
chemically and magnetically equivalent pH-sensitive fluorine atoms. The SNR 
is also improved when the signal is a singlet. To avoid H-F coupling the 
fluorine atoms must be at least 4-5 bonds away from any protons. A slight line 
broadening may also appear if the fluorine atoms are very close to an element 
which has more than one naturally abundant isotope, for example chlorine. The 
isotope effect on 19F resonances can be illustrated with CFCI3, a widely 
accepted 19F NMR chemical shift standard. Careful examination of the 
apparent singlet reveals four peaks in the characteristic pattern also observed in 
mass spectrometry.
(ii) Large sensitivity to changes in pH.
The sensitivity of a 19F resonance to pH is usually related to how close the 
fluorine is to the acicFbase functional group. Many of the probes discussed 
earlier used a single fluorine atom directly attached to an aromatic ring. The 
acid/base group was either a heteroatom in the ring or another substituent. This 
produced a highly pH-sensitive 19F resonance. Unfortunately, using only one 
fluorine atom leads to poor SNR. If trifluoromethyl groups are used there will 
be a loss in pH-sensitivity. However, this may be worthwhile in order to
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increase the SNR and the ease of detection, and thus improve the accuracy of 
measuring a shift. Greater shifts in 19F resonances may also be obtained if 
protonation of the probe results in a large conformational change, for example 
going from an sp3 centre to sp2
(iii) The influence of factors other than pH on the 19F resonance must be 
limited.
19F NMR probes specifically designed to chelate with metal ions have been 
discussed. Examination of these compounds reveals that carboxylic acid groups 
should be avoided.
(iv) pKa values should be close to physiological pH.
Evaluation of a large number of compounds provides information about how 
different functional groups can influence the pKa. This knowledge allows 
strategic selection of suitable synthetic targets and the careful modulation of 
their pK*.
(v) An internal reference for 19 F NMR chemical shift determination.
The incorporation of pH-insensitive fluorine atoms into the probe provides a 
suitable reference peak. That is, fluorine atoms not positioned next to 
acids/base functional groups. It would be preferable if the signal was at a 
distinctly different chemical shift value to that of the pH-sensitive peak. A 
different number of equivalent fluorine atoms would also aid a positive peak 
assignment.
(vi) Good water solubility.
The presence of polar functional groups generally increases water solubility. 
However, groups which may interfere the 19F sensitivity must be placed with 
care. The influence that the functional groups may have on the pKa of the 
probe must also be considered. One possibility is to incorporate a polyether 
chain.
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(vii) An ability to cross a cell membrane and accumulate inside the cell.
To increase cell membrane permeability a careful balance must be made in the 
choice of functional groups with respect to water solubility. If the probe is 
highly ionised it may not be able to penetrate the membrane. It may be useful 
to attach a targetting moiety to the probe. For example, a 2-nitroimidazole 
group would lead to an accumulation of the probe in hypoxic cells.
(viii) Low toxicity.
If the probe has many equivalent pH-sensitive fluorine atoms rather than just 
one, lower concentrations of the probe will be required to reach an adequate 
molar concentration of 19F for detection.
Using these criteria, a series of model probes was designed as synthetic targets. 
Chemical synthesis has been towards azaheterocycles bearing one or more 
trifluoromethyl groups. An important synthetic consideration has been the 
incorporation of a "handle". This could be a point of attachment for linking to 
targetting moieties and pH-insensitive fluorine containing groups. The pKa 




5.1 3,5-Bis(trifluoromethyI)pyrazole and Related Compounds.
5.1.1 3,5-Bis(trifluoromethyI)py razole.
Elguero et a l .m  have investigated the effects of a trifluoromethyl group on the 
acid-base properties of pyrazoles. It was reported that 3,5-bis(trifluoro- 
methyl)pyrazole (2) has an acidic pKa value of 7.51 at 25°C, determined 
spectrophotometrically according to a method described by Ernst and 
Menashi111. This compound has six equivalent fluorine atoms and a pKa value 
close to physiological pH Therefore, it is an ideal candidate for the probing 
nucleus of a 19F NMR pH-sensor. The preparation of 3,5-bis- 
(trifluoromethyl)pyrazole (2) has been reported to have been carried out by 
treatment of l,l,l,5,5,5-hexafluoropentane-2,4-dione (1) with hydrazine 
hydrate under various conditions112,113 and by dipolar cycloaddition of 2-diazo-
1,1,1-trifluoroethane with 3,3,3-trifluoropropyne114. The pyrazole (2) was 
synthesised by the treatment of dione (1) with an equimolar amount of 
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The volatile white solid was obtained in 62% yield. The yield of this reaction 
strongly depends on the distillation procedure, as observed recently by Venanzi 
et al..113. It has been suggested115 that the high volatility of pyrazole (2), 
compared to pyrazoles such as 3,5-dimethylpyrazole, is partly due to the 
weakening of N-H - H hydrogen bonds between two molecules. This is 
supported by experimental and theoretical calculations of their solid and gas 
phase geometries which show interactions between the fluorine atoms and the 
Nl-H (attractive) and the N2 lone pair (repulsive). A possible mechanism for 
the synthetic reaction is illustrated in Scheme 2. The dione (1) is shown here in 
its enol form P-Diketones exist in tautomeric equilibrium between the enol and
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keto forms. It is known116 that electron withdrawing groups increase the 
content of the enol form, while solvents of high polarity will shift the 
equilibrium back slightly towards the keto form. The presence of two 
trifluoromethyl groups in dione (I) will have the greatest influence on the 
equilibrium; thus, the enol is the predominant form under these conditions.
The mechanism proceeds through 3,5-dihydroxypyrazolidine and 5-hydroxy- 
4,5-dihydropyrazole intermediates which have been characterised by Elguero et 
al..ul using special stop-flow NMR techniques. The participation of the N1 
lone pair in the elimination of the second water molecule is supported by the 
isolation of 5-hydroxy-4,5-dihydropyrazoles when the N1 atom is substituted 
by an electron-withdrawing group. The isolation of 5-hydroxy-4,5- 
dihydropyrazoles is a topic of discussion later in this chapter.
The pKa was determined by 19F NMR to be 7.55 at 25°C (see Chapter 8). 4- 
Substituted derivatives of bis(trifluoromethyl)pyrazole (2) would allow the 
attachment of the other necessary ingredients for a pH-probe such as, a 
targetting moiety, groups to increase water solubility in aqueous media and 
pH-insensitive fluorine atoms.
5.1.2 Alkylation of 3,5-Bis(trifluoromethyI)pyrazole.
It was proposed that the 4-position of pyrazole (2) may be activated by 
lithiation, followed by alkylation with a suitable electrophile.
Lithiation of heterocyclic compounds containing an N-H group usually only 
yields the N-lithio derivative118, but when the nitrogen is substituted, C- 
lithiation can often occur. If the N-substituent can later be removed, it serves 
as a protecting group for the N-H, thus maintaining the pK* of the new 
pyrazole close to that of the parent pyrazole. Katritzky et al..m  have reported 
a method for a "one-pot” protection, lithiation and alkylation reaction of
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pyrazole. Formaldehyde was used as a protecting group for the N-H of 























In addition to this, it has been demonstrated by Tanaka et al.119 that lithiation 
of 1 -phenyl-3,5-bis(trifluoromethyl)pyrazole (3) occurs in the 4-position of the 
pyrazole ring as well as in the or//?o-position of the phenyl substituent, as 
shown in Scheme 4
N— N






Combining the methods of Katritzky et al.118 and Tanaka et a/.119, the synthetic
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route illustrated in Scheme 5 was devised. Unfortunately, this reaction 
sequence failed to yield any of the 4-substituted pyrazole (4). It is likely that 
the excess amount of paraformaldehyde and its unsuitability as a protecting 
























Therefore, a "multi-step” synthesis was devised, involving an initial step of 
N-H protection by lithiation and alkylation by the method of Katritzky et al.120, 










Surprisingly, even this simple N-(dialkylamino)methyl protection of the 
electron-deficient pyrazole (2) did not work. Therefore, methods of 
incorporating a 4-substituent into the pyrazole (2) prior to ring closure were
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examined.
5.1.3 Alkylation of l,l,l>5,5,5-Hexafluoropentane-2,4-dione.
If a 4-substituted derivative of the bis(trifluoromethyl)pyrazole (2) is to be 
constructed by a condensation reaction similar to that shown in Scheme 1, then 
modification of the dione would be the next obvious solution.
101A report by Wright and Coville , suggested that 1,1,1,5,5,5- 
hexafluoropentane-2,4-dione (1) may be alkylated with an alkyl halide. Heer122, 
a co-worker, briefly investigated this option. The electron-withdrawing effect 
of the two trifluoromethyl groups of the dione (1) allowed a proton from the 3- 
position to be removed with ease using potassium carbonate. However, the 
resulting anion was so deactivated by the trifluoromethyl groups that it would 
not react with benzyl bromide










An alternative point of disconnection is demonstrated by the retrosynthetic 
analysis shown in Scheme 7. Two possible nucleophiles are suggested in the 
second disconnection steps; a trifluoromethyl ketone anion (route A) and a 
trifluoromethyl enol ether nucleophile (route B).
5.1.4.1 Trifluoroacetylation of Trifluoromethyl Enol Ethers.
The trifluoroacetylation of enol ethers has been reported by Hojo et al.123 using 
trifluoroacetic anhydride (TFAA) and pyridine in DCM at room temperature 
(R.T.), as shown in Scheme 8
RY H RY H
\  /  TFAA \  f
C = C  ----------------- ► C = C  R = aryL alkvi
/  \  pyridine /  Y =O ,SO 2N , 0 0 N
H H D C M  H COCF3
R.T.
Scheme 8
The extension of this reaction to trifluoromethyl enol ethers had not been 
demonstrated. Therefore, this reaction was investigated as a potential route to 
3-substituted derivatives of the dione (1).
Ph Ph R F3C R
_  \ ©  „  N a H /T H F  V  J  O ^ C O ^ H ,  \  /
P h — P — CH2— R  ---------------------►  P h — P = C  ---------------------►  C = C
w /  /  \  /  \
0 1  Ph H C2 HsO H
Scheme 9
The most conventional method of making an enol ether would be from the 
corresponding ketone. However, in 1992, Begue et al.124 reported a more 
direct route to the synthesis of trifluoromethyl enol ethers. The preparation 
involves Wittig reaction of a phosphonium ylide with perfluoroalkyl acid 
derivatives, which in this case meant ethyl trifluoroacetate, as illustrated in 
Scheme 9 The phosphonium ylides can be prepared by treatment of the 
phosphonium salt with a suitably strong, non-nucleophilic base, such as sodium
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hydride in THF. A phosphonium salt can be made from its corresponding
in preference to the bromide salt because it is reputed to be more likely to 
crystallise.
Investigations into this reaction sequence began with a model compound. The 
hydroxy compound chosen for the trial run was 2-(2-methoxyethoxy)ethanol 
(5). Its conversion to the iodo derivative (6) was initially carried out by the 
addition of triphenylphosphine and iodine in the presence of pyridine, as shown 
in Scheme 10










It is currently thought125 that such reactions involve the in situ formation of 
triphenylphosphorus-diiodine (7), which then acts as the halogenating agent, 
Scheme 11.
However, the poor yield (21%) of this reaction was not satisfactory and 
another approach was sought. As suggested in the mechanism of Scheme 11, 
despite the fact that iodide is a relatively efficient nucleophile, it is not able to 
substitute the hydroxy group without activation. Another mode of activation is 
















This was carried out using a method reported by Prugh et a lne. This method 
of tosylation is unconventional in that potassium hydroxide is used rather than 
pyridine. However, the reduced toxicity and the high yield of 94%, suggest it 
could be a useful alternative A simple exchange reaction to the iodo- 
compound (6) was carried out by the Finkelstein reaction, using sodium iodide 
in acetone, with a good yield of 71%.
The conversion of iodo-compound (6) to the phosphonium salt (9) was 
accomplished with triphenylphosphine in toluene. As predicted, the 
phosphonium salt crystallised out and in high yield.
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Running parallel with this trial set of experiments, investigations were carried 
out into suitable protecting groups for a hydroxy function at the non-reacting 
end of the compound. The 2-methoxyethoxymethyl ether (MEM ether) 
protecting group appeared to have ideal characteristics for the reaction 
sequence. It has been reported127 to be stable under a wide variety of 
conditions, including those of reactions attending the use of strong bases, 
reducing agents, organometallic agents, many oxidising agents, and mild acids.
Maintaining the use of compounds containing ether linkages (for enhanced 
water solubility of the pH-sensor compounds) as with the trial compound, 2- 
(2-(2-chloroethoxy)ethoxy)ethanol (10) was chosen as a starting material. 










The result of this reaction was a very small quantity of product (11) and a 
mixture of dimers, as indicated by the NMR spectra. Due to the expense of the 
chlorohydrin (10), another starting material was used in the modification of 
reaction conditions and testing of the purity of the MEMC1 The hydroxy 
function of 3-chloro-1-propanol (12) was protected with a MEM group with 
ease in 98% yield. This was followed by an exchange reaction to the iodo- 
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The moderate yield of the halogen-exchange reaction was explained by the 
NMR spectra, which indicated that some of the MEM protecting group had 
been lost, thus making it unsuitable for our reaction sequence This was 
unexpected, considering the relatively high stability usually associated with this
127protecting group
In a parallel series of experiments, the Wittig reaction was attempted with the 
model phosphonium salt (9), Scheme 15 However, no enol ether (16) was 
isolated The spectra of the recovered material corresponded to the betaine 
intermediate (15), as illustrated in Scheme 15, or another intermediate 
compound with a very similar structure. The suspected intermediate compound 
was redissolved in toluene and heated under reflux for 23 h, but no change was 
observed. Sodium hydride (0.7 equivalents) and hexamethyldisilazane (HMDS) 
(0.05 molar equivalents) were added and heating was continued for 24 h, after 
which there was still no change.
The isolation and identification of an intermediate with a structure related to 
that of the betaine intermediate indicates that the problem does not lie with the 
reactivity of the alkylidene part of the phosphorane towards the carbonyl group 
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Scheme 15
and triphenylphosphine oxide. The only difference between this starting 
material and those described by Begue et al.m , is the presence of an oxygen 
atom close to the reacting centre Assuming that this was in fact the problem, 













(i) A ia 3  / L1AIH4  / ether










Once again, a protected hydroxy function was desired, and the more robust 
benzyl ether group was chosen in preference to MEM ether. 1,3-Propanediol 
(17) was, therefore, a suitable starting place.
Benzyl ether protection of the hydroxy group is usually carried out by rather 
drastic conditions (e.g. PhCH2Cl and KOH at 130-140°C)128 although milder 
conditions are now appearing In the case of diols, most methods produce a 
mixture of mono- and disubstituted derivatives and therefore give lower yields 
and require separation. However, as shown in Scheme 16, the mono-protected 
diol (19) was synthesised exclusively. This was accomplished by first making
66
the acetal (18), 90% yield, followed by reduction with AICI3 / LiAlH* in 
ether129, with a 94% yield. In this reaction the A1C13 acts as a Lewis acid and 
opens-up the acetal, as shown in Scheme 17. The resulting intermediate is then 
reduced by A1H3 (alane) which is formed in situ. The steps to the phosphonium 
salt (22) were carried out as previously described, all with high yields.
A ia 3  
Scheme 17
The Wittig reaction with the phosphonium salt (22) did eventually work after 
modification of the reaction conditions. This involved increasing the amount of 
HMDS to a total of 1.2 equivalents and replacing the THF, after 20 h, with 
toluene to allow a higher reaction temperature. The moderate yield of 46% 
was comparable to those reported by Begue et al.124 for analogous 
compounds, Scheme 18
(i) NaH/HMDS/THF
(ii) CF3 CQ2 C2 H5  / reflux





Following our proposed reaction sequence, the next step involved the
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trifluoroacetylation of the enol ether (23) by the general method of Hojo et 
a/.123, Scheme 19. Unfortunately, even with the addition of 4- 









A possible mechanism for this type of reaction could be that illustrated in 
Scheme 20. When R = H, as with the examples reported by Hojo et al.123, the 
reaction would be expected to work. When R = CF3, as with our examples, the 
electron-withdrawing effect of this trifluoromethyl group results in a decrease 
in the nucleophilicity of the double bond, hence reducing its reactivity towards 











5.1.4.2 Trifluoroacetylation of TrifluoromethyI Ketones
The classical method for the synthesis of l,l,l,5,5,5-hexafluoropentane-2,4- 
dione (1) is a Claisen-type reaction described by Henne et a l m  in 1947. This 
involved the treatment of ethyl trifluoroacetate with sodium ethoxide in ether 
followed by the addition of trifluoroacetone, and is shown in Scheme 21.
O O O Ox  + X ^  X X
F3 < r ^ O C 2 H5  H3 ( T ^ C F 3  ether/reflux
(1)
Scheme 21
We anticipated that a substituted derivative of the dione (1) may be attained by 
replacing trifluoroacetone with a different trifluoromethyl ketone, as illustrated 
in Scheme 22 This could then be cyclised to the corresponding pyrazole with 
hydrazine hydrate in the usual way.
O O O O
+ J I  BASE,  ^
o c 2h 5 reflux f 3c ^  Y  ^ c f
R
Scheme 22
Using a simple method similar to that described by Archer et a l131, 5-methoxy-
l,l,l-trifluoropentan-2-one (27) was synthesised, as shown in Scheme 23. This 
method used relatively harsh reaction conditions and only gave poor yields of 
the trifluoromethylketone (27). Further, the small amount of product (27) 
obtained was eventually lost in additional steps of purification. Consequently, 
another route was sought. The method of Archer et a /.131 was reported in 
1979. Since then, a large number of other methods have appeared in the 
literature and in 1991 a very good and extensive review by Begue and Bonnet-
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Delpon132 was published. Therefore, only the methods actually used in this 
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conc. H2 S0 4  
Yield 67%
H3( X i ^ Sv^ ^ C 0 2 C 2H5
(25)
A selection of newer methods available for the synthesis of trifluoromethyl 
ketones have been investigated All of these methods had some limitations and 
problems were encountered with many.
In 1992, Zard et a/.133 reported a method of synthesising trifluoromethyl 
ketones ffom acid chlorides, which has very recently been updated134 135. The 
reaction involves generation of a ketene ffom the acid chloride, which is then 
trapped with TFAA. Hydrolysis and decarboxylation yields the corresponding 
ketone, as illustrated in Scheme 24 This procedure was applied to 4- 
phenylbutanoic acid, which was converted in situ to its acid chloride using 













Unfortunately, a black tar-like mixture was produced following the "work-up" 
ffom which no trifluoromethyl ketone (28) could be isolated. Zard et al. 133 
reported that their procedure was impractical for the acid chloride of 2 - 
phenylethanoic acid. Together with our result, this indicates that this reaction 
does not tolerate all functionalities.
r ii y ClOOCOCl ----------------- ► r  ir itDCM
X TFAApyridine
Scheme 25
Problems were also experienced using a method reported by Villuendas et 
a / . 136 in 1994. This method involves the lithiation of iodo-compounds with 1.1
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equivalents of ter/-butyllithium followed by treatment with a 
trifluoroacetylating agent. This procedure was tested using l-iodo-3- 
(phenylmethoxy)propane (21), which was synthesised as described earlier. The 





3 : 2 
(ii)CF3 CX)2 C2 H5
Scheme 26
Once again, no trifluoromethyl ketone (29) was isolated. This may be due to 
the presence of an excess of base in the reaction mixture, resulting in lithiation 
on and around the benzyl moiety or possibly proton extraction from the solvent 
(ether). Moreover, the primary organolithium derivative initially formed may 
give rise to an intramolecular cyclisation reaction with the benzyl moiety. 
Therefore, this procedure proved to be unsuitable for our requirements.
The trifluoroacetylation of an ethyl ether followed by decarboxylation was 
described earlier in the synthesis of 5-methoxy-l,l,l-trifluoropentan-2-one 
(27) using the method of Archer et a lm . The yields in this reaction sequence 
were not satisfactory. Therefore, modified reaction conditions were developed 
based on this sequence. A trifluoromethyl ketone with a relatively low volatility 
for subsequent trial reactions was required The ethyl ester (30) of 4- 
phenylbutanoic acid was prepared in the usual way in high yield. The ester (30) 
was trifluoroacetylated using lithium diisopropylamine (LDA) as the base and 
ethyl trifluoroacetate as the trifluoroacetylating agent with a very good yield. 
Decarboxylation of the P-keto ester (31) was carried out using water / lithium 
chloride as described by Langlois et al. 137 The corresponding trifluoromethyl- 









(i) LDA / THF 
-78°C
(ii) CF3  CO2 C2 H5  
THF
-78°C to R.T.






A very versatile method for making trifluoromethyl ketones is described by 
Langlois et a/.137. This involves the C-alkylation of ethyl 4,4,4-trifluoro-3- 
oxobutanoate (ETOB) with an alkyl halide, in which the ketone carbonyl of 
ETOB is masked
The carbonyl function of ETOB was protected as the dioxole (32) by treatment 
with sodium ethoxide followed by 2-chloroethanol in 60% yield The anion 
was formed using LDA in HMPA / THF and an attempt to alkylate with the 















This illustrated that the tosylate was not an adequate leaving group for the 
reaction and that an iodo-derivative was necessary The commercially available 
1 -iodobutane was used to test the reaction. The desired alkylation product (33) 
was obtained in 84% yield, as illustrated in Scheme 29. The carbonyl group 
was deprotected using 1.5 equivalents of boron tribromide in hexane to give 
the p-keto ester (34) in 69% yield. This yield is an estimate from the NMR. 
Enolisation meant that isolation and purification were difficult and, therefore, 
the crude material was carried forward to the next step. Decarboxylation was 
carried out with 1 equivalent of water in the presence of lithium chloride in 
DMF. Isolation and purification were straightforward at this stage and the 
trifluoromethyl ketone (35) was obtained in 13% yield, as shown in Scheme 
29 The low yield was due to the high volatility of the product (bp 80°C).
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f 3< t  ^  ' o c 2 H5
(32)
(35)
(i) LDA / THF
HMPA /  0°C to -78°C
-78°C to R.T. 
Yield 84%
u a  / H2Q 
DMF
Yield 13%










At this stage it was realised that boron tribromide would be unsuitable for the 
deprotection of the ketone in the presence of a benzyl protection group. 
Therefore, a hydrazone protecting group was used for the ketone. The 
dimethylhydrazone (36) of ETOB was synthesised using the method of 
Langlois et al. 137 in 77% yield, as illustrated in Scheme 30.
O O
(CH3 )2 NNH2  
OQjHs C2 H5 OH/ reflux 
Yield 77%




The 2-position of the hydrazone (36) was deprotonated using LDA in HMPA / 
THF and alkylated with the iodo-compound (21) with a good yield of 61%, as 








HMPA / 0°C to -78°C





Deprotection of the ketone was carried out in 81% yield by heating the 
hydrazone (36) with iodomethane in ethanol : water (95 : 5) for 3 days. 
Isolation and purification of the alkylated hydrazone (37) and the P-keto ester 
(38) were difficult, as described earlier for compounds (33) and (34). Column 
chromatography at each stage did "clean-up" the samples enough to allow 
relatively good 19F NMR spectra to be recorded. The peaks obtained were in 
good agreement with those reported by Langlois et al. 137 for compounds with 
different alkyl chains. This meant that the reaction sequence was carried 
through to the trifluoromethyl ketone (39) for complete characterisation. The 
decarboxylation to the trifluoromethyl ketone (39) was carried out using water 




c r ^ o c 2)
(37)
CH3I / C2 H5OH









This method of synthesising trifluoromethyl ketones was shown to be very 
versatile and applicable to compounds containing a variety of functionalities. 
The tumour-selective retention of fluorinated 2-nitroimidazoles has been 
demonstrated by Maxwell et a/.18. We anticipated that the incorporation of a 2- 
nitroimidazole group into the pH-probe will allow the accurate determination 
of pH; in hypoxic cells. To investigate whether or not this functionality may be 
introduced into a trifluoromethylketone, the iodo-derivative (41) was 
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The initial step involved the N-alkylation of 2-nitroimidazole with 1,6- 
dibromohexane. The imidazole was deprotonated using 1 equivalent of 
potassium tert-butoxide in DMF at 130°C. Three equivalents of 1,6- 
dibromohexane were added at ambient temperature followed by further heating 
at 130°C. This procedure gave a 54% yield of the mono-addition product (40) 
The bromo-compound (40) was converted to its iodo-derivative (41) by the 
Finkelstein reaction using sodium iodide in dry acetone, with a high yield of 
93%.
The hydrazone (36) was alkylated with the iodo compound (41), followed by 
deprotection of the ketone and decarboxylation to the corresponding 
trifluoromethyl ketone (44), as described earlier For this example, the 
alkylated hydrazone (42) and the corresponding (3-keto ester (43) were isolated 
with less difficulty and purified to a higher standard but this led to a low yield 
of 23% for the p-keto ester (43). This was partially compensated for by a high 
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Yield 6 6 %
(42)
CH3 I /C 2 H5OH 










Since this work was carried out, a method of deprotecting hydrazones of 
trifluoromethylketones has been reported by Felix et a / . 138 They used 20% 
HC1 aqueous solution in ether. An example is illustrated in Scheme 35. This
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may be a useful alternative to the iodomethane method which was often very 
long and messy.
H a /H 2Q ^  
ether / 16h
Scheme 35
A small quantity of the 2-nitroimidazole trifluoromethylketone (44) was 
selectively reduced to the corresponding alcohol (45) using 0.5 molar 




A number of attempts were made to trifluoroacetylate a trifluoromethyl ketone 
using a variety of reaction conditions Firstly, a set of conditions were derived 
ffom the synthesis of l,l,l,5,5,5-hexafluoropentane-2,4-dione (1) as described 
by Henne et al.130 and was discussed earlier The readily available potassium 
/er/-butoxide was used as the base rather than sodium ethoxide formed in situ 
ffom ethanol and sodium. Ethyl trifluoroacetate was used as the 
trifluoroacetylating agent, ether was used as the solvent and the trifluoromethyl
'N (C H 3 )2
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ketone (39) was used as the substrate, as illustrated in Scheme 37. These 
reaction conditions failed to produce any of the desired (3-diketone (46).
(39)
O
\ \ y  CF3OO2C2H5 





The next attempt used LDA as the base in THF and ethyl thiotrifluoroacetate 
as the trifluoroacetylating agent, as illustrated in Scheme 38. The thio- 
derivative of ethyl trifluoroacetate was used because it contains a more 
efficient leaving group. These reaction conditions were also unsuccessful in 
producing a p-diketone (47)









Finally, the base was changed back to potassium /e/7-butoxide. This was 
because from trifluoroacetylation reactions using LDA as the base, a colourless 
crystalline material was recovered which was had signals in the NMR 
similar to a diisopropylamide and a signal in the 19F NMR consistent with a 
trifluoroacetamide. The high resolution chemical-impact (Cl) mass spectrum 
showed a major (M + H)+ peak at m/z 197.1027, corresponding to the 
molecular formula C8H 14F3NO This suggests that either LDA or non-lithiated 
diisopropylamine reacts with the trifluoroacetylating reagent to produce N,N- 
diisopropyl-2,2,2-trifluoroacetamide. Therefore, to avoid any possible 
interference of the reaction by this side reaction, LDA was avoided Lower 
yields for trifluoroacetylation reactions where LDA was used as the base have 
been reported139. Further, potassium fe/7-butoxide is soluble in THF. Again, 
ethyl thiotrifluoroacetate was used as the trifluoroacetylating agent, as 
illustrated in Scheme 39 Unfortunately, these reaction conditions failed to 
trifluoroacetylate the trifluoromethyl ketone (28)
(28)








5.1.4.3 Reduction of P-(Trifluoroacetyl)vinyI Ethers.
Hojo et a / . 140 described the synthesis of p,P-bis(trifluoroacetyl)vinyl ethers 
(48), as illustrated in Scheme 40 It was anticipated that selective reduction of 
the vinylic double bond may be feasible This would lead to a 3-substituted 
derivative (49) of l,l,l,5,5,5-hexafluoropentane-2,4-dione (1) which could
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then be cyclised with hydrazine hydrate to the corresponding pyrazole (50). 
Furthermore, the ether group of pyrazole (50) is benzylic to the pyrazole ring. 
Therefore, if necessary, this bond may be cleaved by catalytic hydrogenation 












To investigate the potential of this reaction sequence, 3,4-dihydro-2//-pyran 
(51) was trifluoroacetylated with TFAA and pyridine in DCM, as shown in 
Scheme 41. The 97% yield of this reaction is notably higher than that reported 
by Hojo et a l Hl.
The trifluoroacetylpyran (52) was used as a model compound of p,p- 
bis(trifluoroacetyl)vinyl ethers (47), noting that the reduction potential of the 





Three possible outcomes of the reduction of pyran (52) are illustrated in 
Scheme 42; the desired product from mono-reduction of the vinylic bond (53), 












Hydrogenation of carbonyl groups to the corresponding alcohol is usually 
carried out under mild conditions over platinum, Raney nickel or ruthenium. 
Therefore, these catalysts were not investigated. Hydride reducing agents such 
as LiAlH* and NaBHi were also avoided Conversely, palladium is generally 






group of enones has also been reported142.
Various conditions under which 10% palladium on activated charcoal was used 
are listed in Table 2, together with other methods to be discussed later.
Method Result
(a) Pd / C, H2 / CH3OH / R T (55) in 98% yield
(b) Pd / C, H2 / hexane / THF / R T (55) in 100% yield
(c) Pd / C, H2 / CH3OH / -78°C to -0°C (55) in 100% yield
0 0 Pd / C, H2 / CH3OH / CH3C 02K / R T (55) in 76% yield
(e) Bu3SnH / Cul / LiCl / THF / N2 starting material (52) recovered
( 0 aqueous TiCl3 starting material (52) recovered
Table 2
Firstly, a general reduction in methanol at ambient temperature was carried 
out, entry (a) After 4 h, none of the starting material (52) was visible by t l.c 
Under these conditions, both the vinylic double bond and the carbonyl group 
were reduced to give the alcohol (55) in 98% yield. Under these conditions, 
the reduction of a ketone would not be expected to occur142. If the first step of 
this double reduction involves the reduction of the vinylic double-bond to give 
ketone (53), then enolisation may occur, followed by further reduction. Thus, a 
second reduction could effectively remove the ketone functionality to give the 
alcohol (55). This mechanism is illustrated in Scheme 43. Further, the NMR 
spectra showed the presence of both diastereoisomers of alcohol (55) 
Hydrogenation of an unsaturated compound takes place by adsorption of the 
compound onto the catalyst surface, followed by transfer of hydrogen from the 
catalyst to the molecule which is adsorbed onto it. When two functionalities 
are being reduced, there are two possible mechanisms, (i) The compound may 
be adsorbed onto the catalyst, during which both of the functionalities are 
reduced, (ii) The compound may be adsorbed onto the catalyst and one of the 
two functionalities is reduced, followed by desorption and then readsorption to
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reduce the second functionality. This information together with the NMR data 








Attempts were made to reduce the amount of enolisation and to allow the 
isolation of the desired ketone (53). To investigate the effects of solvent 
polarity on the extent of enolisation, a similar reaction was carried out in 
hexane, using a small amount (5%) of THF to aid solvation, entry (b). This 
produced the alcohol (55) in quantitative yield and in only 0.5 h.
The effect of temperature on the degree of enolisation was also investigated, 
entry (c). It was anticipated that lowering the temperature of the reaction 
mixture would reduce the rate of enolisation of the ketone (53) and allow the 
isolation of the ketone or, at least, allow the intermediate to be viewed by t .l.c.. 
The reaction was begun at -78°C and maintained at this temperature for 3 h, 
after which t.l.c. indicated mostly starting material (52) together with a 
material with the same Rf value as the alcohol (55). The temperature of the 
reaction mixture was allowed to rise in 10°C increments over a 3 h period, 
however, t.l.c. indicated little change until -10°C was reached. No other spots 
appeared on the t.l.c plate during this period and after 0.5 h at -10°C, t.l.c.
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indicated that there was no starting material (52) left. From the reaction 
mixture was isolated the alcohol (55) in quantitative yield.
The effect of the presence of potassium acetate on the selectivity of a reduction 
with Pd / C was briefly investigated. This approach also proved to be 
unsuccessful and the alcohol (55) was isolated in 76% yield, entry (d).




Another method of selective reduction investigated was with low-valent 
titanium species Titanium ( hi) ,  conveniently available as TiCl3, is a mild 
reducing agent in aqueous solution143,144 The reagent has found particular use 
in the selective reduction of ene-diones, as illustrated in Scheme 44. Reactions 
such as those illustrated are usually complete within 0.25 h at ambient 
temperature However, these conditions do not work for diesters, presumably 
because of the more negative reduction potential of esters versus ketones145. In 
the case of the trifluoroacetylpyran (52), the a,P-unsaturated ketone portion of 
the compound favours this reaction, but the enol ether portion does not. The 
treatment of the trifluoroacetylpyran (52) with aqueous TiCl3 resulted in the 
recovery of the starting material, entry (f) in Table 2. This suggests that the
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reduction potential of the trifluoroacetylpyran (52) is too negative for these 
conditions
The selective reduction of a,P-unsaturated ketones has been reported146 using 
in situ generated hydridocuprates. The trifluoroacetylpyran (52) was treated 
with a mixture of BU3 S11H, Cul and LiCl in DMF, however, only starting 
material was recovered, entry (e). The active reagent formed from this 
combination of reagents is thought to be a hydridohalocuprate species (56) 
arising as shown in Scheme 45146
Cul + Bu3SnH -----— ------ ► X(H)CuU + Bu3SnX
(56)
X = Cl, I
Scheme 45
5.1.4.4 Synthesis of 3-(Dimethylaminomethylene)-l,l»l»5,5,5-hexafluoro-
2,4-dione and Related Compounds.
°v P  °v P  ^ / /  V /'s' 's' Ov O Ov O





Rf — CF3 , C4F9
R R'
Scheme 46
The reason for the failure of attempted C-alkylations of 1,1,1,5,5,5- 
hexafluoropentane-2,4-dione (1) was attributed to the high stability of the 
easily formed anion due to the strong inductive effect of the two 
trifluoromethyl groups. Hannock et al. 147 reported a similar problem with the 
reaction of bis(perfluoroalkanesulphonyl)methanes (57) with aldehydes and
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ketones (58), as illustrated in Scheme 46
This problem was recently addressed by Zhu148. It was reported that 
bis(perfluoroalkanesulphonyl)methanes (57) may be condensed with aromatic 
aldehydes (59) in acetic anhydride to give 1 -aryl-2,2-bis(perfluorosulphonyl)- 
ethylenes, as shown in Scheme 47. Furthermore, it was demonstrated148 that 
the carbon-carbon double bond in the condensation product (60) is very polar 
due to the strong electron-withdrawing groups. This should allow the addition 
of a nucleophile. So far, this has been demonstrated using dimethylphosphite as 
the nucleophile in benzene, Scheme 47.
O O O O
V / V /
r /  V  >  Ov O 0 ^ 0
(57) Ac20
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It was anticipated that l,l,l,5,5,5-hexafluoropentane-2,4-dione (1) would 
condense with carbonyl compounds in a similar fashion to the bis-sulphonyl 
compounds (57) and subsequently undergo addition reactions with 
nucleophiles. This should lead to a 3-substituted derivative of dione (1) which
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could then be cyclised with hydrazine hydrate to the corresponding pyrazole.
It was noted from the work of Zhu148 that the presence of an electron- 
withdrawing substituent in the 4-position of the aromatic ring led to lower 
yields of the condensation product (60). The carbonyl group of 
dimethylformamide (61) is relatively electron rich due to the positive 
mesomeric effect of the dimethylamino group. Therefore, to examine the 
required electrophilicity of the carbonyl compound, an equimolar mixture of 
the dione (1 ) and dimethylformamide (61) were heated in acetic anhydride for 
16 h A low melting yellow solid was isolated from the reaction mixture, which 
was shown to be 3-(dimethylaminomethylene)-1,1,1,5,5,5-hexafluoropentan-
2,4-dione (62). The condensation product (62) was obtained with an excellent 
yield of 95% and the reaction is illustrated in Scheme 48
A possible mechanism for the reaction is illustrated in Scheme 49 An extensive 
NMR study has been carried out on the dione (62). The NMR data suggest 
that the structure of the condensation product (62) is closer to that of 
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The NMR spectrum at 20°C in (CD3 )2 SO showed two sharp singlets at 
2.78 and 3.54 ppm, corresponding to the two methyl groups. At 100°C, these 
signals became very broad and moved together slightly to resonate at 2.84 and 
3 .51 ppm. When 150°C was reached, the signals coalesced into a broad singlet 
resonating at 3.05 ppm. These data are illustrated in the lH NMR spectra 
shown in Figure 26. As can be seen, there is an impurity visible in the *H NMR 
spectra The samples examined at high temperature were also examined at 
ambient temperature before and after raising the temperature. This was to 
evaluate the effects of high temperatures on the dione (62) when dissolved in 
(CD3)2 SO. This indicated no significant further decomposition. It appears that 
the dione (62) may be sensitive to moisture, as reported by Zhu148 for the 
sulphonyl analogues (60). It would have been interesting to evaluate the 
potential of this compound to act as a 19F NMR pH-sensor. Unfortunately, this 
was not possible due to its moisture-sensitivity.
The 19F NMR spectrum of dione (62) at 21°C in CDC13 showed a sharp singlet
at -73.39 ppm. At -50°C, the singlet broadened and resonated at -72.94 ppm. 
In c/g-THF at 20°C, the sharp singlet was observed at -73.16 ppm. c/«-THF 
allowed the NMR to be run at -90°C, where the signal became very broad and 
resonated at -72.6 ppm. These data are illustrated in the 19F NMR spectra 
shown in Figure 27.
These data show that rotation about the newly formed carbon-carbon bond of 
the dione (62) is less restricted than rotation about the C-N(CH3)2 bond. A 
temperature of 150°C was required before the two separate signals for the two 
methyl groups would coalesce. If this is taken to be the coalescence 
temperature (Tc), then the free energy for the activation for the rotation (AG*) 
may be calculated using Equation 3149. Where, Tc is expressed in Kelvin, R is 
the gas constant and Av is the frequency separation of the individual sharp lines 
at ambient temperature.
AG* = R.Tc [23+ln(Tc/Av)]
Equation 3
Thus, the free energy of activation for the rotation about the C-N(CH3)2  bond 
in dione (62) is approximately 81.92 Umol'1. It may also be assumed that the 
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Figure 26 *H NMR spectra of dione (62) at 20.5°C (A), 100°C (B) and 150°C
(C).
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(a) 4-(CF3)C6H4 H acetal (66)
(b) 3-(CF3)C6H4 H acetal (66)
(c) CH3(CH2)8 H acetal (66)
(d) C6H5(CH2)2 H acetal (66)
(e) C6H5CH20(C H 2)3 H acetal (66)
(0 4-(C6H4CH20 )C 6H4 H mixture
(g) c6h 5s H mixture
(h) c6h 5 c f3 acetal (66)
Table 3
The general reaction illustrated in Scheme 50 was attempted with a variety of 
carbonyl-containing compounds (64), as listed in Table 3. Two major possible 
outcomes of the reaction could be the formation of the desired condensation 
product (65) or the formation of the corresponding acetal (6 6 ). Most of the 
carbonyl compounds (64) were chosen for testing the limitations of the 
reaction.
If a trifluoromethyl-containing aromatic group could be incorporated into the 
dione adduct (65), then it would serve as a relatively pH-insensitive reference
peak in the 19F NMR spectrum. From the treatment of 1,1,1,5,5,5- 
hexafluoropentane-2,4-dione (1) with 4-trifluoromethylbenzaldehyde in acetic 
anhydride was isolated a compound containing only one trifluoromethyl signal 
in the 19F NMR spectrum and a NMR spectrum which suggested that the 
acetal (66) had formed, entry (a) in Table 3. The trifluoromethyl group in 3- 
trifluoromethylbenzaldehyde should have less of an electron-withdrawing effect 
on the aldehyde. However, this also led to the isolation of its corresponding 
acetal (66) under the same reaction conditions, entry (b).
Aliphatic aldehydes were also examined, entries (c-e) in Table 3 These 
compounds also failed to condense onto the dione (1), as indicated by their 19F 
NMR spectra. Once again, the corresponding acetals were shown by the 'H 
NMR spectra. The aliphatic aldehyde for entry (e) was synthesised by the 
mono-benzylation of 1,4-butanediol (67), followed by a Swem150 oxidation of 
the alcohol (68) to the aldehyde (69), both with very good yields, as illustrated 
in Scheme 51. Swem oxidations involve the use of an activated DMSO 
reagent The most popular activator of DMSO is oxalyl chloride and the 
suitability of this reagent for the conversion of alcohols to aldehydes was 













The more electron-rich carbonyl group of 4-benzyloxybenzaldehyde showed a 
much higher reactivity towards the dione (1), entry (f). The reaction mixture 
was carefully distilled and the *H NMR spectra of the fractions did not show 
the presence of the corresponding acetal (66). The 19F NMR confirmed that the 
aldehyde had reacted with the dione (1), but showed a mixture of adducts. The 
mixture was examined by t.l.c. using a large number of solvent systems. 
However, most of the compounds were present as streaks. An attempt was 
made to separate the mixture by column chromatography, but no individual 
compound could be isolated. Closer inspection of the *H and 19F NMR spectra 
suggested that a condensation reaction had occurred between the aldehyde and 
the dione (1), together with intramolecular cyclisation reactions involving the 
benzyl groups.
2-Thiophenecarboxaldehyde also reacted with the dione (1), entry (g). The JH 
NMR spectra of the distillation fractions did not indicate the presence of an 
acetal (66). The 19F NMR spectra confirmed that a reaction had taken place, 
but showed the presence of a large number of adducts. Unfortunately, the 
mixture could not be separated by distillation or chromatography.
Finally, the reactivity of trifluoroacetophenone was examined, entry (h). This 
failed to react with the dione (1), as shown by 19F NMR, and the NMR 
spectrum indicated the presence of the corresponding acetal (66).
5.1.5 The Reaction of 1,14*5*5,5-Hexafluoropentane-2,4-dione with
Substituted Hydrazines.
McCleverty et a l ul have reported the synthesis of 3,5-bis(trifluoromethyl)- 
pyrazole (2). In the same report, the synthesis of 1-aryl and l-aroyl-3,5- 
bis(trifluoromethyl)pyrazoles (76-79) was claimed by the reaction of 
substituted hydrazines (70) with l,l,l,5,5,5-hexafluoropentane-2,4-dione (1) in
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boiling ethanol. Since it is difficult to rationalise the spectroscopic data 
reported112 with the aromatic pyrazole claimed, and there are reports117,151 that 
5-hydroxy-4,5-dihydropyrazoles are often isolated when the nitrogen atom is 
substituted with an electron-withdrawing group, a re-investigation of the 
reaction of dione (1) with hydrazines (70) was undertaken, as illustrated in 
Scheme 52.
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(71): R = H
(72): R = 4 4 NQ2 )C6 H4  ; Yield 99%
(73): R = Q F5 ; Yield 98%
(74): R = PhCO; Yield 99%





(2): R = H ; Yield 62%
Scheme 52
The synthesis of 3,5-bis(trifluoromethyl)pyrazole (2) from the treatment of 
dione (1) with hydrazine hydrate in boiling ethanol was discussed earlier. The 
NMR is consistent with an aromatic pyrazole structure. The 4-H atom gives 
a resonance at 6.95 ppm, which is slightly broadened by coupling to fluorine. 
Only one 19F NMR signal is evident in pyrazole (2), owing to rapid site
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exchange of the NH proton. The electron-impact (El) mass spectrum of this 
pyrazole shows an abundant molecular ion at m/z 204, with no evidence of ions 
at higher mass (e.g. m/z 222 for the hydroxydihydropyrazole structure).
However, the NMR spectra of the heterocycles formed from dione (1) and 
the substituted hydrazines (70) showed no signal in the region expected for the 
4-H atom of an aromatic pyrazole (5.8-7.2 ppm)152,153. McCleverty et a l n2 
also report no signals in this region but claim that 4-H resonates at 
approximately 3.6 ppm; no integral or multiplicity data were given. The 
extensive study by Tensmeyer and Ainsworth153 of substituent effects on the 
chemical shifts of pyrazoles does not support this assignment. In our work, the 
signals in the region 3-4 ppm comprised two doublets, the integral of each 
doublet corresponding to one proton. The coupling constants between these 
doublets were >14 Hz, typical values for geminal coupling. Thus these signals 
can be assigned to a prochiral CH2 group in an asymmetric environment. Broad 
resonances due to OH were also observed. On the bases of these data, the 
hydroxydihydropyrazole structures (72-75) are proposed rather than the 
pyrazoles (76-79) claimed112.
The El mass spectra of the 5-hydroxydihydropyrazoles (72-75) at 70 eV 
ionisation energy revealed abundant molecular ions. The molecular ion of 1- 
benzoyl-3,5-bis(trifluoromethyl)-4,5-dihydro-5-hydroxypyrazole (74) was 
present in the El spectrum only at 1% abundance but abundant ions were 
observed at m/z 326 (M) in the Cl spectrum and at m/z 327 (M + H) in the 
positive ion fast atom bombardment (FAB) spectrum. Dehydration was not 
favoured (giving M - 18) but loss of CF3 gave highly abundant peaks at (M - 
69) in all cases. The reported interpretation112 of similar data, representing the 
ions at highest mass as molecular clusters of (pyrazole + H20), is unlikely 
under El conditions.
Various conditions for the dehydration of 5-hydroxy-4,5-dihydropyrazoles (72-
99
75) to the corresponding pyrazoles (76-79) were investigated. Dehydration of
3,5-bis(trifluoromethyl)-4,5-dihydro-5-hydroxy-1 -(4-nitrophenyl)pyrazole (72) 
was achieved by treatment with a small quantity of acid in boiling ethanol for 4 
days This method proved to be very effective for this example and the 
corresponding pyrazole (76) was obtained in high yield, as illustrated in 
Scheme 53. The presence of the acid will favour the protonation of the 






For 3,5 -bis(trifluoromethyl)-4,5-dihydro-5 -hydroxy-1 -(pentafluorophenyl)-
pyrazole (73), the presence of acid did not lead to dehydration. Therefore, an 
alternative method was investigated involving a better leaving group. The 
hydroxypyrazole (73) was treated with acetic anhydride and acetic acid under 
reflux for 16 hours The corresponding pyrazole (77) obtained in good yield, as 
illustrated in Scheme 54. These reaction conditions led to the conversion of the 












For the dehydration of 1 -benzoyl-3,5-bis(trifluoromethyl)-4,5-dihydro-5- 
hydroxypyrazole (74), relatively non-nucleophilic conditions are required. 
Consider the mechanism illustrated in Scheme 55.
The ability of a nucleophile to attack the carbonyl group is affected by the pKa 
of the resulting anionic leaving group. The pKa of 3,5-bis(trifluoromethyl)- 
pyrazole (2) is 7.55 at 25°C (see Chapter 8 ). This value may be compared to p - 
nitrophenol, which is known to be a good leaving group and has a pKa value of 
7.15 . It was anticipated that formation of the mesylate of hydroxypyrazole (74) 
would allow dehydration to occur, without elimination of the pyrazole. Thus, 
hydroxypyrazole (74) was treated with triethylamine and methane 
sulphonylchloride in DCM, as illustrated in Scheme 56. A large mixture of 
products was obtained, but none of the corresponding acylpyrazole (78) was 
isolated. It is likely that the acylpyrazole (78) may have been made but was 
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However, similar reaction conditions did lead to the dehydration of 3,5- 
bis(trifluoromethyl)-4,5-dihydro-1 -(2,4-dinitrophenyl)-5-hydroxypyrazole (75) 
to the corresponding pyrazole (79), as illustrated in Scheme 57.
MsQ/tQHs^N
DCM




5.2.1 4-Alkyl-3(5)-T rifluoromethylpy razoles.
In Section 5.1.4.3, the synthesis of 5-trifluoroacetyl-3,4-dihydro-2//-pyran (52) 
by the trifluoroacetylation of 3,4-dihydro-2//-pyran was described and is 
illustrated in Scheme 41. It was observed that trifluoroacetylpyran (52) 
contains a masked 1,3-diketone Condensation of trifluoroacetylpyran (52) 
with hydrazine hydrate produced 3-(trifluoromethyl)pyrazole-4-propanol (80) 
in high yield, as illustrated in Scheme 58 Furthermore, this condensation
revealed a co-hydroxyalkyl function as a leaving group, thus obviating the need
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for earlier introduction and possible protection of the hydroxy group. The 
trifluoromethylpyrazole (79) has a single resonance peak in the ,9F NMR which 
is sensitive to pH. The pKa value was determined by 19F NMR to be 12.07 at 
25°C (see Chapter 8 ). To ensure that the hydroxy group could be derivatised 
without interference from the pyrazole, the corresponding benzoate ester (81) 


















Since this work was carried out, Tang and Hu154 have reported the synthesis of 
3-(trifluoromethyl)pyrazole-4-propanol (80) by the addition of the expensive 
iodopentafluoroethane across the enol ether of 3,4-dihydro-2//-pyran, in the 
presence of sodium dithionitrite, and treatment of the pentafluoroethyl- 
tetrahydropyran with hydrazine.
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It was anticipated that 3-trifluoroacetyl-4,5-dihydrofuran (82) would undergo a 
condensation reaction with hydrazine hydrate, analogous to that performed by 
5-trifluoroacetyl-3,4-dihydro-2//-pyran (52). The trifluoroacetylfuran (82) was 
synthesised by the treatment of 2,3-dihydrofuran with TFAA and pyridine in 
DCM. However, treatment of the five-membered ring compound with 
hydrazine did not give the expected pyrazoleethanol (84) directly. Under 
essentially the same conditions as described for trifluoroacetylpyran (52), a 
quantitative yield of the dimer (83) was formed. In this dimer, one molecule of 
the fully condensed aromatic pyrazole (84) has intercepted another molecule 
where the elimination of water from the intermediate is not complete. It is 
noteworthy that no material could be isolated where ethanol, rather than the 
pyrazoleethanol (84), has reacted as the incoming nucleophile, despite the 
much higher concentration of the former The dimer (83) readily formed the 
target trifluoromethylpyrazole (84) upon reflux in the presence of a trace of 












H (84) H H (83)
Scheme 59
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In a control experiment, it was demonstrated that pyrazole (84) was not 
converted into the dimer (83) under the condensation conditions. This indicates 
that the dimer had not been formed from two molecules of the 
trifluoromethylpyrazole (84). The pKa value of trifluoromethylpyrazole (84) 
was determined by 19F NMR to be 11.97 at 25°C (see Chapter 8).
5.2.2 3-Alkyl-5-Trifluoromethylpyrazoles.
In an approach to 3-alkyl-5-trifluoromethylpyrazoles, ring formation from 
hydrazine and an a,p-acetylenic ketone was investigated. In this case, it was 
not possible to design a process in which the hydroxyalkyl group was revealed 
during the condensation reaction and it was necessary to assemble an 
appropriate trifluoromethyl ketone containing the alcohol in a protected form. 
Butan-3-ynol (85) was protected as its TBDPS ether (86), essentially by the 
method of Delome et a/.155. This allowed formation of the acetylenic carbanion 
by treatment with butyl lithium at low temperature. Addition of 2,2,2- 
trifluoroethyl trifluoroacetate as the electrophile afforded the TBDPS- 
protected acetylenic trifluoromethylketone (88) in high yield. Other 
electrophilic trifluoroacetylating agents, such as trifluoroacetic anhydride, ethyl 
trifluoroacetate and ethyl thiotrifluoroacetate were considerably less effective. 
Condensation of this ketone (88) with hydrazine hydrate formed the TBDPS- 
protected pyrazole-5-ethanol (90) in virtually quantitative yield. Unexpectedly, 
however, it proved impossible to remove the silyl protecting group with 
fluoride under any conditions under which the product hydroxyethylpyrazole
(92) could be isolated, as illustrated in Scheme 60. Repetition of the sequence 
using O-benzyl-protection was more successful. The alcohol (86) was 
benzylated, essentially by the method of Johnson et a l 156, to give the ether 
(87). As before, formation of the acetylenic anion and trifluoroacetylation, with
2,2,2-trifluoroethyl trifluoroacetate, gave the ketone (89) in very high yield. 
Condensation with hydrazine hydrate in boiling ethanol afforded the protected
3,5-disubstituted pyrazole (91). Exposure of the hydroxy group was effected
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by hydrogenation under acidic conditions to afford the target 
trifluoromethylpyrazoleethanol (92) with substituents in the desired 3,5- 
arrangement, as illustrated in Scheme 60 The pKa value of 
trifluoromethylpyrazole (92) was determined by 19F NMR to be 12.79 at 25°C 
(see Chapter 8 ).
The reaction sequences towards the synthesis of 4-substituted-3,5- 
bis(trifluoromethyl)pyrazoles were generally unsuccessful. The deactivating 
nature of a trifluoromethyl group was a hindrance in many of the reactions. 
The condensation reactions of carbonyl compounds with 1,1,1,5,5,5- 
hexafluoropentane-2,4-dione (1) were carried out towards the end of this study 
and are probably the most promising development towards the synthesis of a
3-substituted derivative of dione (1). The synthesis of trifluoromethylpyrazoles 
has been much more successful. Convenient and generally high yielding 






(85): R = H
(8 8 ): R = Bu' Ph2Si Yield 95%
(89): R = Bn Yield 97%
i, Buf Ph2 SiCL, inidazole, DMF 
Yield 100%
ii, PhCH2 Br, NaH. DMF 
Yield 75%
N2H4.H20 
C ^ O l  / reflux
Pd/C, H2  
HQO4 / MeQH




(90): R =Buf Ph2Si Yield 99%




6. 2-(Trifluoromethyl)benzimidazoles and 2-(Trifluoromethyl) 
imidazopyridines.
Smith et al. 157 have reported the synthesis of 2-(trifluoromethyl)benzimidazole
(93) from the condensation reaction of the corresponding diamine with 
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The acidic pK* value of 2-(trifluoromethyl)benzimidazole (93) was reported 
to be 8.13. This value is too alkaline to act as a pH sensor in biological 
systems. It was anticipated that inclusion of a fluorine atom or a 
trifluoromethyl group into the benzene ring may lower the pKa value closer to 
the physiological pH range Smith et a l 157 described the synthesis of 5-fluoro- 
2-(trifluoromethyl)benzimidazole (94) by the condensation reaction of the 
corresponding diamine with TFA in the presence of aqueous dilute acid. 
They157 obtained the benzimidazole (94) with a low yield (32%). A much 
improved set of reaction conditions for the synthesis of the benzimidazole (94) 
and related compounds has been devised.
4-Fluorobenzene- 1,2-diamine was heated with TFA under reflux for 5 days 
The excess TFA was removed by evaporation. *H and 19F NMR indicated the 
presence of partial condensation products. Therefore, the crude material was 
sublimed at high temperature to complete the condensation. This 
straightforward method produced 5-fluoro-2-(trifluoromethyl)benzimidazole
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Using similar reaction conditions, 2,5-bis(trifluoromethyl)benzimidazole (95) 






Unfortunately, both of these benzimidazoles (94, 95) were insufficiently soluble 
in aqueous media to allow determination of the pKa values by 19F NMR.
It was predicted that 2-(trifluoromethyl)imidazopyridines may have appropriate 
pKa values and have better solubilities in water. 2-(Trifluoromethyl)imidazo- 
[4,5-6]pyridine (96) and 2-(trifluoromethyl)imidazo[4,5-c]pyridine (97) where 
synthesised by condensation of the corresponding diamine with TFA. Once 
again, pyrolysis was necessary to complete the elimination and both 
compounds were obtained in very high yield, as illustrated in Scheme 64. As 
predicted, both compounds were sufficiently soluble in aqueous media to allow 
















Doherty159 reported briefly the synthesis of 2,6-bis(trifluoromethyl)imidazo- 
[4,5-£]pyridine (99), as illustrated in Scheme 65.
TFA / reflux
> r ^ N H





They159 implied that the mono-trifluoroacetylated intermediate (98) is isolated 
before pyrolysis in aqueous acid to form the imidazopyridine (99).
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A high yielding set of reaction conditions have been developed for the 
synthesis of 2-(trifluoromethyl)benzimidazoles and 2-(trifluoromethyl)- 
imidazopyridines. The pK« values of the imidazopyridines (96, 97) are very 
promising. Furthermore, both sets of compounds have many positions available 
for attachment of other substituents, such as groups to modulate the pKa value 
and groups to increase the solubility in aqueous media. Therefore, 2- 
(trifluoromethyl)benzimidazoles and 2-(trifluoromethyl)imidazopyridines are 
ideal candidates for further development as 19F NMR pH-sensors. It is 
unfortunate that this work was carried out towards the end of the study.
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CHAPTER SEVEN
7. Triazoles, Imidazoles and Pyrroles.
7.1 Triazoles.
A 1,2,4-triazoie bearing trifluoromethyl groups in the 3- and 5-positions would 
provide a symmetrical compound with 6  fluorine atoms which would be 
equivalent in the 19F NMR spectrum. A fimctionalised substituent could occupy 
the N-4 position without affecting the symmetry. The synthesis of symmetrical
3,5-bis(trifluoromethyl)-4-alkyl-l,2,4-triazoles has been described by Reitz and 
Finkes160. The technique involves the synthesis of 2,5-bis(trifluoromethyl)-
1,3,4-oxadiazole (101) from the corresponding diacylhydrazine (100), followed 
by condensation with a suitable amine. In a modification of the technique used 
by Reitz and Finkes160, l,2-bis(trifluoromethyl)hydrazine (100) was cyclised to 
form the oxadiazole ( 1 0 1 ) in good yield by dehydration with phosphorus 
pentoxide at high temperature, as illustrated in Scheme 6 6  The pyrolysis is 
carried out without the use of solvent. Therefore, it is essential that the 
reactants are intimately mixed.
O O
(i) N 2H4.H20  II H
f , c ^ o c 2 h 5  c 2 h 5 o h / k 2 c o ,  ^
(ii) TFA / TFAA
Yield 94%
Scheme 66
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Other methods for the synthesis of oxadiazoles from the corresponding diacyl 
hydrazines have been reported161,162. The use of SO3 (in oleum) as the 
dehydrating agent has been described by Vasilier et al.161. Milder conditions 
have been reported by Sitzman et al.162 for the synthesis of SF5 containing
1,3,4-oxadiazoles, which should be applicable to trifluoromethyloxadiazoles. 
These conditions involve dehydration with either phosphorus pentachloride and 
/ or phosphorus oxychloride in refluxing DCM. The techniques described 
above avoid the use of high temperatures. This may be desirable in the 
presence of certain functional groups.
As with all fluorinated heterocycles in this report, it was desirable to introduce 
a functionalised substituent into the triazole. At first, a condensation reaction 
between the oxadiazole (101) and unprotected 2 -(2 -aminoethoxy)ethanol (102) 
was attempted This resulted in the isolation of N-(2-(2-hydroxyethoxy)ethyl)-
2,2,2-trifluoroacetamide (104) rather than the desired triazole (103), as 
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It is likely that acetamide (104) was produced from the reaction of the amine
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with TFA (either residual or a decomposition product). To avoid possible 
interference in the reaction from the hydroxy group, an O-protected 
hydroxyalkylamine was synthesised. Once again, the relatively robust benzyl 
protection group was chosen. 3-Benzyloxypropylamine was synthesised from 
the mono-O-benzyl-protected propane-1,3-diol (19). Activation of the alcohol 
as the tosylate (20) was achieved as described earlier and illustrated in Scheme 
16. Substitution with the anion derived from trifluoroacetamide served to 
introduce the nitrogen atom, giving N-(3-(phenylmethoxy)propyl)-2,2,2- 
trifluoroacetamide (105) in very high yield. Selective hydrolytic deprotection 
under basic conditions afforded the required O-benzyl-protected 








Yield 6 6 %
Scheme 6 8
The amine (106) was condensed with the oxadiazole (101) with a yield which 
is comparable to those reported by Reitz and Finkes160 for other 4-substituted
3,5-bis(trifluoromethyl)-l,2,4-triazoles. Exposure of the hydroxy group was 
effected by hydrogenation under acidic conditions to afford 3,5- 
bis(trifluoromethyl)-4-(3-hydroxypropyl)-4//-1,2,4-triazole (108) in high yield, 
as illustrated in Scheme 69
F3C
N—N
J i  V  
( 101)








Triazole (108) gave a single resonance peak in the 19F NMR spectrum. The 
position of the peak was sensitive to pH, but only over a very narrow chemical 
shift range. Furthermore, the pKa of the conjugate acid was estimated to be 
approximately 4, which is too acidic for the pH-sensor requirements (see 
Chapter 8 ).
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A mono-trifluoromethyltriazole could have a more appropriate pKa value and 
may show a greater sensitivity in its 19F chemical shift to pH (c.f the greater 
pH-sensitivity shown by mono-(trifluoromethyl)pyrazoles (80, 84, 92) 
compared to bis(trifluoromethyl)pyrazole (2)). The synthesis of a 
trifluoromethyltriazole was briefly investigated towards the end of this study. 
Unsymmetrical 1,2,4-triazoles are commonly made by thermal condensation of 
an acylhydrazine with a (thio)amide (the Pellizzari reaction) 163 or by 
condensation of a diacylamine with hydrazine (the Einhom-Brunner 
reaction)164. It was anticipated that the synthesis of trifluoromethyltriazole 
(111) could involve the reaction of trifluoroacetylhydrazine (109) with 
thiobenzamide (1 1 0 ), as illustrated in Scheme 70. Unfortunately, none of the 
desired triazole (1 1 1 ) was isolated under these conditions.













An imidazole bearing a trifluoromethyl group in the 2-position and a 
functionalised substituent in the 5-position was required for evaluation as a 19F 
NMR pH-sensor. The synthesis of 2-trifluoromethylhistamine (114) has been
reported by Cohen et a / . 165 involving Bamberger cleavage of histamine (112), 
followed by cyclisation with boiling TFAA and acid-catalysed hydrolysis of the 
side chain benzamide. Cohen et a / . 165 also noted the formation a major 
unidentified side-product. An attempt to reproduce this reaction led to the 
isolation and characterisation of the side product as a trifluoromethyl-4- 
alkenyloxazole which is formed by an interesting alternative cyclisation, as 
illustrated in Scheme 71
NHCOPh
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As expected166, Bamberger fragmentation of histamine (112) gave S'-1,2,4- 
tris(benzamido)butene (113). Treatment with boiling TFAA, followed by 
methanol, gave a poorly soluble solid in moderate yield. The high resolution Cl 
mass spectrum showed a major (M + H)+ peak at m/z 492.1535, corresponding 
to the molecular formula C27H20F3N3O3. 19F NMR showed only one singlet at 6 
-58.89, thus one trifluoromethyl group or two equivalent trifluoromethyl 
groups are present. The NMR spectrum revealed the presence of only one 
CH2 (8 4.19) and one alkene proton, along with fifteen aromatic protons and
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two NH protons. Hence one of the CH2 of the triamide (113) has become 
involved in the reaction. A ^ ^ H  COSY spectrum indicated coupling from the 
CH2 to the vinylic-H and the upheld NH, as illustrated in Figure 28 . No 
coupling was evident between the alkene-H and either NH. These data show 
compound (115) to have the alkenyloxazole structure shown. A ^ ^ H  
NOESY experiment gave a cross peak between the downfield NH (8 10.5) and 
the CH2 showing Z stereochemistry about the carbon-carbon double bond, as 
shown in Figure 28
iH-'H COSY >H-‘H NOESY
Figure 28 ‘H^H COSY and NOESY correlations of alkenyloxazole (115)
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■H— ►'°FNOE 19 F— ►'H NOE
Figure 29. H-F NOE correlations of alkenyloxazole (115).
An NOE enhancement was observed in the 19F signal of the trifluoromethyl 
group on irradiation at the frequency of the alkene-H but not on irradiation 
at the frequency of the CH2, which corroborated this structural assignment, 
as illustrated in Figure 29. The converse NOE experiment, involving irradiation 
at the 5f of the trifluoromethyl group, showed enhancement of the signals 
of the downfield NH, the vinylic-H and, more weakly, to the 2,6-H2 of one 
benzamide, shown in Figure 29.
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To rationalise this unexpected cyclisation, a mechanism such as that shown in 
Scheme 72 is proposed. Acylation of the triamide (113) at the more sterically 
accessible enamine position is followed by nucleophilic attack of the amide 
oxygen on the trifluoromethyl ketone. Trifluoroacetylation of the tetrahedral 
intermediate at oxygen provides an excellent leaving group for the 1,4- 
elimination to afford the alkenyloxazole (115).
After numerous attempts, these reactions did not produce any of the required
2-trifluoromethylhistamine (114).
7.3 Pyrroles.
A trifluoromethylated pyrrole bearing a functionalised substituent would be an 
interesting candidate for evaluation as an acidic 19F NMR pH-sensor. Although 
some pyrroles possessing a perfluoroalkyl group have been prepared by 
classical methods, such as Knorr condensation167, more specific approaches 
have been developed to meet more complicated design requirements. The 
synthesis of trifluoromethylpyrroles has been carried out by direct 
trifluoromethylation168,169 or by the use of trifluoromethyl-containing synthetic 
precursors170,171,172,173. Direct trifluoromethylation is usually carried out by 
electrochemical or photochemical techniques which require special 
equipment168. Other direct methods involve highly reactive, often very 
hazardous reagents, for example bis(perfluoroalkanoyl)peroxides174. Most 
methods involving trifluoromethyl-containing synthetic precursors require high 
temperatures and pressures in thick-walled reaction vessels171,172,173,175.
7.3.1 Transition Metal-Induced Transformations of 5,6-Dihydro-4//-
1,2-Oxazines and the Synthesis of 2-Trifluoromethyl Pyrroles.
Reiflig et al.176 have reported the synthesis of 1,2-oxazines (116). They have 
demonstrated that such compounds contain the required carbon backbone, at 
the correct oxidation level, for the corresponding pyrroles (117) or dicarbonyl 
derivatives (118), as illustrated in Scheme 73. The cleavage of N-O bonds with 
molybdenum hexacarbonyl has been well supported177,178,179. Reiflig et a l 176,177 
showed that treatment of 1,2-oxazines (116) with molybdenum hexacarbonyl in 
boiling acetonitrile may lead directly to the formation of the corresponding 















They176 suggested that this reaction may be applied to 3-(trifluoromethyl)-1,2- 
oxazines with one example. This involved the treatment of 5-methyl-5,6- 
dihydro-3 -(trifluoromethyl)-6-(trimethylsiloxy)-4//-1,2-oxazine (119) with
molybdenum hexacarbonyl in the presence of trifluoroacetic acid (TFA) in 
boiling acetonitrile The result was the isolation of the corresponding 2- 
(trifluoromethyl)pyrrole (120), as illustrated in Scheme 74.
The pyrrole formed in this reaction has a trifluoromethyl group next to a free 
N-H group and an alkyl substituent in the 4-position. If a compound with a 
functionalised alkyl substituent could be provided by this reaction, then it 
would be an ideal candidate for evaluation as a 19F NMR pH-sensor. In the 
design of a reaction sequence for the synthesis of a 2,4-disubstituted pyrrole, 
the possibility of revealing a hydroxyalkyl group during ring cleavage with 
molybdenum hexacarbonyl was investigated.
(i) Mo(CO) 6  / CH3CN 































(i) Mo(CO) 6  / CH3CN 
T F A /reflux/14 h
(124)
Scheme 75
ReiBig et al.176 described the synthesis of 4,4a,5,6,7,8a-hexahydro-3- 
(trifluoromethyl)pyrano[4,5-e]-l,2-oxazine (124) involving the [4n + 2n] 
cycloaddition reaction of l,l,l-trifluoro-2-nitroso-2-propene (123) with 3,4- 
dihydro-2//-pyran (51). Treatment of l-bromo-3,3,3-trifluoropropan-2-one 
(121) with hydroxylamine in a two-phase system (CHC13 / H20 ) and careful 
distillation gave the a-bromooxime (122) which is converted in situ to the 
nitroso alkene (123) by treatment with base. From the deterioration of an 
NMR sample, it was observed that the a-bromooxime (122) is sensitive to 
light. ReiBig et a lm  reported a low yield (31%) for the cycloaddition reaction, 
which was attributed to the relatively low reactivity of nitrosoalkenes towards 
Z enol ethers. However, considering that reaction usually takes five days for 
completion, the low yield is more likely to be due to decomposition of the 
starting material by light. As predicted, the yield of the reaction was increased 
dramatically using essentially the same reaction conditions described by ReiBig 
et al.176 but keeping the reaction mixture in darkness, as illustrated in 
Scheme 75. NMR indicated that only the c/5-isomer of the pyrano-1,2-
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oxazine (124) had formed. The coupling constant between the bridgehead 
protons is 2.5 Hz. From this information, the protons could be axial-equatorial 
or equatorial-equatorial. However, an equatorial-equatorial arrangement of the 
protons would required the ring bonds to be axial-axial which is extremely 
unlikely for this compound. Furthermore, an axial-equatorial arrangement of 
the bridgehead protons would be expected from a [47c + 2k ]  cycloaddition 
reaction. Unfortunately, treatment of the oxazine (123) with molybdenum 
hexacarbonyl in the presence of TFA failed to produce any of the desired 
pyrrole (125).
The one example of a 2-(trifluoromethyl)pyrrole described by ReiBig et a l 176, 
involved a 6-(trimethylsiloxy)-l,2-oxazine (119). The trimethylsiloxy group 
(TMSO) may play an important role in this reaction. Therefore, a reaction 
sequence leading to a 6-(trimethylsiloxy)-l,2-oxazine was devised. The target 















Trimethylsilyl enol ethers may be prepared from the aldehyde using the method 
described by Corey et a lm . The aldehyde (69) corresponding to the 
trimethylsilyl enol ether (127) shown in Scheme 76 was synthesised as 
described in Chapter Five and in Scheme 51 The enolate of the aldehyde (69) 
was formed using lithium hexamethyldisilazide (LiHMDS) and was trapped 
with trimethylchlorosilane (TMSC1). However, the ‘H NMR of the crude 
material did not contain the characteristic signals of the vinylic protons of a 
silyl enol ether. Rather, it suggested that the corresponding acetal (126) had 
formed, as illustrated in Scheme 77. Elimination of one of the TMSO groups 
was attempted by distillation of the crude material at high temperature. The *H 
NMR of the distillation fractions indicated that elimination of a TMSO group 
had occurred However, this was accompanied by decomposition, possibly
124
involving an intramolecular cyclisation of the enol ether into the benzyl group.
A further investigation into the reactivity of the nitrosoalkene (123) was 
carried out. This involved the generation in situ of the nitrosoalkene (123), 
followed by treatment with ethyl 4,4,4-trifluoro-3-oxobutanoate (ETOB) in 
THF at room temperature. A pale yellow solid was recovered from the 
reaction mixture. The *H and 19F NMR spectra were consistent with that of 
ETOB. Therefore, the solid recovered from the reaction mixture was probably 
the sodium salt of ETOB. The Cl mass spectrum showed a major (M + H)+ 
peak at m/z 185, a moderate sized peak at m/z 310 and a small peak at m/z 264. 
The major peak represents ETOB Two products expected from this reaction 
are the adduct (128) and its cyclised derivative (129), as illustrated in Scheme 
78 It is possible that these compounds are represented in the Cl mass 










7.3.2 Synthesis of 3-AIkyI-2,5-Bis(trifluoromethyI)pyrroles.
A suitable precursor for the synthesis of a 3-alkyl-2,5-bis(trifluoromethyl)- 
pyrrole (130) could be the corresponding 2,5-diketone (131), as illustrated by 
the retrosynthetic analysis of Scheme 79.
2,2,2-trifluoroethanol and an a,p-unsaturated ketone, as illustrated in Scheme
It was anticipated that a similar microbial carbon-carbon bond forming reaction 
may be induced between 2,2,2-trifluoroethanol and an a,P-unsaturated 
trifluoromethyl ketone (132) to produce a l,6-bis(trifluoromethyl)carbinol 
(133) The alcohol may be oxidised using the Dess-Martin182 reagent (135). 
The planned reaction sequence is illustrated in Scheme 81. The synthesis of p- 
alkyl-a,p-unsaturated trifluoromethyl ketones (132) has been reported by 
Linderman et a/.183,184. This involves the reduction of the corresponding 
acetylene followed by oxidation of the alcohol back to the ketone using the 
















trifluoromethyl ketones (88, 89) was described in Section 5.2.2 and in Scheme 
60. A reduction of 6-(( 1,1 -dimethylethyl)diphenylsilyloxy)-1,1,1 -trifluorohex-
3-yn-2-one (88) was carried out using lithium aluminium hydride. This led to 
the elimination of the silyl protection group. However, the relatively more 
robust benzyl-protected acetylene (89) was reduced under essentially the same 















The Dess-Martin reagent (135) was prepared in two steps from 2- 
iodosobenzoic acid, as illustrated in Scheme 82
KBiG,
H2 SQ4
CD2H Yield 8 8 %





This reagent allowed the successful oxidation of the a,p-unsaturated alcohol
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(136) to the corresponding ketone (137) in good yield. Unfortunately, the 
microbial transformation using bakers' yeast failed to produce the required 












A trifluoromethylated pyrrole bearing a functionalised substituent was not
obtained from either of the synthetic routes described. However, it is possible 
that 3-(trifluoromethyl)- 1,2-oxazines may lead to other interesting chemistry. 
In the case of the microbial transformation described, it is likely that the 
presence of either the trifluoromethyl group or the benzyl group are not 





Investigations were carried out into the potential of fluorinated pyrazoles, 
imidazopyridines, benzimidazoles, triazoles and pyridines to act as sensors of 
pH through variation of 19F chemical shift with state of ionisation and hence 
pH in aqueous media. This involved making NMR samples of each compound 
in a range of buffer solutions. Immediately before examining the 19F NMR 
spectrum, the pH of the solution was measured. Preliminary investigations 
revealed that the pKa value was only slightly different when the experiments 
were carried out at 25°C rather than at 37°C. Therefore, for the initial 
evaluation of the compounds, the pH measurement of each solution and the 
NMR accumulations were all carried out at 25°C. It was also found that 
adjusting the ionic concentrations of the samples to a particular value had an 
insignificant effect on the pR* value obtained. Deuterated solvents were not 
used and, therefore, the NMR samples were run without a deuterium lock. 
CFCI3 was used as external chemical shift standard before and after each 
experiment and no drift was experienced. Each NMR sample was run three 
times and all the 19F chemical shift values obtained were plotted with the 
corresponding pH value.
8.2 Pyrazoles.
Unsubstituted pyrazole has an acidic pKa value of 14.18110 The effect of a 
trifluoromethyl group on the acid-base properties of pyrazoles has been 
investigated by Elguero et al.uo (entries (a-d) in Table 4). The pKa values in 
their report were determined spectrophotometrically according to a method 
described by Ernst and Menashi111. Habracken et a/.185 investigated the effects
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of a nitro-substituent on the absorption spectra of pyrazoles. The report by 
Habracken et a l 185 also discusses the effects of various substituents on the pK* 
value of pyrazoles (entries (e-1) in Table 4). The pKa values reported185 were 
once again obtained spectrophotometrically. The data of these two reports are 
combined in Table 4.
The 19F chemical shift of 3,5-bis(trifluoromethyl)pyrazole (2) was found to be 
pH-dependent between pH 5 and pH 10. The total shift observed in the 19F 
NMR spectrum over this pH range was 1.47 ppm. The data are listed in Table 
8  in the Appendix and are illustrated in Figure 30. The curve shown in Figure 
30, has a sigmoidal shape which is characteristic of one acid-base equilibrium. 
As the acidity of the medium decreases, there will be an increase in the degree 
of ionisation of the pyrazole, associated with proton loss. This increases the 
degree of negativity of the N-l atom, resulting in an upfield shift in the 19F 














Table 4. pKa values of pyrazoles (entries (a-d) are from a report by Elguero et 
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Figure 30 19F chemical shift (ppm) of 3,5-bis(trifluoromethyl)- 
pyrazole (2 ) vs pH
The pKa value is the pH value where half of the mixture is ionised. On the 
curve, this is the point of inflection, which is where the curve is changing from 
being concave upwards to being concave downwards. On a symmetrical 
sigmoidal curve, such as that shown in Figure 30, this is usually taken to be the 
point on the curve which falls halfway between the maximum and the 
minimum. Thus, the pKa value of bis(trifluoromethyl)pyrazole (2) is 7.55 at 
25°C. This value is comparable to the value reported110 by Elguero et al. and 
shown in Table 4.
The pKa values of 3-(trifluoromethyl)pyrazole-4-propanol (80), 2-(3-trifluoro- 
methylpyrazol-4-yl)ethanol (84) and 2-(5-trifluoromethylpyrazol-3-yl)ethanol 
(92) were also determined using 19F NMR. The report by Elguero et al.no 
suggests that the absence of a trifluoromethyl group would lead to a large 
increase in the pKa value, as shown for entry (c) in Table 4. In fact, the pKa 
values of trifluoromethylpyrazoles (80, 84, 92) were shifted such that the
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maxima of the corresponding pH-§F curves were beyond the practical limits of 
this technique. However, extrapolation of the curves allowed good estimates of 
the pKa values. The pKa value of 3-(trifluoromethyl)pyrazole-4-propanol (80) 
was estimated to be 12.07 at 25°C (Table 9 in the Appendix and Figure 31), 
while the pK» value of 2-(3-trifluoromethylpyrazol-4-yl)ethanol (84) was 
estimated to be 11.97 at 25°C (Table 10 in the Appendix and Figure 32). The 
slightly lower pKa value of pyrazole (84) compared to pyrazole (80) is 
probably due to a combination of effects. This may include the increasing 
degree of hyperconjugation (compare 4-methyl-3(5)-nitro-pyrazole, entry (g) 
in Table 4, with 4-ethyl-3(5)-nitro-pyrazole, entry (h)) and the increasing 
importance of the negative inductive effect of the hydroxy group. The pKa 
value of 2-(5-trifluoromethylpyrazol-3-yl)ethanol (92) was estimated to be 
12.79 at 25°C, as illustrated in Table 11 in the Appendix and Figure 33. The 
different pKa values encountered when moving the ethanol group from the 4- 
position to the 3(5)-position is unexpected when compared the pKa value of 
3(5)-(trifluoromethyl)-5(3)-methyl-pyrazole (entry (c) in Table 4). It is 
interesting that the total shifts with pH observed in the 19F NMR spectra for 
the trifluoromethylpyrazoles (80, 84, 92) (2.21 ppm, 2.09 ppm and 2.33 ppm, 
respectively) are significantly larger than that observed for 
bis(trifluoromethyl)pyrazole (2). The three 8 f-pH plots of trifluoromethyl­
pyrazoles (80,84,92) are combined in Figure 34.
3-(Pyridin-4-yl)-5-(trifluoromethyl)pyrazole was kindly donated by Professor 
S. P. Singh, Kurukshetra University, Kurukshetra, India. The pKa value of this 
compound was determined by 19F NMR to be 9.49, as illustrated in Table 12 in 
the Appendix and Figure 35. The 19F chemical shift was sensitive the pH of the 
medium over the range pH 8  to pH 11 with a total shift in the 19F NMR 
spectrum of 2.04 ppm. This value suggests that it may be feasible to shift the 
pKa of a trifluoromethylpyrazole to a value close to that of physiological pH. 
This may also allow the greater total shift observed for 
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Figure 32. 19F chemical shift (ppm) of 2-(3-trifluoromethylpyrazol-4-
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Figure 34 19F chemical shift (ppm) of pyrazoles (80, 84, 92) vs pH.
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Figure 35. 19F chemical shift (ppm) of 3-(pyridin-4-yl)-5- 
(trifluoromethyl)pyrazole vs pH.
8.3 Benzimidazoles and Imidazopyridines.
The pKa values of a number of benzimidazoles are listed in Table 5. The acidic 
pKa value of unsubstituted benzimidazole is much lower than physiological pH, 
entry (a) in Table 5. The introduction of a trifluoromethyl group into the 2- 
position was reported158 to raise the pKa value to 8.13, entry (d). If the 
reported158 pKa value of 2-trifluoromethylbenzimidazole is correct, then the 
introduction of a trifluoromethyl group or a fluorine atom into the benzene ring 
would be expected to lower the pKa, possibly to a value closer to physiological 
pH Furthermore, this may serve as an internal reference peak in the 19F NMR.
2,5-Bis(trifluoromethyl)benzimidazole (95) and 5-fluoro-2-(trifluoromethyl)- 
benzimidazole (94) were synthesised but are insufficiently soluble in aqueous 




(b) 2 -ethyl- 6.18
(c) 2 -phenyl- 5.23
(d) 2 -trifluoromethyl- 8.13
Table 5. pKa values of benzimidazoles (entries (a-c) are from a report by 
Weast186 and entry (d) is from a report by Elguero et al. 158
Fortunately, 2-(trifluoromethyl)imidazopyridines (96, 97) were sufficiently 
soluble in aqueous media. The 19F chemical shift of 2-(trifluoromethyl)imidazo- 
[4,5-&]pyridine (95) was found to be pH-dependent between pH 1 and pH 8 . 
The data are listed in Table 13 in the Appendix and are illustrated in Figure 36 
As can be seen in Figure 36, the total shift is comprised of two sigmoidal 
curves, both with positive gradients. The two pKa values are 6.92 and 
approximately 2 . 2  at 25°C. The larger of the two sigmoidal curves, which has a 
pKa value of 6.92, represents the N-H of the imidazole The smaller sigmoidal 
curve, which has an estimated pKa value of 2.2, could either correspond to the 
N-3 position, the N-7 position or to the basic pKa of the imidazole N-H. 
Considering reported186 pKa values and pKa values determined in this study for 
pyridines, this pKa value probably represents the N-7 position. The total shift 
observed in the 19F NMR spectrum for the higher pKa value is 0.55 ppm, which 
is the difference between the minimum and maximum of the corresponding 
sigmoidal curve. The total shift observed in the 19F NMR spectrum for the 
lower pKa value is 0.23 ppm. The combined shift observed between pH 1 and 
pH 8  is 0.78 ppm. The acidic pKa value of the imidazole N-H is very close to 
physiological pH. Furthermore, the introduction of an alkyl substituent on the 
pyridine ring should result in a minor shift in the pKa value towards 
physiological pH.
The 19F NMR chemical shift of 2-(trifluoromethyl)imidazo[4,5-c]pyridine (97) 
was found to be pH-dependent between pH 2 and pH 10.5. The data are listed
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in Table 14 in the Appendix and are illustrated in Figure 37. The total shift is 
comprised of one sigmoidal curve with a positive gradient and a downwards 
drift at lower pH values, probably associated with a second pKa. The pKa value 
of the sigmoidal curve is 8  .78 at 25°C and is the acidic pKa of the N-H of the 
imidazole-portion of the compound. The total shift observed in the 19F NMR 
spectra is 0.87 ppm, which is the difference between the minimum and 
maximum of the sigmoidal curve.
Both of the imidazopyridines have very promising pKa values. It would be 
interesting to measure the pKa of a 4-, 5- or 7-trifluoromethyl derivative of 2- 
(trifluoromethyl)imidazo[4,5-c]pyridine (97). The presence of an extra 
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Figure 36. 19F chemical shift (ppm) of 2-(trifluoromethyl)imidazo- 
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Figure 37. 19F chemical shift (ppm) of 2-(trifluoromethyl)imidazo- 
[4,5-c]pyridine (97) vs pH.
8.4 Pyridines.
The reported pKa values of substituted pyridines are listed in Table 6  The 
effect of a trifluoromethyl group on the pKa was investigated. The 19F chemical 
shift of 4-(trifluoromethyl)pyridine was examined between pH 3 and pH 11. 
No shift in the position of the peak in the 19F NMR spectra was observed. It is 
likely that the pKa value lies below pH 3, which was considered to be too low 
to warrant further investigation.
The 19F chemical shift of 3-(trifluoromethyl)pyridine was also initially examined 
between pH 3 and pH 11 A slight upfield shift of the trifluoromethyl peak was 
observed Therefore, further examinations of the 19F chemical shift were 
carried out at lower pH values. The data are listed in Table 15 in the Appendix 
and are illustrated in Figure 38 The 19F chemical shift of 3-(trifluoro- 
methyl)pyridine was found to be pH-dependent between pH 1 and pH 4. The
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sigmoidal curve has a positive gradient and the total shift between the 
minimum and maximum is 1 . 0 0  ppm. The pKa value is 2.67 at 25°C. As 
expected, this value is much lower than physiological pH. The presence of 
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Figure 38. 19F chemical shift (ppm) of 3-(trifluoromethyl)pyridine vs pH.
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8.5 Triazoles.
The 19F chemical shift of 3,5-bis(trifluoromethyl)-4-(3-hydroxypropyl)-4//- 
1,2,4-triazole (108) was examined between pH 0.02 and pH 10. Below pH 5, a 
slight downfield shift was observed. The data are listed in Table 16 in the 
Appendix and are illustrated in Figure 39 The total shift observed in the 19F 
NMR spectra was only 0.09 ppm. If the curve shown in Figure 39 is assumed 
to be a sigmoidal curve with a negative gradient, then the pKa value is 
approximately 4 at 25°C. Due to the very small shift observed, further 









0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
PH
Figure 39. 19F chemical shift (ppm) of 3,5-bis(trifluoromethyl)-4-(3- 
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signal (ppm)
3,5-bis(trifluoromethyl)pyrazole (2) 7.55 1.47
3 -(trifluoromethyl)pyrazole-4-propanol (80) 12.07 2 . 2 1
2-(3-trifluoromethylpyrazol-4-yl)ethanol (84) 11.97 2.09
2-(5-trifluoromethylpyrazol-3-y!)ethanol (92) 12.79 2.33
3 -(pyridin-4-yl)- 5 -(trifluoromethyl)pyrazole 9.49 2.04




2-(trifluoromethyl)imidazo[4,5-c]pyridine (97) 8.67 0.87




Table 7. Summary of pKa values.
The pKa data discussed in this section are combined in Table 7. The 
trifluoromethylpyrazole showed the largest total shifts in the 19F NMR spectra. 
It may be possible to modulate the pKa of these compounds to a more suitable 
value The pKa of 3-(pyridin-4-yl)-5-(trifluoromethyl)pyrazole suggests that the 
attachment of two heterocycles to the pyrazole may result in a pKa value close 
to physiological pH. If such a compound could be constructed, then it would 
provide many more points of attachment for other substituents. The pKa values 




A variety of reaction sequences towards the synthesis of 4-substituted-3,5- 
bis(trifluoromethyl)pyrazoles have been attempted. The targets have been 
approached at three different oxidation levels. Many reactions in each approach 
were hindered by the deactivating nature of the trifluoromethyl group. Progress 
was made towards the synthesis 3-substituted derivatives of 1,1,1,5,5,5- 
hexafluoropentane-2,4-dione. This involved the condensation reaction of 
carbonyl compounds with the dione. Convenient and generally high yielding 
syntheses of three a>-(trifluoromethylpyrazolyl)alkanols have been developed. 
19F NMR pH studies of these compounds and other pyrazoles have provided 
information about the effects of various substituents on the pK* of the parent 
pyrazole.
A reinvestigation into a previous report of the claimed synthesis of 1-aryl and
l-aroyl-3,5-bis(trifluoromethyl)pyrazoles was carried out. It was revealed that 
the reaction of substituted hydrazines with l,l,l,5,5,5-hexafluoropentane-2,4- 
dione produces the corresponding 5-hydroxy-4,5-dihydropyrazoles, contrary to 
the previous report. A number of methods leading to the dehydration of these 
compounds to the corresponding aromatic pyrazoles have been developed.
The structure of a major unidentified side-product, from a report regarding the 
synthesis of 2 -trifluoromethylhistamine, was determined using a variety of 
spectroscopic techniques. The compound was characterised as a 5-trifluoro- 
methyl-4-alkenyloxazole.
Two 2-(trifluoromethyl)benzimidazoles and two 2-(trifluoromethyl)imidazo- 
pyridines were synthesised, all with high yields. The pKa values of the 2-(tri- 
fluoromethyl)imidazopyridines were found to be close to physiological pH. 
Furthermore, both sets of compounds have many positions available for 
attachment of other substituents, such as groups to modulate the pKa value,
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groups to increase the solubility in aqueous media and targetting groups. 
Therefore, 2-(trifluoromethyl)benzimidazoles and 2-(trifluoromethyl)imidazo- 




NMR data were recorded on a Jeol FX90Q spectrometer (84.25 MHz 19F), a 
Jeol GX270 spectrometer (270.05 MHz *H; 67.8 MHz 13C), a Jeol EX400 
spectrometer (399.65 MHz *H; 100.4 MHz 13C; 376.05 MHz 19F) and a 
Bruker AM 250 (1H->I9F and 19F—>!H heteronuclear NOE experiments). 
CFCI3 was used as an internal standard for 19F NMR samples dissolved in 
(CD3)2SO, t/g-THF or CDC13 and as an external standard for samples dissolved 
in D20. Tetramethylsilane was used as an internal standard for *H / 13C NMR 
samples dissolved in CDCI3 or (CD3)2SO, and 3-(trimethylsilyl)propanoic acid- 
2, 2,3,3-J4 acid was used for samples dissolved in D20. Multiplicities are 
indicated by s (singlet), d (doublet), t (triplet), q (quartet), qu (quintet) and m 
(multiplet). Non-phase sensitive two dimensional COSY and NOESY spectra 
(Jeol) were acquired with 16 scans. During data processing a 90°-shifted 
squared sine bell function was used in both ©1 (1024) and ©2 (512) 
dimensions. The FID in ©2 was zero-filled to IK prior to Fourier 
transformations to give a IK x IK spectrum. Infrared spectra were recorded 
on a Perkin-Elmer 782 IR spectrometer, either as liquid film (film), Nujol mull 
(Nujol) or KBr disc (disc). Peak intensities in the IR spectrum are indicated by 
s (strong), m (medium) and w (weak). Mass spectra (MS) were obtained by 
electron-impact (El), chemical-ionisation (Cl) or fast atom bombardment 
(FAB) using a VG7070 spectrometer and a ZAB-E spectrometer. Data are 
reported in the form m/z (intensity relative to base = 1 0 0 ) for selected ions.
Where repetitive experimental procedures were employed, only one description 
is provided. All solutions were aqueous unless stated otherwise. Solvents for 
reactions, extractions and chromatography were distilled from the indicated 
drying agents according to standard procedures: tetrahydrofuran, pentane
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(sodium/benzophenone); dichloromethane, chloroform (phosphorus (v) oxide); 
diethyl ether, toluene (sodium). Analytical thin layer chromatography was 
carried out on Merck Kieselgel 60F plates. Visualisation was accomplished by 
UV light, iodine, phosphomolybdic acid, or iron (m) chloride. Flash 
chromatography was performed using Merck Silica Gel 60 (0.040 - 0.063 mm) 
flash silica. Melting points and boiling points are uncorrected. Kugelrohr 
distillations were carried out in a Biichi GKR-51 apparatus and the boiling 
points given correspond to the Kugelrohr oven temperature.
pH Studies.
pH values were obtained using a Coming 240 pH meter and a 3.7 mm pH 0-14 
Russell CLSCHll/lm electrode. Buffer solutions were made using the 
standard procedures of the British Pharmacopoeia 1988187 19F NMR data were 
recorded on a Jeol EX400 spectrometer at 376.05 MHz. 19F chemical shifts 
were recorded in parts per million (ppm) and were referenced relative to the 
19F resonance peak of an external sample of CFCI3 in CDCI3 (0 . 0 0  ppm, 
298 K). The 19F NMR spectra were collected between -100 ppm and 0 ppm 







dione (6.45 g, 31.0 mmol) was added to hydrazine hydrate (1.5 ml, 31.0 mmol) 
in ethanol (60 ml) and acetic acid (0.05 ml). The mixture was boiled under 
reflux for 5 h and allowed to cool. The solvent was distilled off carefully at 
atmospheric pressure. The residue, in DCM (30 ml), was dried (MgS04) and 
the solvent was distilled off. Pentane (15 ml) was added and colourless crystals 
formed with scratching. Due to presence of an oil, the pentane was removed by 
distillation to yield 3.95 g (62%) of 3,5-bis(trifluoromethyl)pyrazole (2), after 
distillation (Kugelrohr). Data: colourless crystals, mp 69-70°C; bp 120-130°C 
(literature112 mp 71-72°C); I9F NMR (376 MHz, D20 ) -62.02 (s).
l-Iodo-2 -(2 -methoxyethoxy)ethane (6 ).
Method A:
To a solution of 2-(2-methoxyethoxy)ethanol (6.89 ml, 6.00 mmol) in 
anhydrous DCM (100 ml) and anhydrous pyridine (62.3 ml, 769 mmol), under 
a nitrogen atmosphere, was added triphenylphosphine (22.8 g, 9.00 mmol) 
followed by the slow addition of iodine (24.3 g, 100 mmol) at ambient 
temperature. When iodination was complete by t.l.c. (3.3 h), the reaction 
mixture was washed with saturated aqueous sodium metabisulphite solution (3 
x 25 ml), saturated sodium hydrogen carbonate solution (3 x 25 ml) and brine 
(25 ml). The organic layer was dried (MgS04) and the solvent was evaporated. 
The residue was dissolved in ether (30 ml) and the triphenylphosphine oxide 
was removed by filtration through silica gel. The solvent of the filtrate was 
evaporated and the yellow oil was distilled (Kugelrohr) to yield 2.85 g (21%) 






To a stirred solution of 2-(2-methoxyethoxy)ethyl-4-methyl-benzenesulphonate 
(8 ) (12.7 g, 46.1 mmol) in anhydrous acetone (150 ml) was added sodium 
iodide (25.0 g, 167 mmol). The solution was stirred at ambient temperature in 
the dark and in a nitrogen atmosphere for 24 h. The reaction mixture was 
filtered and most of the acetone was evaporated. To the residue was added 
ether (90 ml) and water (100 ml) and the organic layer was washed with half 
saturated metabisulphite solution (2 x 25 ml) and brine (25 ml). After drying 
(MgSO,*), the solvent was evaporated and the crude material was distilled 
(Kugelrohr) to yield 7.70 g (71%) of l-iodo-2-(2-methoxyethoxy)ethane (6 ).
Data: colourless oil; bp2o 130-135°C (literature126 bpio- 1 2 107-109°C); NMR 
(270 MHz, CDCI3) 3.26 (2 H, m, CH2CH2-I), 3.38 (3H, s, CH3 OCH2), 3.56 
(2H, m, OCH2 CH2-I), 3 64 (2H, m, CH3OCH2CH2 O), 3 75 (2H, m, 
CH3OCH2 CH2O); IR (film) 1 1 2 0  (s).
2-(2-Methoxyethoxy)ethyl 4-methylbenzenesulphonate (8 ). 2-(2-Methoxy- 
ethoxy)ethyl-4-methylbenzenesulphonate (8 ) was synthesised essentially by the 
method described by Prugh's group126. To a solution of 2-(2-methoxy- 
ethoxy)ethanol (6.54 ml, 50.0 mmol) in anhydrous ether (50 ml) was added 
powdered potassium hydroxide (2.80 g, 50.0 mmol). To this suspension was 
added 4-methylbenzenesulphonyl chloride (9.53 g, 50.0 mmol), with caution. 
Stirring was continued under a nitrogen atmosphere for 3 h. The reaction 
mixture was filtered and the filtrate was washed with water ( 2  x 2 0  ml) and 
dried (MgS04). The solvent was evaporated to yield 12.9 g (94%) of 2 -(2 - 
methoxyethoxy)ethyl 4-methylbenzenesulphonate (8 ). Data: colourless oil; IR 
(disc) 1365 (s), 1180 (s).
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2-(2-Methoxyethoxyethyl)triphenylphosphonium iodide (9). 
Triphenylphosphine (16.9 g, 64.0 mmol) was dissolved in anhydrous toluene 
(100 ml) and l-iodo-2-(2-methoxyethoxy)ethane (6 ) (7.20 g, 31.0 mmol) in 
toluene (50 ml) was added. The mixture was boiled under reflux for 14 h under 
a nitrogen atmosphere. After cooling, a yellow oil separated and ether was 
added (50 ml). Crystals were produced by agitation of the oil and were filtered 
and washed with cold ether (10 ml) to yield 14.6 g (96%) of 2-(2- 
methoxyethoxyethyl)triphenylphosphonium iodide (9) Data: white solid; mp
101.5-102.5°C, *H NMR (270 MHz, (CD3 )2 SO) 3.06 (3H, s, CH30), 3.15 
(2 H, m, CH3OCH2CH2O), 3 28 (2H, m, CH3 OCH2CH2), 3.69 (2H, dt, J  = 20.9 
Hz, J = 5.5 Hz, CH2CH2P), 3 96 (2 H, m, OCH2CH2P), 111 (15H, m, Ph3P).
(13)
l-Chloro-3-(2-methoxyethoxymethoxy)propane (13). A mixture of 3- 
chloro-1-propanol (3.30 g, 35.0 mmol) and MEMC1 (5.99 ml, 52.5 mmol) in 
DCM (60 ml) was cooled to 0°C and N,N-diisopropylethylamine (9.1 ml, 52.5 
mmol) was added dropwise. The colourless solution was allowed to warm 
gradually to ambient temperature and then was stirred for 3 h. The reaction 
mixture was washed with water ( 2 x 1 5  ml), 5% HC1 solution ( 2 0  ml) and 
saturated sodium hydrogen carbonate solution ( 2 0  ml). The organic layer was 
dried (MgS04) and the solvent evaporated to yield 6.29 g (98%) of 1 -chloro- 
3-(2-methoxyethoxymethoxy)propane (13) following distillation (Kugelrohr). 
Data: colourless liquid; bp0 .7 40-50°C; 'H NMR (270 MHz, CDCI3) 2  04 (2 H, 
qu, J  = 6.0 Hz, CH2CH2 CH2), 3.40 (3H, s, CH30), 3.6 (8 H, m, CH20), 3.70 
(2H, t, J=  5.9 Hz, CH2C1), 4.73 (4H, s, OCH20); IR (film) 1050 (s).
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(14)
l-Iodo-3-(2-methoxyethoxymethoxy)propane (14) l-Chloro-3-(2-methoxy- 
ethoxymethoxy)propane (13) (6.00 g, 32.8 mmol) was dissolved in anhydrous 
acetone (100 ml) and sodium iodide (10.0 g, 66.7 mmol) was added slowly 
producing a slight exotherm. The mixture was stirred at ambient temperature in 
the dark under a nitrogen atmosphere for 4 h The reaction mixture was filtered 
and most of the solvent evaporated. The residue was redissolved in ether ( 1 0 0  
ml) and washed with water (2 x 25 ml) and half saturated sodium 
metabisulphite solution (2 x 25 ml). The organic extracts were dried (MgSOJ 
and the solvent was evaporated to yield 5.15 g (57%) of l-iodo-3-(2- 
methoxyethoxymethoxy)propane (14) Data: yellow oil; *H NMR (270 MHz, 
CDC13) 2.06 (2 H, m, CH2CH2CH2), 3.40 (3H, s, CH30), 3 65 ( 1 0 H, m, 4 x 
CH20  and CH2I), 4 73 (2H, s, OCH20 )
©
QEt
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(16)
(Z)-1,1,1 -Trifluoro-2-ethoxy-4-(2-(2-methoxyethoxy))but-2-ene (16) The 
attempted synthesis of (Z)-1,1,1 -trifluoro-2-ethoxy-4-(2-(2-
methoxyethoxy)methyl)but-2 -ene (16) led to the isolation of an intermediate 
(2-(2-Methoxyethoxyethyl)triphenylphosphonium iodide (9) (7.39 g, 15.0 
mmol) and HMDS (0.3 ml) were added to a suspension of sodium hydride 
(80% dispersion in oil, 0.43 g, 15.0 mmol) in anhydrous THF (40 ml). The 
mixture was boiled under reflux in a nitrogen atmosphere for 3 h. The deep 
red-brown slurry was cooled to ambient temperature and ethyl trifluoroacetate 
(1.78 ml, 15.0 mmol) in THF (5 ml) was added dropwise The mixture was 
boiled under reflux for 16 h. The reaction mixture was cooled to ambient 
temperature and pentane (40 ml) was added The suspension was filtered
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through silica gel (eluted with pentane : ether ; 97 : 3) and the solvents 
evaporated to give a mixture of triphenylphosphine oxide and the suspected 
intermediate (15). After analysis, the mixture was dissolved in anhydrous 
toluene (20 ml) and boiled under reflux for 23 h. T.l.c. indicated no change and 
sodium hydride (80% dispersion, 0.3 g) and HMDS (0.01 ml) were added and 
boiling under reflux was continued for 24 h. After cooling to ambient 
temperature, the suspension was filtered and the solvent of the filtrate was 
evaporated. The residue was columned (petroleum ether bp 40-60°C : ethyl 
acetate , 2 : 1). Data: red-brown amorphous powder; lH NMR (270 MHz, 
(CD3)2 SO) 3.32 (3H, s, CH30), 3.50 (2H, t, J =  4.2 Hz, CH2 O), 3.74 (2H, t, J  




2-Phenyl-l,3-dioxane (18). A mixture of benzaldehyde (10.0 g, 94.2 mmol), 
propane-1-3-diol (7.89 g, 104 mmol) and 4-methylbenzenesulphonic acid (0.18 
g, 0.90 mmol) in toluene (100 ml) was stirred and boiled under reflux in a 
Dean and Stark apparatus. After V/2  h the reaction mixture was allowed to 
cool to ambient temperature and then ether (100 ml) was added (1.4 ml of 
water had been produced of the 1.72 ml expected). This was washed with 0.6 
M sodium hydrogen carbonate solution (3 x 15 ml) and the organic layer dried 
(MgS0 4 ). The solvents were evaporated and the crude yellow liquid was 
distilled (Kugelrohr) to yield 18.8 g (90%) of 2-phenyl-1,3-dioxane (18). Data: 
white crystals, mp <25°C; bp2o 145-155°C (literature129 bpi2 115°C); lH NMR 
(270 MHz, (CD3)2 SO) 1.45 (1H, dtt, J^  = 13.6 Hz, JB.D = 2.6 Hz, JB-c =1.3 
Hz, H ^ )) , 2.23 (1H, m, J gem = 13.6 Hz, JA.D = 10.1 Hz, A-c = 4.9 Hz, H ^ ) ,  
3.99 (2H, m, J gem= 12.5 Hz, Jd.a = 10 1 Hz, Ju.B = 2.6 Hz, H*^)), 4.26 (2H, 
m, J gcm = 12.5 Hz, Jc.a = 4.9 Hz, Jc.b = 1.3 Hz, H ^q), 5.50 ( 1 H, s, H ^ ) ,
151
7.35 (3H, m, Ar 2 ,4 ,6 -H3), 7.48 (2H, m, Ar 3,5-H2); 13C NMR ( 6 8  MHz, 
(CD3)2 SO) 25.75 (CH2£H 2CH2), 67.35 (CHjCHjO), 101.64 (OjCCHR), 
125.96 (Ar 4-C), 128.22 (Ar 3,5-C), 128.75 (Ar 2,6-C); IR (disc) 3020 
(m),l 105 (s).
3-(Phenylmethoxy)propan-l-ol (19) 3-(Phenylmethoxy)propan-l-ol (19) 
was synthesised essentially by the method described by Kozikowski's group129 
Cold, anhydrous ether (250 ml) was added cautiously to aluminium trichloride 
(24.4 g, 183 mmol) at 0°C resulting in a moderate exotherm Following 
dissolution, lithium aluminium hydride (1.73 g, 48.7 mmol) was added 
portionwise to the mixture. Stirring was continued at 0°C for 30 min, followed 
by the dropwise addition of 2-phenyl-1,3-dioxane (18) (8.00 g, 48.7 mmol) in 
ether (50 ml). The suspension was allowed to warm to ambient temperature. 
After stirring for a further 2 h, the mixture was cooled to 0°C and quenched by 
the slow addition of 2 M sulphuric acid solution (250 ml). A heavy precipitate 
formed which required some agitation before stirring could be continued. After 
warming to ambient temperature, two layers formed. The layers were 
separated and the aqueous phase was extracted with ether (2 x 50 ml). The 
combined organic extracts were dried (MgS04) and the solvent evaporated to 
yield 7.63 g (94%) of 3-(phenylmethoxy)propan-l-ol (19) following distillation 
(Kugelrohr). Data: colourless liquid, bp0 7  115-120°C; !H NMR (270 MHz, 
CDC13) 1 83 (2 H, qu, J  = 5 9 Hz, CH2CH2CH2), 3.66 (2 H, t, J  = 5.9 Hz, 
CH2CH2OH), 3 78 (2H, t, J=  5.7 Hz, BnOCILCHz), 4.53 (2H, s, PhOHhO),
7.33 (5H, m, PhCH20), IR (film) 3800 (br), 1 1 0 0  (s), 745 (s), 705 (s); MS 




3-(Phenylmethoxy)propyl 4-methylbenzenesulphonate (20) 3-(Phenyl- 
methoxy)propyl 4-methylbenzenesulphonate (20) was synthesised by the 
procedure described by Prugh's group63. To a solution of 3-phenyimethoxy-l- 
propanol (19) (7.61 g, 45.8 mmol) in anhydrous ether (50 ml) was added 
powdered potassium hydroxide (2.60 g, 45.8 mmol). To this suspension was 
added 4-methylbenzenesulphonyl chloride (8.73 g, 45.8 mmol), with caution. 
Stirring was continued under a nitrogen atmosphere for 6  h. Another portion 
of powdered potassium hydroxide (2.00 g, 35 . 6  mmol) was added and stirring 
was continued for another 2.5 h. The reaction mixture was filtered and the 
filtrate was washed with water ( 2  x 25 ml) and dried (MgS04). The solvent 
was evaporated to yield 13.3 g (91%) of 3-(phenylmethoxy)propyl 4- 
methylbenzenesulphonate (2 0 ). Data: colourless crystals; mp <30°C
(literature188 mp 37°C), !H NMR (270 MHz, CDC13) 1 8 8  (2H, qu, J=  6.1 Hz, 
CH2CH2 CH2), 2.45 (3H, s, ArCHs), 3.52 (2H, t, J  = 6 . 0  Hz, BnOC^CH,), 
4 19 (2H, t, J  = 6 . 2  Hz, CHzCI^OTs), 4 43 (2H, s, PhC^O ), 7 30 (7H, m), 
7.82 (2H, d , J =  8.3 Hz, 2,5-H2, Ts), IR (Nujol) 1370 (s) 1185 (s); MS (Cl, 
iso-butane) 321 (M+ + H, 17), 181 (9), 155 (10), 107 (12), 91 (100).
l-Iodo-3-(phenylmethoxy)propane (21). To a stirred solution of 3- 
(phenylmethoxy)propyl 4-methylbenzenesulphonate (20) (6.00 g, 18.7 mmol) 
in anhydrous acetone (60 ml) was added sodium iodide (9.60 g, 64.2 mmol) 
The solution was stirred at ambient temperature in the dark and under a 
nitrogen atmosphere for 6  h. The reaction mixture was filtered and most of the 
acetone was evaporated To the residue was added ether (50 ml) and water (10 
ml) and the organic layer was washed with half saturated metabisulphite
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solution (2 x 15 ml) and brine (10 ml). After drying (MgS04), the solvent was 
evaporated and the crude material was distilled (Kugelrohr) to yield 4.87 g 
(87%) of l-iodo-3-(phenylmethoxy)propane (21). Data: pale yellow liquid; 
bp20 150-165°C (literature189 bp7.io 123-130°C); 'H NMR (270 MHz, CDCU) 
2.09 (2H, qu, J  = 6.6 Hz, CHjOfcCHj), 3.31 (2H, t, 6.6 Hz, CH2CH2 I), 
3.54 (2H, t , J =  5.7 Hz, BnOCHjCHj), 4.53 (2H, s, PhOfcO), 7.34 (5H, m, 
PhCH20); IR (film) 1110 (s), 740 (s), 705 (s).
3-(Phenylmethoxy)propyItriphenylphosphonium iodide (22). 
Triphenylphosphine (9.20 g, 35.0 mmol) was dissolved in anhydrous toluene 
(60 ml) and l-iodo-3-(phenylmethoxy)propane (21) (4.36 g, 15.8 mmol) in 
toluene (20 ml) was added. The mixture was boiled under reflux for 16 h under 
a nitrogen atmosphere After cooling, a yellow oil separated and ether was 
added (50 ml). The crystals were produced by agitation of the oil and were 
filtered and washed to yield 7.94 g (93%) of 3-(phenylmethoxy)propyl- 
triphenylphosphonium iodide (22) Data: white crystals, mp 94.5-95.0°C, 
NMR (270 MHz, (CD3)2SO) 1 89 (2H, m, CH2CH2 CH2 ), 3,82 (2H, m, 





(Z)-l,l,l-Trifluoro-2-ethoxy-5-(phenylmethoxy)pent-2-ene (23) (Z)-1,1,1- 
Trifluoro-2-ethoxy-5-(phenylmethoxy)pent-2-ene (23) was synthesised using a 
procedure based on that described by Begue's group124. 3- 
(Phenylmethoxy)propyltriphenylphosphonium iodide (22) (3.00 g, 5.57 mmol)
154
was added to a stirred suspension of sodium hydride (80% dispersion in oil, 
0.17 g, 5.57 mmol) in anhydrous THF (20 ml). HMDS (0.2 ml, 1.50 mmol) 
was added to the mixture and a small exotherm was observed. The reaction 
mixture was boiled under reflux and under a nitrogen atmosphere. A pale 
orange colour was observed and, after 3 h, a further portion of HMDS (0.7 ml, 
5 .25 mmol) was added dropwise This resulted in the formation of a deep red 
mixture which was boiled under reflux for 14 h and cooled. Ethyl 
trifluoroacetate (0.66 ml, 5.57 mmol) in THF (0.5 ml) was added slowly to the 
mixture at ambient temperature. The mixture was boiled under reflux for 7 d. 
T.l.c showed that the reaction was proceeding very slowly, therefore the THF 
was distilled off under a nitrogen atmosphere and anhydrous toluene (15 ml) 
was added. The suspension was boiled under reflux for 7 d. After cooling, the 
reaction mixture was filtered and the solvent of the filtrate was evaporated. 
Pentane (40 ml) was added to the residue and the suspension was filtered. The 
solvent was evaporated from the filtrate to yield 0.71 g (46%) of (Z)-1,1,1- 
trifluoro-2-ethoxy-5-(phenylmethoxy)pent-2-ene (23) following distillation 
(Kugelrohr). Data: colourless liquid, bp20 140-145°C, !H NMR (400 MHz, 
CDCI3) 1.30 (3H, t, J=  7.0 Hz, CH3 CH2O), 2.50 (2 H, m, C C -C H 2 CH2), 3.52 
(2H, t, J  = 6  4 Hz, BnOCH2 CH2), 3.91 (2H, q, J =  7.0 Hz, CH3CH2O), 4.52 
(2H, s, PhQLO), 5.73 ( 1 H, t, J  = 7.3 Hz, CHCCH2), 7.33 (5H, m, PhCH20), 
19F NMR (376 MHz, CDC13) -70.04 (s); IR (film) 1690 (s), 740 (s), 700 (s); 
MS (El) 274.1138 (NT, 1) (C14H 17F3 0 2 requires 274.1181), 188 (2), 91 (100).
(24)
4-Methoxybutanoic acid (24). 4-Methoxybutanoic acid (24) was synthesised 
essentially by the method described by Archer's group131. A mixture of 
tetrahydrofuran-2-one (43 .0 g, 500 mmol) in 2 M NaOH solution (500 ml) was 
stirred at ambient temperature for 2 d and was heated under reflux for 3.5 h. 
After cooling, the alkaline solution was washed with ether (3 x 50 ml) and the 
was solvent evaporated to give a white slurry. The slurry was dissolved in 10
155
M NaOH solution (75 ml) and was then treated alternately with dimethyl 
sulphate (3 x 25 ml) and 10 M NaOH solution (3 x 25 ml). The mixture was 
heated to 90°C resulting in a moderate exotherm and the precipitation of a 
white solid. The temperature was maintained between 60-70°C for 1 h. After 
cooling, the reaction mixture was extracted with ether (3 x 100 ml) and the 
combined extracts were washed with brine (50 ml) and dried (MgS04). The 
solvent was evaporated to give a yellow oil which was distilled (Kugelrohr) to 
give a colourless oil, later found to still contain some lactone The oil was 
dissolved in ether ( 1 0 0  ml) and washed with saturated sodium hydrogen 
carbonate solution (2 x 100 ml). The alkaline solution was then acidified and 
extracted with ether (3 x 100 ml). The organic extracts were dried (MgS04) 
and the solvent was evaporated to yield 3 .93 g (7%) of 4-methoxybutanoic 
acid (24). Data: colourless oil; bp2o 125-130°C (literature131 bp8 103-105°C); 
•H NMR (270 MHz, CDC13) 1 8 8  (2 H, qu, J  = 7.3 Hz, CH2CH2 CH2), 2  43 
(2H, t, J=  7.3 Hz, CH2CH2CO2H), 3.32 (3H, s, CH30), 3 41 (2H, t, J  = 6.2 
Hz, CH3OCH2 CH2), 10.70 ( 1 H, br, C 0 2H); IR (film) 3000 (br), 1715 (s), 1150 
(s).
(25)
Ethyl 4-methoxybutanoate (25). Ethyl 4-methoxybutanoate (2) was 
synthesised essentially by the method described by Archer's group131. A 
solution of 4-methoxybutanoic acid (24) (20.8 g, 17.6 mmol) was heated for 
16 h in ethanol (70 ml) and concentrated HC1 (0.5 ml). Most of the solvent was 
removed by evaporation and to the remaining residue was added saturated 
sodium hydrogen carbonate solution (150 ml). The mixture was extracted with 
ether (5 x 50 ml) and the combined organic extracts were washed with brine 
(50 ml), dried (MgS04) and the solvent evaporated The residue was distilled 
(Kugelrohr) to yield 2.57 g (67%) of ethyl 4-methoxybutanoate (25). Data: 
colourless oil; bp 170-175°C (literature131 bpi5 75-76°C); lH NMR (270 MHz, 
CDCI3 ) 1.26 (3H, t, J  = 7.1 Hz, CO2CH2CH3), 1.82 (2 H, qu, J  = 6  4 Hz,
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CH2CH2CH2), 2.31 (2H, t, J  = 7.5 Hz, C H ^ C O ;,) ,  3.25 (3H, s, CH30),
3.34 (2H, t, J  = 6.2 Hz, CH3OCH2 CH2), 4 06 (2H, q, J  = 7.2 Hz, 
C 02CH2CH3); IR (film) 1740 (s).
(26)
Ethyl 4-methoxy~2-(trifluoroacetyl)butanoate (26). Ethyl 4-methoxy-2- 
(trifluoroacetyl)butanoate (26) was synthesised essentially by the method 
described by Archer’s group131. Ethanol (0.01 ml) was added to a stirred slurry 
of NaH (80% dispersion in oil, 1.00 g, 42.0 mmol) in THF (10 ml) under a 
nitrogen atmosphere. This was followed by the dropwise addition of ethyl 4- 
methoxybutanoate (25) (1.60 g, 10.0 mmol) in THF (5 ml) and ethyl 
trifluoroacetate (1 45 ml, 12.0 mmol) in THF (10 ml). The mixture was heated 
under reflux for 2 h followed by stirring at ambient temperature for 48 h. After 
acidification with 2 M HC1, water (100 ml) was added and the aqueous layer 
was extracted with ether (3 x 100 ml). The combined organic extracts were 
washed with brine (50 ml) and dried (MgS04). The solvent was evaporated 
and the crude residue was distilled (Kugelrohr) to yield 2.66 g (69%) of ethyl
4-methoxy-2-(trifluoroacetyl)butanoate (26). Data, colourless oil; bp20 100°C 
(literature131 bp13 85-86°C), 19F NMR (84 MHz, CDC13) -84.28 (s, hydrate?),
-78.19 (s, keto), -67.40 (s, enol); IR (film) 2750 (br), 1790 (s), 1750 (s), 1170 
(s), 700 (m).
5-Methoxy-l,l,l-trifluoropentan-2-one (27). 5-Methoxy-l,l,l-trifluoro- 




Archer's group131. A solution of ethyl 4-methoxy-2-(trifluoroacetyl)butanoate
(26) (1.73 g, 7.16 mmol) in acetic acid : water (87 : 13) (2 ml) and 
concentrated HC1 (0.02 ml) was heated under reflux for 16 h. The mixture was 
allowed to cool and then was carefully neutralised with potassium carbonate. 
Water (5 ml) was added and the mixture was extracted with ether ( 4 x 5  ml). 
The combined organic extracts were washed with 4% aqueous sodium 
hydrogen carbonate solution (10 ml), they were then dried (MgS04) and the 
solvent was removed by evaporation. The crude material was distilled 
(Kugelrohr) to yield 0.50 g (41%) of 5-methoxy-l,l,l-trifIuoropentan-2-one
(27). Data: colourless oil; bp 115-125°C at atmospheric pressure (literature131 
bp 120-123°C); lU NMR (270 MHz, CDC13) 1.99 (2H, qu, J  = 6.4 Hz, 
CH2CH2CH2), 2 83 (2H, t, J  = 7 0 Hz, CH2CH2COCF3), 3.33 (3H, s, 
CH3 0 CH2), 3 42 (2H, t, J  = 5.7 Hz, CHsOO^CH^; 19F NMR (84 MHz, 
CDC13) -77.40 (s); IR (film) 3250 (br), 1715 (s), 1400 (m), 1110 (m).
CF
(28)
5-Phenyl-l,l»l-trifluoropentan-2-one (28). A solution of ethyl 4-phenyl-2- 
(trifluoroacetyl)butanoate (31) (3.00 g, 10.4 mmol) in anhydrous DMF (24 ml) 
was heated under reflux in the presence of lithium chloride (0.88 g, 20.8 mmol) 
and water (0.19 ml, 10.4 mmol) for 4.5 h. Water (12 ml) and DCM (100 ml) 
were added and the organic phase was washed with water ( 5 x 1 0  ml) and 
dried (MgS04). Chromatography (hexane : ethyl acetate ; 5 : 1) of the 
evaporation residue gave a yellow liquid which was further purified by 
distillation (Kugelrohr) to yield 1.13 g (50%) of 5-phenyl-1,1,1-trifluoro- 
pentan-2-one (28). Data: colourless liquid; bp20 100°C (literature190 bpio 90°C), 
lU NMR (270 MHz, CDC13) 2.01 (2H, qu, J  = 7.3 Hz, CH2CH2 CH2), 2.67 
(2H, t, J=  7.7 Hz, CH2CH2 COCF3), 2.71 (2H, t, J=  7.2 Hz, PhCHzCH^, 7.24 
(5H, m, Ph); 19F NMR (376 MHz, CDC13) -79.80 (s).
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(30)
Ethyl 4-phenylbutanoate (30). 4-Phenylbutanoic acid (10.0 g, 60.9 mmol) 
was dissolved in ethanol (500 ml) and concentrated sulphuric acid (5 ml) was 
added cautiously The solution was boiled under reflux for 3 h. The reaction 
mixture was allowed to cool to ambient temperature and most of the solvent 
was evaporated. Ether (250 ml) was added followed by the slow addition of 
saturated sodium hydrogen carbonate solution (50 ml), which resulted in a 
moderate exotherm. The mixture was stirred for 30 min then separated. The 
organic phase was washed with saturated sodium hydrogen carbonate solution 
(50 ml), water (2 x 50 ml) and brine (30 ml). The organic phase was dried 
(MgS04) and the solvent evaporated to yield 11.7 g (96%) of ethyl 4- 
phenylbutanoate (30) Data: pale yellow oil; *H NMR (270 MHz, CDC13) 1.21 
(3H, t, J  = 7.2 Hz, C 02CH2CH3), 1.91 (2H, qu, J  = 7.5 Hz, CH2CH2 CH2), 
2 28 (2H, t, J=  7.7 Hz, CH2CH2CO2), 2 61 (2H, t, J=  7.3 Hz, PhCHbCH,), 
4.08 (2H, q, J =  7.1 Hz, C 02CH2CH3); IR (film) 1740 (s).
CF
(31)
Ethyl 4-phenyl-2-(trifluoroacetyl)butanoate (31). LDA (19.5 mmol) was 
prepared by the addition of w-butyl lithium (2.5 M solution in hexanes, 8.6 ml, 
21.5 mmol) to a stirred solution of diisopropylamine (2.74 ml, 19.5 mmol) in 
THF (30 ml) at 0°C. After 15 min stirring, the temperature was reduced to 
-78°C and a solution of ethyl 4-phenylbutanoate (30) (2.50 g, 13 .0 mmol) in 
THF (15 ml) was added dropwise. The mixture was stirred at -78°C for 30
159
min. A solution of ethyl trifluoroacetate (3 .1 ml, 26.0 mmol) in THF (10 ml) 
was added dropwise. The mixture was maintained at -78°C for 20 min before 
being allowed to warm gradually to ambient temperature After stirring for a 
further 24 h the reaction was quenched with 1 M aqueous HC1 solution (15 
ml). The organic phase was washed with water (10 ml) and brine (10 ml). The 
aqueous phase of the reaction mixture was extracted with ether (2 x 25 ml) 
and the organic extracts washed with brine (10 ml). The combined organic 
phases were dried (MgS04) and the majority of the solvent was evaporated. 
The remaining solvent and TFA was removed by distillation (Kugelrohr) at 
atmospheric pressure yielding 3.00 g of ethyl 4-phenyl-2-(trifluoroacetyl)- 
butanoate (31). Data: yellow oil; NMR data includes values for the 10% 
enolisation of (31) observed, 'H NMR (400 MHz, CDC13) 1.26 (2.7H, t, J  = 
6.7 Hz, CO2CH2CH3), 1.27 (0.3H, m, CO2 CH2CH3 , enol), 2.30 (2H, m, 
PhCHhCHz), 2.65 (1.8H, m, CH2CH2CHC02Et(C0CF3)), 2.70 (0.2H, m, 
CH2CH2CC02Et(CCF3OH), enol), 3.81 (0.9H, t, J  = 7.3 Hz,
CH2CHC02Et(C0CF3)), 4 21 (1.8H, q, J = 5 9 Hz, C 02CH2CH3), 4 24 (0.2H, 
q, J  = 5 9 Hz, C 02CH2CH3, enol), 7.24 (5H, m, Ph), 12.91 (0.1H, s, OH, 
enol); 19F NMR (376 MHz, CDC13) -84.01 (s, hydrate?), -77.10 (s, keto), 
-67.37 (s, enol); IR (film) 1750 (s), 1680 (s)
(32)
Ethyl 2-trif1uoromethyl-4,5-dihydro-l,3-dioxole-2-acetate (32) Ethyl 2- 
trifluoromethyl-4,5-dihydro-l,3-dioxole-2-acetate (32) was synthesised 
essentially using the method described by Langlois's group137. Ethyl 4,4,4- 
trifluoro-3-oxobutanoate (7.94 ml, 54.3 mmol) was added to sodium hydride 
(80% dispersion in oil, 1.63 g, 54.3 mmol) in ethanol (40 ml) The mixture was 
stirred for 40 min and the solvent was evaporated to give an off white solid 
Chloroethanol (10 ml) was added to the solid and the solution was boiled
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under reflux for 2 d. After cooling to ambient temperature, ice («ca. 15 g) was 
added followed by 5 M HC1 solution (0.5 ml). The aqueous layer was extracted 
with ether (3 x 2 0  ml) and the combined organic extracts were washed to 
neutrality with water (3 x 2 0  ml) followed by a wash with brine ( 2 0  ml). The 
organic phase was dried (MgS04) and the was solvent evaporated to yield 7.44 
g (60%) of ethyl 2-trifluoromethyl-4,5-dihydro-1,3-dioxol-2-acetate (32) 
following distillation (Kugelrohr). Data: colourless liquid; bp2o 90-95°C 
(literature137 bp20 96-98°C); ‘H NMR (400 MHz, CDC13) 1.28 (3H, t, . /=  7.3 
Hz, CO2CH2CH3), 2.89 (2H, s, RCH2C 02), 4.20 (6 H, m, CH20); 19F NMR 
(376 MHz, CDCI3) -84 16 (s); IR (film) 1750 (s), 1175 (s).
(33)
Ethyl 2-trifluoromethyl-4,5-dihydro-1 ,3-dioxol-a-(l-butyl)acetate (3 3 ) 
LDA (4.90 mmol) was prepared by the addition of «-butyl lithium (2.5 M 
solution in hexanes, 3.19 ml, 5.38 mmol) to diisopropylamine (0.69 ml, 4.90 
mmol) at 0°C. After 15 min stirring, the temperature of the gel was reduced to 
-78°C and ethyl 2-trifluoromethyl-4,5-dihydro-l,3-dioxol-2-acetate (32) ( 1 . 0 0  
g, 4.40 mmol) in anhydrous THF ( 8  ml) was added dropwise forming a yellow- 
brown solution which was stirred in a nitrogen atmosphere at -78°C for 1 h 
HMPA (2.04 ml, 11.4 mmol) (caution: carcinogen) was added to the solution 
followed by 1-iodobutane (0.5 ml, 4.38 mmol) in THF (2 ml) after 15 min. The 
mixture was stirred at -78°C for 1 h before being allowed to warm to ambient 
temperature during a 16 h period. The reaction mixture was quenched by the 
addition of 2 M HC1 solution (5ml) and extracted with ethyl acetate ( 5 x 1 0  
ml) The combined organic extracts were washed with half saturated sodium 
metabisulphite solution (2 x 15 ml) and washed to neutrality with water (3 x 
15 ml) The solvent was evaporated and the residue was dissolved in ether
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(100 ml) and further washed with water (5 x 10 ml) to remove any HMPA. 
After drying (MgS04), the solvent was evaporated to yield 1.04 g (84%) of 
ethyl 2-trifluoromethyl-4,5-dihydro-1,3-dioxol-a-( 1 -propyl)acetate (33) 
following distillation (Kugelrohr). Data: pale yellow oil; bp04 95-105°C; !H 
NMR (400 MHz, CDC13) 0.89 (3H, t, J = 7.0 Hz, CHzCH.CH,), 1.27 (3H, t, J  
= 7.0 Hz, OCH2CH3), 1 2-1.8 (6H, m, CHzOfcCHzCH,), 2.97 (1H, dd, J  = 
3.1, 11.9 Hz, CHC02), 4 17 (6H, m, 0CH2CH20  and CChCIkCH,); 19F NMR 




Ethyl 2-(trifluoroacetyI)hexanoate (34) To a stirred solution of ethyl 2- 
trifluoromethyl-4,5-dihydro-1,3-dioxol-a-(l-butyl)acetate (33) (1.00 g, 3.50 
mmol) in hexane (20 ml) at -10°C was added boron tribromide (5.25 ml, 5.25 
mmol). After 1.5 h, water (10 ml) was added carefully. The mixture was 
extracted with ether (3 x 15 ml) and the combined organic extracts were 
washed to neutrality with water (5 x 10 ml) and then washed with brine (10 
ml). After being dried (MgS04), the solvent was evaporated to yield 0.56 g 
(69%) of ethyl 2-(trifluoroacetyl)hexanoate (34). Data: yellow oil; JH NMR 
(400 MHz, CDC13) 0.92 (3H, t, J  = 6 8 Hz, CH2CH2CH3 ), 1.27 (3H, m, 
OCH2CH3), 1.35 (4H, m, OLCHiCfLCH^, 3.85 (1H, m, CH, chiral centre),
4.22 (2H, q, J =  7.1 Hz, O C ^C H ^; 19F NMR (376 MHz, CDC13) -78.32 (s, 
enol), -78.55 (s, keto); MS (El) 241.0998 (M% 28, l3C isotope) 






l,l,l-Trifluoroheptan-2-one (35). A solution of ethyl 2-(trifluoroacetyl)- 
hexanoate (34) (0.55 g, 2.30 mmol) in anhydrous DMF (8 ml) was heated to 
100°C in the presence of lithium chloride (0.28 g, 6.66 mmol) and water (0.11 
ml, 3 .33 mmol) for 2 h 15 min. The solution was allowed to cool to ambient 
temperature and water (4 ml) was added. The mixture was extracted with 
petroleum ether bp 40-60°C (4 x 10 ml) and the combined organic extracts 
were washed with water ( 5 x 1 0  ml) and with brine (10 ml). After being dried 
(MgS04), the solvent was evaporated to yield 0.05 g (13%) of 1,1,1-trifluoro- 
heptan-2-one (35) following distillation (Kugelrohr) Data: colourless liquid, 
bp 80-85°C (literature191 bp 100°C) ;!H NMR (400 MHz, CDC13) 0.91 (3H, t, 
J =  6.7 Hz, CHzCIL), 1.63 (4H, m, QfedfcQfeGHs), 2 04 (2H, qu, J =  7.3 
Hz, CF3COCH2CH2CH2), 2 70 (2H, t, J = 7.3 Hz, CF3COCH2), 19F NMR (84 
MHz, CDC13) -79.75 (s).
(CHjfeK
(36)
Ethyl 1,1 ,l-trifluoro-2-(dimethyIhydrazono)butanoate (36). Ethyl 1,1,1- 
trifluoro-2-(dimethylhydrazono)butanoate (36) was synthesised essentially 
using the method described by Langlois's group137 A solution of ethyl 4,4,4- 
trifluoro-3-oxobutanoate (6.90 g, 37.5 mmol) and 1,1-dimethylhydrazine (2.75 
g, 45.8 mmol) in ethanol (14 ml) was boiled under reflux for 20 h After 
cooling, the solvent was evaporated to yield 6.50 g (77%) of ethyl 1,1,1- 
trifluoro-2-(dimethylhydrazono)butanoate (36) following distillation 
(Kugelrohr). Data: pale yellow liquid, bp20 85-90°C (literature137 bpn 85- 







pentanoate (37). LDA (8.15 mmol) was prepared by the addition of w-butyl 
lithium (2.5 M solution in hexanes, 3.58 ml, 8.95 mmol) to diisopropylamine 
(1.14 ml, 8.15 mmol) in THF (15 ml) at 0°C. After 15 min stirring, the 
temperature was reduced to -78°C and ethyl l,l,l-trifluoro-2- 
(dimethylhydrazono)butanoate (36) (1.68 g, 7.41 mmol) was added to the 
solution dropwise. After being stirred for 15 min at -78°C, the temperature of 
the reaction mixture was allowed to warm to 0°C for 30 min The temperature 
was lowered to -78°C and l-iodo-3-(phenylmethoxy)propane (21) (2.25 g,
8.15 mmol) in THF (5 ml) was added dropwise, followed immediately by 
HMPA (caution: carcinogen) (3.98 ml, 22.2 mmol). The temperature was 
allowed to warm to 0°C for 2 h and then to ambient temperature for 31 h The 
reaction mixture was quenched by the addition of 10% aqueous HC1 solution 
(10 ml) and stirring continued for 1 h. The mixture was extracted with ether (5 
x 10 ml) and the combined organic extracts were washed with half saturated 
sodium metabisulphite solution ( 2 x 1 5  ml) and with water (3 x 10 ml) The 
organic phase was dried (MgS04) and the solvent was evaporated to yield 
1.67g (61%) of ethyl 5-(phenylmethoxy)-2-(2,2,2-trifluoro-l-(dimethyl- 
hydrazono)ethyl)pentanoate (37) after chromatography (DCM). Data: pale 
yellow liquid, l9F NMR (84 MHz, CDC13) -66.01
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Ethyl 5-(pheny!methoxy)-2“(triflucroacetyI)pentanoate (38). To a solution 
of ethyl 5-(phenylmethoxy)-2-(2,2,2-trifluoro-1 -(dimethylhydrazono)ethyl)- 
pentanoate (37) (1.47 g, 3.93 mmol) in ethanol : water (95 : 5) (15 ml) was 
added iodomethane (3.67 ml, 59.0 mmol) and the mixture was boiled under 
reflux for 3 d. After cooling, the solvent and reagent were evaporated to give 
an orange liquid and white solid. DCM (50 ml) was added and the suspension 
was filtered. The solvent of the filtrate was evaporated to yield 1.06 g (81%) of 
ethyl 5-(phenylmethoxy)-2-(trifluoroacetyl)pentanoate (38) after 
chromatography (petroleum ether 40/60 : ethyl acetate ,3  : 1). Data: dark 




6-(Phenylmethoxy)-l,l,l-trifluorohexan-2-one (39). A solution of ethyl 5- 
(phenylmethoxy)-2-(trifluoroacetyl)pentanoate (38) (1.02 g, 3.05 mmol) in 
anhydrous DMF (8 ml) was heated to 100°C in the presence of lithium chloride 
(0.26 g, 6.10 mmol) and water (0.06 ml, 3 .05 mmol) for 3 h. The solution was 
allowed to cool to ambient temperature and water (4 ml) and DCM (20 ml) 
were added. The organic layer was washed with water (5 x 5 ml) and the 
solvent was evaporated to yield 0.62 g (78%) of 6-(phenylmethoxy)-1,1,1- 
trifluorohexan-2-one (39) after chromatography (petroleum ether 40/60 : ethyl 
acetate ; 2 : 1). Data: colourless liquid, *H NMR (400 MHz, CDC13) 1.65 (2H, 
ca. qu, J  = 5 8 Hz, CF3COCH2CH2CH2), 1.79 (2H, qu, J  = 7 9 Hz,
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CHsCHbCHzOBn), 2.75 (2H, t , J =  7.3 Hz, CF.COCILCH,), 3.49 (2H, t, J  = 
5 8 Hz, CH2CH20Bn), 4 49 (2H, s, OCHzPh), 7.33 (5H, m, PhCH20); 19F 
NMR (CDCls) -79.82 (s); MS (El) 260.1010 (M+, 5) (Ci3H15F30 2 requires 
260.1024), 107 (31), 91 (100).
(40)
l-(6-Bromohexyl)-2-nitroimidazole (40). A solution of 2-nitroimidazole 
(3 .00 g, 26.5 mmol) in anhydrous DMF (150 ml) was treated with potassium 
te/7-butoxide (3.13 g, 26.5 mmol) and the mixture was heated at 130°C for 20 
min. The resulting solution was cooled to ambient temperature and treated 
with 1,6-dibromohexane (20 g, 79.6 mmol). The solution was heated at 130 °C 
for 1.5 h. After being cooled, most of the solvent was removed by evaporation 
Water (50 ml) was added to the residue and the mixture was extracted with 
DCM (3 x 50 ml). The combined organic extracts were washed with water (5 
x 10 ml) and dried (MgS0 4 ) and the solvent was evaporated. Chromatography 
(hexane : ethyl acetate ; 4 : 3 to 1 : 1) yielded 3.99 g (54%) of l-(6- 
bromohexyl)-2-nitroimidazole (40) Data: yellow oil; *H NMR (400 MHz, 
CDC13) 1.39 (2H, m, imidazole-CH2CH2CH2CH2CH2CH2Br), 1.52 (2H, m, 
imidazole-CH2CH2CH2CH2CH2CH2Br), 1.89 (4H, m, imidazole-
CH2CH2CH2CH2CH2CH2Br), 3.41 (2H, t, J=  6 6 Hz, CH.QEBr), 4.43 (2H, 
t, J =  7.3 Hz, imidazole-CH2 CH2), 7.10 (1H, d, J =  1.1 Hz, imidazole 4-H),
7.15 (1H, d,J= 1.1 Hz, imidazole 5-H); IR (film) 1540 (s).
f = \
l-(6-IodohexyI)-2-nitroimidazole (41). To a stirred solution of l-(6-
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bromohexyl)-2-nitroimidazole (40) (3.94 g, 12.3 mmol) in anhydrous acetone 
(40 ml) was added sodium iodide (7.20 g, 48.0 mmol). The solution was 
stirred at ambient temperature in the dark and in a nitrogen atmosphere for 16 
h. The reaction mixture was filtered and most of the acetone was evaporated. 
To the residue was added ether (50 ml) and water (10 ml) and the organic 
layer was washed with half saturated metabisulphite solution (2 x 15 ml) and 
brine (10 ml). After being dried (MgS0 4 ), the solvent was evaporated to yield 
3.69 g (93%) of l-(6-iodohexyl)-2-nitroimidazole (41). Data: pale yellow 
liquid, ‘H NMR (270 MHz, CDC13) 1.43 (4H, m, imidazole-
CH2CH2CH2CH2 CH2CH2I), 1 84 (4H, m, imidazole-CHjCHiCHiCHjCJi,- 
CH2I), 3.19 (2H, t , J  = 6 8 Hz, CH2CH2I), 4.49 (2H, t, 7.3 Hz, imidazole-




l-yI)octanoate (42). LDA (11.1 mmol) was prepared by the addition of n- 
butyl lithium (2.5 M solution in hexanes, 4.9 ml, 12.3 mmol) to 
diisopropylamine (1.56 ml, 11.1 mmol) in THF (5 ml) at 0°C. After 15 min 
stirring, the temperature was reduced to -78°C and ethyl l,l,l-trifluoro-2- 
(dimethylhydrazono)butanoate (36) (2.29 g, 10.1 mmol) in THF (8 ml) was 
added to the solution dropwise. After stirring for 15 min at -78°C, the 
formation of a green anion was observed and the temperature was allowed to 
warm to 0°C for 40 min. The temperature was lowered to -78°C and l-(6- 
iodohexyl)-2-nitroimidazole (41) (3 .60 g, 11.1 mmol) in THF (7 ml) was added 
dropwise, followed immediately by HMPA (caution: carcinogen) (5.29 ml,
30.4 mmol). The temperature was allowed to warm to 0°C for 2 h and then to
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ambient temperature for 19 h. The reaction mixture was quenched with 10% 
aqueous HC1 solution (5 ml) and stirring continued for 30 min. The mixture 
was extracted with ether (5 x 20 ml) and the combined organic extracts were 
washed with half saturated sodium metabisulphite solution ( 2  x 2 0  ml) and 
with water (3 x 1 0  ml) to neutrality. The organic phase was dried (MgS04) 
and the solvent was evaporated to yield 2.80 g (6 6 %) of ethyl 2 -(2 ,2 ,2 - 
trifluoro-1 -(dimethy!hydrazono)ethyl)-8-(2-nitroimidazol-1 -y!)octanoate (42) 
after chromatography (hexane : ethyl acetate ; 2 : 1). Data, yellow oil; !H 
NMR (400 MHz, CDC13) 1.24 (3H, t , J =  7.3 Hz, CO2CH2CH3 ), 1.38 (4H, m, 
imidazole-CH2CH2CH2 CH2 CH2CH2), 1.85 (6 H, m, imidazole-
CH2CH2CH2 CH2CH2CH2CH(C(NNMe2)CF3 )C0 2Et), 2.62 (6 H, s, NMe2), 
4.17 (2 H, t, J  = 6.41 Hz, imidazole-CHzCHz), 4.28 ( 1 H, t, J  = 7.02 Hz, 
CH2CH(C(NNMe2)CF3)C0 2Et), 4 41 (2 H, q, J  = 7 6  Hz, CO2CH2CH3), 7 1 0  
(1H, d , J=  0.9 Hz, imidazole 4-H), 7.14 (1H, d, J =  0.9 Hz, imidazole 5-H), 
19F NMR (376 MHz, CDC13) -66.25 (s); MS (Cl) 422.2015 (M" + H, 100) 
(C 17H27F3N5O4 requires 422.2015), 392 (25), 324 (20).
(43)
Ethyl 2-(trifluoroacetyl)-8-(2-nitroimidazol-l-yl)octanoate (43) To a 
solution of ethyl 2-(2,2,2-trifluoro-l-(dimethylhydrazono)ethyl)-8-(2-nitro- 
imidazol-l-yl)octanoate (42) (2.60 g, 6.17 mmol) in ethanol : water (95 : 5) 
(26 ml) was added iodomethane (5.8 ml, 92.5 mmol) and the mixture was 
boiled under reflux for 5 d. After cooling, the solvent and reagent were 
evaporated, and DCM (50 ml) was added. The suspension was washed with 
half saturated sodium metabisulphite solution ( 2 x 1 0  ml) and brine (10 ml). 
The organic phase was dried (MgS04) and the solvent was evaporated to yield 
0.63 g (27%) of ethyl 2-(trifluoroacetyl)-8-(2-nitroimidazol-l-yl)octanoate
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(43) after chromatography (hexane : ethyl acetate ; 4 : 3 to 3 : 4). Data: dark 
red oil; ‘H NMR (270 MHz, CDC13) 1.27 (3H, t, J =  7.0 Hz, C 02CH2CH3), 
1.37 (6H, m, imidazoIe-CH2CH2CH2CH2CH2CH2CH(COCF3)C02Et)), 1 95 
(4H, m, imidazole-CH2CH2CH2CH2CH2CH2), 4.22 (2H, q, J  = 7.1 Hz, 
C 02CH2CH3), 4.26 (1H, m, CH2CH(C0CF3)C02Et), 4 41 (2H, t, J =  7.5 Hz, 
imidazole-OfcCH,), 7.09 (1H, d, J=  0.9 Hz, imidazole 4-H), 7.15 (1H, d, J  = 
1.1 Hz, imidazole 5-H); 19F NMR (376 MHz, CDC13) -84.02 (s, hydrate), -
78.22 (s, keto), -67.26 (s, enol), MS (Cl) 380 (M+ + H, 100), 350 (20), 333 
(38).
2-Nitro-l-(8-oxo-9,9,9-trifluorononyI)imidazole (44) A solution of ethyl 2- 
(trifluoroacetyl)-8-(2-nitroimidazol-l-yl)octanoate (43) (0.62 g, 1.63 mmol) in 
anhydrous DMF (4 ml) was heated to 100°C in the presence of lithium chloride 
(0.14 g, 3 .26 mmol) and water (0.03 ml, 1.63 mmol) for 4 h. The solution was 
allowed to cool to ambient temperature and water (4 ml) and DCM (20 ml) 
were added. The organic layer was washed with water (5 x 5 ml) and the 
solvent evaporated to yield 0.47 g (94%) of 2-nitro-l-(8-oxo-9,9,9- 
trifluorononyl)imidazole (44). Data: pale yellow oil, *H NMR (400 MHz, 
CDC13) 1.37 (6H, m, im idazole-CH^HzCH^H ^H^H^H.COCF,), 1.68 
(2H, qu, J  = 6.7 Hz, CH2CH2CH2COCF3), 1 86 (2H, qu, J  = 7.3 Hz, 
imidazole-CH2CH2CH2), 2.72 (2H, t, J  = 7.0 Hz, CH.CEhCOCF,), 4.41 (2H, 
t, J =  7.3 Hz, imidazole-CH2 CH2), 7.11 (1H, d, J =  0.9 Hz, imidazole 4-H), 
7 15 (1H, d, J=  0.9 Hz, imidazole 5-H); 19F NMR (376 MHz, CDC13) -79.85 






(±)-l,l,l-Trifluoro-9-(2-imidazoI-l-yl)nonan-2-oI (45) 2-Nitro-l-(8-oxo- 
9,9,9-trifluorononyl)imidazole (44) (0.10 g, 0.33 mmol) was dissolved in 
ethanol : water (95 : 5) (1 ml) and sodium borohydride (0.006 g, 0.16 mmol) 
was added The mixture was stirred at ambient temperature for 3 h, then 
quenched with 2 M aqueous HC1 solution (3 ml). Extraction of the reaction 
mixture with ether ( 3 x 1 0  ml) followed by washing of the extracts with brine 
(5 ml), drying (MgS04) and evaporation of the solvent yielded 0 .09 g (87%) of 
(±)-l,l,l-trifluoro-9-(2-imidazol-l-yl)nonan-2-ol (45). Data: colourless oil; 
NMR (400 MHz, CDC13) 1 29 (8H, m, imidazole-CH2CH2CH2CH2 - 
CH2CH2CH2CH(OH)CF3), 1.54 (2H, m, CH2CH2CH(OH)CF3), 1.78 (2H, m, 
imidazole-CH2CH2 CH2), 3 85 (1H, m, CH2CH(OH)CF3), 4 34 (2H, t, J =  7.7 
Hz, imidazole-QECHA 7.04 (1H, s, imidazole 4-H), 7.06 (1H, s, imidazole 5- 
H), 19F NMR (376 MHz, CDC13) -80.44 ( d ,  J H-f  = 5.8 Hz), IR (film) 3350 (br), 




5-TrifluoroacetyI-3,4-dihydro-2/f-pyran (52) 5-Trifluoroacetyl-3,4- 
dihydro-2//-pyran (52) was synthesised essentially by the method described by 
Hojo's group141. To stirred solution of 3,4-dihydro-2//-pyran (5.0 g, 59.4 
mmol) and pyridine (1.6 ml, 19.8 mmol) in DCM (40 ml) was added TFAA 
(12.0 ml, 85.14 mmol) with caution. This produced a large exotherm which 
was controlled with cooling. Stirring was continued at ambient temperature for 
16 h. Water (10 ml) was added to the reaction mixture producing a moderate
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exotherm. The organic phase was washed with water (10 ml) and 0.6 M 
sodium hydrogen carbonate solution ( 1 0  ml). After being dried (MgS04), the 
solvent was evaporated to yield 10.4 g (97%) of 5-trifluoroacetyl-3,4-dihydro- 
2//-pyran (52) following distillation (Kugelrohr). Data: colourless liquid, bp2o 
65-70°C (literature141 bp , 0 64.6°C); ‘H NMR (400 MHz, CDC13) 1 .96(2H, br 
qu, J  = 6. 0  Hz, CH2CH2CH2), 2.34 (2H, t, 6.0 Hz, CH2C H rC =C ), 4.21
(2 H, t, J  = 6. 0  Hz, CH2CH2O), 7.83 (1H, s, O C H C R J , 13C NMR ( 1 0 0  MHz, 
CDCI3 ) 17.93 (CH2CH2CH2), 20.53 (CH2-C=C), 67.84 (CH20 ), 116 74 (q, 
f  =292 Hz, CF3), 162.35 (q, JC-f = 35 Hz, C=0 ); l9F NMR (376 MHz, CDC13) 
-70.37(s); IR (film) 1685 (s), 1615 (s); MS (El) 180 0395 (M*. 29) (C7H7F3O2 
requires 180.0398), 1 1 1  (100), 83 (35), 55 (28), 27 (31)
a-(Trifluoromethyl)tetrahydropyran-3-methanol (55).
Method A:
5-Trifluoroacetyl-3,4-dihydro-2//-pyran (52) (0.50 g, 2.78 mmol) was 
dissolved in methanol (9 ml) and a slurry of 10% palladium on activated carbon 
(0 . 1 0  g) in methanol (1 ml) was added. The suspension was evacuated and 
charged with hydrogen (x3) before being stirred in a hydrogen atmosphere for 
4 h. The flask was evacuated, air was admitted, the suspension was filtered 
through a pad of Celite® and the solvent was evaporated to yield 0.50 g (98%) 
of a-(trifluoromethyl)tetrahydropyran-3-methanol (55).
Method B:
5-Trifluoroacetyl-3,4-dihydro-2//-pyran (52) (0.50 g, 2.78 mmol) was 
dissolved in hexane (9 ml) and THF (0.5 ml) and a slurry of 10% palladium on 
activated carbon (0.10 g) in hexane (1 ml) was added. The suspension was 
evacuated and charged with hydrogen (x3) before being stirred in a hydrogen
(55)
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atmosphere for 30 min. The flask was evacuated, air was admitted, the 
suspension was filtered through a pad of Celite® and the solvent was 
evaporated to yield 0.50 g (100%) of a-(trifluoromethyl)tetrahydropyran-3- 
methanol (55).
Method C:
5-Trifluoroacetyl-3,4-dihydro-2//-pyran (52) (0.50 g, 2.78 mmol) was 
dissolved in methanol (9 ml) and potassium acetate (0.20 g) and a slurry of 
10% palladium on activated carbon (0.10 g) in methanol (1 ml) were added. 
The suspension was evacuated and charged with hydrogen (x3) before being 
stirred in a hydrogen atmosphere for 2 h. The flask was evacuated, air was 
admitted, the suspension was filtered through a pad of Celite® and the solvent 
was evaporated. To the residue was added DCM (30 ml), and the resulting 
precepitate filtered. Removal of the solvent by evaporation yielded 0.39 g 
(76%) of a-(trifluoromethyl)tetrahydropyran-3-methanol (55).
Method D:
5-Trifluoroacetyl-3,4-dihydro-2//-pyran (52) (0.30 g, 1.67 mmol) was 
dissolved in methanol (9 ml) and a slurry of 10% palladium on activated carbon 
(0.08 g) in methanol (1 ml) was added. The temperature of the reaction 
mixture was reduced to -78°C and the suspension was evacuated and charged 
with hydrogen (x3) before being stirred in a hydrogen atmosphere. The 
temperature of the reaction mixture was maintained at -78°C for 3 h, after 
which t.l.c. indicated mostly starting material together with a small amount of a 
material with the same Rf value as that of the hydroxy compound (55). The 
temperature of the reaction mixture was allowed to rise in 10°C increments 
over a 3 h period, however, t.l.c. indicated little change until -10°C was 
reached. After 30 min at -10°C t.l.c. indicated that there was no starting 
material left. The flask was evacuated, air was admitted and the suspension 
was filtered through a pad of Celite®. The solvent was evaporated to yield 0.31 
g (100%) of a-(trifluoromethyl)tetrahydropyran-3-methanol (55).
Data: colourless crystals; mp 35.0°C; *H NMR (270 MHz, CDC13) 1.52 (3H, 
m, pyran 4-H, OH), 1.77 (2H, m, pyran 5-H), 3.25 (2H, m, pyran 6-H), 3.76
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(3H, m, pyran 2-H, 3-H), 6.21 (1H, m, pyran-CH(OH)CF3), ,9F NMR (376 
MHz, (CD3)2SO) -74 87 (d, J=  8.1 Hz), -74.63 (d, J=  8.1 Hz), IR (film) 3380 
(br), 1280 (s); MS (El) 184 0709 (NT, 12) (C7H„F30 2 requires 184 0711), 
166 (13), 57 (100), Anal. Calcd for C7H3F30 2: C, 45.65, H, 6.02. Found: C, 
44.60; H, 5.90,
3-(Diinethylaminomethylene)-l,l?l'575’5-liexafluoropentan-2,4-dione (62). 
Anhydrous DMF (0.73 g, 10.0 mmol) was dissolved in acetic anhydride (10 
ml) and l,l,l,5,5,5-hexafluoropentane-2,4-dione (1.41 ml, 10.0 mmol) was 
added slowly and the mixture was heated at 80°C for 18 h. Most of the solvent 
was removed by evaporation and the resulting residue was distilled (Kugelrohr) 
to yield 2.49 g (95%) of 3-(dimethylaminomethylene)-l,l,l,5,5,5- 
hexafluoropentan-2,4-dione (62). Data: yellow crystals, bp3 80°C; mp 36.5- 
37.5°C; NMR (400 MHz, (CD3)2SO, 20°C) 2.83 (3H, br s, NCH3), 3 51 
(3H, br s, NCH3), 8.13 (1H, s, C=CH); lH NMR (400 MHz, (CD3)2SO, 
100°C) 2 78 (3H, s, NCH3), 3.54 (3H, s, NCH3), 8.03 (1H, s, C=CH); lH 
NMR (400 MHz, (CD3)2SO, 150°C) 3.05 (6H, br s, NCH3), 7.94 (1H, s, 
C=CH); *H NMR (400 MHz, CDC13, 21°C) 2.81 (3H, s, NCH3), 3.45 (3H, s, 
NCH3), 7.74 (1H, s, C=CH), JH NMR (400 MHz, CDC13, -50°C) 2.84 (3H, s, 
NCH3), 3.55 (3H, s, NCH3), 7.82 (1H, s, C=CH); *H NMR (400 MHz, ds- 
THF, 20°C) 2.78 (3H, s, NCH3), 3.47 (3H, s, NCH3), 7.87 (1H, s, C=CH), lH 
NMR (400 MHz, c/g-THF, -90°C) 2.77 (3H, s, NCH3), 3.58 (3H, s, NCH3), 
8.08 (1H, s, C=CH); 19F NMR (376 MHz, (CD3)2SO, 20°C) -72.09 (s), ,9F 
NMR (376 MHz, (CD3)2SO, 100°C) -72.26 (s), 19F NMR (376 MHz, 
(CD3)2SO, 150°C) -72.31 (s); 19F NMR (376 MHz, CDC13, 21°C) -73.39 (s); 




THF, 20°C) -73 16 (s); 19F NMR (376 MHz, </8-THF, -90°C) -72.6 (very br); 
13C NMR (100 MHz, CDC13) 43.17 (NCH3), 49.04 (NCH3), 101.45 
((CF3CO)2C=C(H)NMe2), 116.26 (q, Jc.f = 292.4 Hz, COCF3), 159.41 
((CF3CO)2C=C(H)NMe2), 179.65 (q, Jc.F = 36.7 Hz, COCF3), MS (El) 
263.0379 (M*'+ IT) (C8H7F6N 02 requires 263.0381).
4-(Phenylmethoxy)butan-l-ol (68). 1,4-Butanediol (30.0 g, 333 mmol) was 
dissolved in DMF (200 ml) and sodium hydride (60% dispersion in oil, 6.66 g, 
166 mmol) was added portionwise with caution. After 5 min, benzyl bromide 
(19.8 ml, 166 mmol) was added slowly, resulting in a moderate exotherm. The 
mixture was stirred at ambient temperature for 16 h followed by heating to 
70°C for 1.5 h. After cooling, most of the solvent was removed by evaporation 
and to the residue was added DCM (20 ml) and water (30 ml). The aqueous 
phase was extracted with DCM (20 ml) and the combined organic extracts 
were washed with water (5 x 20 ml), 2 M aqueous HC1 solution (20 ml), water 
(20 ml) and, finally, brine (20 ml). After being dried (MgSO^, the solvent of 
the organic extracts was evaporated and the residue was distilled (Kugelrohr) 
to yield 22.5 g (75%) of 4-(phenylmethoxy)butan-l-ol (68). Data: colourless
liquid, bpo.i 150°C; *H NMR (270 MHz, (CD3)2SO) 1.69 (4H, m, 
CH2CH2 CH2 CH2), 3.51 (2H, ca t, J =  6.0 Hz, CHzO^OH), 3.63 (2H, t, J  =
5.7 Hz, BnOCH2 CH2), 4.51 (2H, s, PI1CH2 O), 7.33 (5H, m, Ph).
(69)
4-(Phenylmethoxy)butanaI (69). A solution of oxalyl chloride (15.8 ml, 31.6 
mmol) in anhydrous DCM (60 ml) under a nitrogen atmosphere was cooled to
OH
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-60°C, and a solution of DMSO (4.5 ml, 63.1 mmol) in DCM (20 ml) was 
added slowly. The reaction mixture was stirred for 2 min and a solution of 4- 
(phenylmethoxy)butan-l-ol (68) (5.0 g, 27.8 mmol) in DCM (20 ml) was 
added within 5 min. Triethylamine (20 ml, 143 mmol) was added and the 
reaction mixture was stirred for a further 5 min before being allowed to warm 
to ambient temperature. Water (200 ml) was added and the aqueous phase was 
extracted with DCM (3 x 50 ml). The combined organic phases were washed 
with 0.2 M aqueous HC1 solution (20 ml), water (20 ml), 0.6 M sodium 
carbonate solution (20 ml), water (20 ml) and brine (20 ml). The organic phase 
was dried (MgS04) and the solvent was evaporated to yield 4.94 g (100%) of
4-(phenylmethoxy)butanal (69). Data: colourless oil; !H NMR (270 MHz,
CDC13) 1 95 (2H, qu, J =  6.2 Hz, CH2CH2CH2 ), 2.55 (2H, dt, J =  1.5, 7.0 Hz, 
CH2CH2CHO), 3.50 (2H, t, J= 6.0 Hz, BnOC&CHz), 4.48 (2H, s, PhOLO), 
7.32 (5H, m, Ph), 9.77 (1H, t, J= 1.5 Hz, CH2CHO).
3,5-Bis(trifluoromethyl)-4,5-dihydro-5-hydroxy-l-(4-nitrophenyl)pyrazole
(72). To a solution of 4-nitrophenylhydrazine (0.20 g, 1.30 mmol) in ethanol 
(50 ml) was added l,l,l,5,5,5-hexafluoropentane-2,4-dione (0.30 g, 1.44 
mmol). The mixture was boiled under reflux for 3 h and then was allowed to 
cool to ambient temperature. The solvent was evaporated to yield 0.45 g 
(99%) of 3,5-bis(trifluoromethyl)-4,5-dihydro-5-hydroxy-1 -(4-nitrophenyl)- 
pyrazole (72). Data: yellow solid, mp 105-106°C (literature112 mp 105-108°C 
claimed for pyrazole (76)); NMR (270 MHz, CDC13) 3.42 (1H, d septet, J H- 




pyrazole 4-H), 5.75 (1H, br, OH), 7.60 (2H, d, J =  9.4 Hz, Ar 2,6-H2), 8.12 
(2H, d, J =  9.4 Hz, Ar 3,5-H2); MS (El) 343 (M", 95), 274 (100), 228 (61); 
Anal. Calcd for C hH tF^O s: C, 38.48; H, 2.06; N, 12.25. Found: C, 38.70; 





pyrazole (73). To a solution of pentafluorophenylhydrazine (0.20 g 1.00 
mmol) in ethanol (50 ml) was added l,l,l,5,5,5-hexafluoropentane-2,4-dione 
(0.30 g, 1.44 mmol). The mixture was boiled under reflux for 5 h and then was 
allowed to cool to ambient temperature. The solvent was evaporated to yield 
0.38 g (98%) of 3,5-bis(trifluoromethyl)-4,5-dihydro-5-hydroxy-l-(penta- 
fluorophenyl)pyrazole (73). Data: colourless prisms, mp 61-62°C (literature112 
mp 60-62°C claimed for pyrazole (77)); lH NMR (270 MHz, CDC13) 3.32 
(1H, br d,7 =  18.9 Hz, pyrazole 4-H), 3.59 (1H, dq, J H-h  = 18 9 Hz, J H-f  = 15 
Hz, pyrazole 4-H), 6.13 (1H, br s, OH), MS (El) 388 0099 (M% 15) 






To a solution of benzoic hydrazide (0.14 g, 1.00 mmol) in ethanol (50 ml) was
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added l,l,l,5,5,5-hexafluoropentane-2,4-dione (0.30 g, 1 44 mmol). The 
mixture was boiled under reflux for 5 h and then was allowed to cool to 
ambient temperature. The solvent was evaporated to yield 0.47 g (99%) of 1- 
benzoyl-3,5-bis(trifluoromethyl)-4,5-dihydro-5-hydroxypyrazole (74). Data: 
82-84°C (literature112 mp 84-85°C claimed for pyrazole (78)); lU NMR (270 
MHz, CDC13) 3.38 (1H, d septet, JH-h = 19.5 Hz, JH-f = 1.5 Hz, pyrazole 4-H), 
6.43 (1H, br s, OH), 7 47 (2H, ca t, J =  7.5 Hz, Ar 3,5-H2), 7.59 (1H, tt, J  =
7.5 Hz, J=  1.3 Hz, Ar 4-H), 7.86 (2H, ca d, J=  7.5 Hz, Ar 2,6-H2); 19F NMR 
(84 MHz, CDCI3 ) -81.40 (s), -68.18 (s); MS (El) 326 (M+, 1), 105 (100); MS 




pyrazole (75). To a solution of 2,4-dinitrophenylhydrazine (0.30 g, 1.50 
mmol) in ethanol (50 ml) was added l,l,l,5,5,5-hexafluoropentane-2,4-dione 
(0.41 g, 1.97 mmol). The mixture was boiled under reflux for 5 h and then was 
allowed to cool to ambient temperature. The solvent was evaporated to yield 
0.51 g (88%) of 3,5-bis(trifluoromethyl)-4,5-dihydro-l-(2,4-dinitrophenyl)-5- 
hydroxypyrazole (75). Data: orange-yellow solid, mp 81-83°C (literature112 mp 
82-83°C claimed for pyrazole (79)), }H NMR (400 MHz, CDC13) 3.06 (1H, d, 
J  = 14.6 Hz, pyrazole 4-H), 3.18 (1H, d, J  = 14.6 Hz, pyrazole 4-H), 5 10 
(1H, br, OH), 8 04 (1H, d, J =  9.5 Hz, Ar 6-H), 8 40 (1H, dd, J=  9.5 Hz, 7  =
2.4 Hz, Ar 5-H), 9.14 (1H, d, J  = 2 4 Hz, Ar 3-H); 19F NMR (376 MHz, 
(CD3)2SO) -78.93 (s), -65.60 (s); MS (El) 343 (M+, 95), 274 (100), 228 (61), 






3.5-Bis(trifluoromethyl)-l-(4-nitrophenyl)pyrazole (76). A solution of 3,5- 
bis(trifluoromethyl)-4,5-dihydro-5-hydroxy-1 -(4-nitrophenyl)pyrazole (72) 
(0.10 g, 0.29 mmol) in ethanol (10 ml) and concentrated HC1 (0.5 ml) was 
stirred and heated under reflux for 72 h. The solvent was evaporated and the 
residue was dissolved in DCM (10 ml). Anhydrous MgS04 and sodium 
hydrogen carbonate were added and the suspension was filtered and the 
solvent was evaporated to give 0.09 g (96%) of 3,5-bis(trifluoromethyl)-l-(4- 
nitrophenyl)pyrazole (76). Data: yellow oil^H NMR (400 MHz, CDC13) 7.18 
(1H, s, pyrazole-H), 7.77 (2H, d, J = 8.9 Hz, Ar 2,6-H2), 8.42 (2H, d, J = 8.9 
Hz, Ar 3,5-H2); 13C NMR (100 MHz, CDC13) 108.40 (CH, pyrazole 4-H),
118.74 (q, Jc.f = 270 Hz, CF3), 120.04 (q, JC-f = 270 Hz, CF3), 124.84 (Ar
2.6-CH), 126.32 (Ar 3,5-CH), 134.50 (q, Jc.F = 40 Hz, C-CF3), 142.73 (Ar 4- 
C), 144 04 (q, Jc.F = 40 Hz, C-CF3), 148.36 (Ar 1-C), 19F NMR (376 MHz, 
CDCI3) -63.18 (s, CF3), -58.07 (s, CF3); MS (El) 325.0288 (M", 100) 






(0.85 g, 2.18 mmol) was dissolved in acetic anhydride (20 ml, 210 mmol) and 
acetic acid (15 ml, 260 mmol) and the solution heated under reflux for 16 h. 
Most of the acetic anhydride and acetic acid were removed by evaporation and 
the residue was dissolved in DCM (50 ml) and stirred with saturated sodium 
hydrogen carbonate solution (50ml) for 1 h. The organic phase was separated 
and dried (MgS04) and the solvent was removed by evaporation to yield 0.23 
g (62%) of 3,5-bis(trifluoromethyl)-l-(pentafluorophenyl)pyrazole (77). Data, 
yellow oil; 'H NMR (400 MHz, CDCU) 7.17 (s); 19F NMR (376 MHz, CDC13) 
-159.84 (m, Ar 3,5-F2), -147.30 (m, Ar 4-F), -144.45 (m, Ar 2,6-F2), -63.49 (s, 
CF3), -61.71 (s, CF3); MS (El) 369.9957 (M* , 100) (C„HF„N 2 requires 
369.9964), 351 (35), 301 (50), 206 (45).






(0.13 g, 0.34 mmol) was dissolved in DCM (4 ml) and triethylamine (0.12 ml, 
0.85 mmol), followed by the addition of methanesulphonyl chloride (0.04 g, 
0.34 mmol). The solution was stirred for 7 d. DCM (30 ml) was added and the 
solution was washed with water ( 1 0  ml), 0.5 M H2 S0 4 ( 2  x 1 0  ml) and finally 
with water ( 2x 1 0  ml). The organic phase was dried (MgS04) and the solvent 
evaporated to yield 0.01 g (10%) of 3,5-bis(trifluoromethyl)-l-(2,4-dinitro- 
phenyl)pyrazole (79) after chromatography (petroleum ether bp 40-60°C : 
ethyl acetate ; 5 : 1). Data: bright yellow oil; *H NMR (400 MHz, CDCI3) 6.70 
(1H, s, pyrazole 4-H), 8 .11 (1H, d, J =  9.3 Hz, Ar 6 -H), 8.47 (1H, dd, J=  9.3, 
2 4 Hz, Ar 5-H), 9.17 (1H, d, J  = 2.4 Hz, Ar 6 -H); 19F NMR (376 MHz, 






3-(3-Trifluoromethylpyrazol-4-yl)propanol (80). 5-Trifluoroacetyl-3-4- 
dihydro-2//-pyran (52) (1.00 g, 5.60 mmol) was dissolved in ethanol (10 ml) 
and hydrazine hydrate (0.81 ml, 16.6 mmol) in ethanol (3 ml) was added. The 
mixture was stirred and heated under reflux for 3 h. During this time the 
progress of the reaction was monitored by 19F NMR. The solvent was 
evaporated and the residue was distilled (Kugelrohr) to yield 1.07 g (99%) of 
3-(trifluoromethyl)pyrazole-4-propanol (80). Data: white solid; mp 84.0- 
85.0°C (literature154 mp 85-87°C); bp04 160°C; 'H NMR (400 MHz, D20 ) 1.79 
(2H, qu, J=  7.0 Hz, CH2CH2CH2), 2.62 (2H, t, = 7.3 Hz, RCH2CH2 ), 3.59 
(2H, t, J  = 6.3 Hz, CH2CH2OH), 19F NMR (376 MHz, D20 ) -61.31 (s), MS 






3-(3-Trifluoromethylpyrazol-4-yl)propyl benzoate (81). Benzoyl chloride 
(0.54 g, 3.90 mmol) was added dropwise to 3-(trifluoromethyl)pyrazole-4- 
propanol (80) (0.50 g, 2.60 mmol) and triethylamine (5.20 g, 51.5 mmol) in 
dichloromethane (20 ml) at 0°C and the mixture was allowed to warm to
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ambient temperature during 16 h. The mixture was washed with saturated 
sodium hydrogen carbonate solution (10 ml), 2 M hydrochloric acid (5 x 10 
ml) and brine (10 ml) and was dried (MgS0 4 ). Chromatography (hexane : ethyl 
acetate, 1 : 1) of the evaporation residue gave 0.62 g (81%) of 3-(3-trifluoro- 
methylpyrazol-4-yl)propyl benzoate (81). Data: large white plates, mp 46.0- 
46.5°C, *H NMR (400 MHz, CDC13) 2.09 (2H, qu, J  = 7 Hz, CH^HhCIfc), 
2 80 (2H, t, J =  7 6 Hz, pyrazole-CH2), 4.38 (2H, t, J=  6.1 Hz, CH20), 7 44 
(2H, br t, J=  8 Hz, Ar 3,5-H2), 7.54 (1H, s, pyrazole 5-H), 7.56 (1H, br t, J = 
8 Hz, Ar 4-H), 8 03 (2H, br d, J  = 8 Hz, Ar 2,6-H2); 19F NMR (376 MHz, 
CDC13) -61.30 (s), MS (Cl) 299.1007 (M" + H) (Ci4H,4F3N20 2 requires 




3-Trifluoroacetyl-4,5-dihydrofuran (82). 3-Trifluoroacetyl-4,5-dihydrofuran 
(82) was synthesised essentially by the method described by Hojo's group141 
Trifluoroacetic anhydride (22.5 g, 107 mmol) was added dropwise with 
cooling to 2,3-dihydrofuran (5.00 g, 71.0 mmol) and pyridine (1.88 g, 24.0 
mmol) in dichloromethane (40 ml) and the mixture was stirred for 18 h. 
Distillation gave 9.72 g (82%) of 3-trifluoroacetyl-4,5-dihydrofuran (82). Data: 
colourless liquid, bp20 80°C (literature141 bpio.5 48.5°C), *H NMR (400 MHz, 
CDC13) 2.98 (2H, tq, JH-h  = 9 8 Hz, J H-f  = 0.6 Hz, 4-H2), 4.68 (2H, t, J H-h  =
9.8 Hz, 5-H2), 7.64 (1H, q, J H.r = 1.5 Hz, 2-H), 19F NMR (376 MHz, CDC13) - 
73.88 (br s); 13C NMR (100, CDC13) 26.93 (4-C), 74.01 (5-C), 114.37 (3-C), 
116.62 (q, Jc-F = 190 Hz, CF3), 163.84 (q, J C- f  = 5.0 Hz, 2-C), 176.08 (q, Jc.F 






ethoxy)pyrazol-4-yl)ethanol (83). The furan (82) (1.00 g, 6.02 mmol) was 
boiled under reflux with hydrazine hydrate (0.30 g, 6.02 mmol) in ethanol (13 
ml) for 3 h. Evaporation of the solvent gave 1.09 g (100%) of 2-(3,4-dihydro- 
3 -trifluoromethyl-3 -(2-(3 -trifluoromethylpyrazol-4-yl)ethoxy)pyrazol-4-yl)- 
ethanol (83) Data: white solid, mp 84-85°C; *H NMR (270 MHz, CD3OD)
1.82 (1H, m) and 1.93 (1H, m) (dihydropyrazole-CH2), 2.79 (2H, t, J  = 6.8 
Hz, pyrazole-CH2), 3.31 (1H, br t, J =  7 Hz, dihydropyrazole 4-H), 3.71 (2H, 
t, J  = 6 8 Hz, pyrazole-CH2CH20), 3.73 (2H, m, dihydropyrazole- 
CHzCIizOH), 4.94 (3H, 2 x NH + OH), 6.82 (1H, s, dihydropyrazole 5-H), 
7.67 (1H, s, pyrazole 5-H); l9F NMR (376 MHz, CD3OD) -82.57 (s, 
dihydropyrazole-CF3), -62.20 (s, pyrazole-CF3); 13C NMR (100 MHz, 
CD3OD) 27.60 (CH2), 28.36 (CH2), 49 49 (dihydropyrazole 4-C), 60.92 
(CH2), 62 95 (CH2), 92.93 (q, J h-f = 31.0 Hz, dihydropyrazole 3-C), 117.52 
(pyrazole 4-C), 123.70 (q, Jc-r =268 Hz, CF3), 125.68 (q, JC-f = 281 Hz, CF3), 
131.36 (CH), 140.95 (q, JC.T = 37.0 Hz, pyrazole 3-C), 146.30 (CH), MS (Cl) 
361.1099 (M* + H) (Ci2H15F6N40 2 requires 361.1099); IR (Nujol) 3300 (s), 







2-(3-TrifluoromethylpyrazoI-4-y 1 )ethanol (84) 2-(3,4-dihydro-3-trifluoro- 
methyl-3 -(2-(3 -trifluoromethylpyrazol-4-yl)ethoxy)pyrazol-4-yl)ethanol (83)
(1.00 g, 2.80 mmol) was boiled under reflux with 9 M aqueous HC1 solution 
(0.05 ml) in ethanol (12 ml) for 16 h. The solvent and reagent were evaporated 
to give 0.99 g (100%) of 2-(3-trifluoromethylpyrazol-4-yl)ethanol (84). Data: 
pale yellow solid, mp 90-91 °C; 'H NMR (270 MHz, (CD3)2SO) 2.65 (2H, br t, 
J  = 7.0 Hz, pyrazole-CH2), 3 54 (2H, t, = 7.0 Hz, CH20), 4.9 (1H, br, OH), 
7.78 (1H, br s, pyrazole 5-H); ,9F NMR (84 MHz, (CD3)2SO) -59.66 (br s); 
MS (El) 180.0515 (M*, 30) (C6H7F3N20  requires 180.0510), 159 (100)
4-(l,l-Dimethylethyl)diphenylsilyloxy)but-l-yne (86). A solution of 3- 
butyn-l-ol (9.81 g, 0.14 mmol) in anhydrous DMF (100 ml) was cooled to 0°C 
and imidazole (19.1 g, 0.28 mmol) was added portionwise followed by tert- 
butyldiphenylchlorosilane (35.8 ml, 0.14 mmol). The clear solution was 
allowed to warm to ambient temperature and after 45 min the temperature was 
lowered to 0°C and water (400 ml) was added slowly. The mixture was 
extracted with hexane (5 x 100 ml) and the combined organic extracts were 
washed with water (50 ml) and brine (2 x 50 ml). The organic phase was dried 
(MgS04) and the solvent evaporated to yield 43.2 g (100%) of 4-( 1,1- 
dimethylethyl)diphenylsilyloxy)but-l-yne (86) Data: colourless oil; 'H NMR
(270 MHz, CDC13) 1 06 (9H, s, t-Bu), 1.94 (1H, t, J=  2.8 Hz, CH2O CH ), 
2.45 (2H, dt, J  = 7.1, 2.7 Hz, CH2CH2C=CH), 3.78 (2H, t, J  = 7.1 Hz,
(86)
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OCH2CH2), 7.40 (6H, m, 2 x Ar 3,4,5-H3), 7.68 (4H, m, 2 x Ar 2,5-H2).
(87)
4-Phenylmethoxybut-l-yne (87). To a solution of 3-butynol (9.69 g, 138 
mmol) in anhydrous DMF (65 ml) was added sodium hydride (60% dispersion 
in oil, 5.53 g, 138 mmol) portionwise. The mixture was stirred for 5 min before 
cooling to 0°C, and benzyl bromide (16.4 ml, 138 mmol) was added dropwise. 
The reaction mixture was allowed to rise to ambient temperature and stirred 
for 16 h Most of the solvent was removed by evaporation. To the residue was 
added DCM (100 ml) and water (30 ml). The aqueous phase was extracted 
with DCM (50 ml) and the combined organic extracts were washed with water 
(5 x 20 ml), 2 M HC1 solution (20 ml), water (20 ml) and finally brine (20 ml). 
The organic extracts were dried (MgS04) and the solvent was evaporated to 
yield 16.8 g (75%) of 4-phenylmethoxybut-l-yne (87) after chromatography 
(hexane : ethyl acetate ,1 : 0 to 15 : 1). Data: colourless liquid; *H NMR (270 
MHz, CDCI3) 2.00 (1H, t, J=  2.8 Hz, CH2C=CH), 2.50 (2H, dt, J = 6 8, 2 6 
Hz, CH2CH2C=CH), 3 60 (2H, t, J  = 7.0 Hz, OCHzCHz), 4.56 (2H, s, 
PhOfcO), 7.34 (5H, m, Ph).
O
(88)
6-(( 1,1 - Dimet hy lethy I )d ipheny lsily loxy)-1,1,1 -trifluorohex-3-y n-2-one
(88). A?-Butyl lithium (2.5 M in hexanes, 13 ml, 32.4 mmol) was added to 4- 
(l,l-dimethylethyl)diphenylsilyloxy)but-l-yne (86) (10.0 g, 32.4 mmol) in THF 
(50 ml) at -78°C and the mixture was stirred at this temperature for 30 min.
2,2,2-Trifluoroethyl trifluoroacetate (7.00 g, 35.7 mmol) in THF (60 ml) was
184
added, followed immediately by boron trifluoride diethyl etherate (5.65 g, 40.0 
mmol), and the mixture was stirred at -78°C for 90 min. Saturated aqueous 
ammonium chloride (18 ml) was added and the mixture was allowed to warm 
to ambient temperature. The solvent was evaporated and the residue, in diethyl 
ether (100 ml), was washed with water (20 ml) and with brine (2 x 20 ml) and 
was dried (MgS04). Evaporation of the solvent gave 12.4 g (95%) of 6-(( 1,1- 
dimethylethyl)diphenylsilyloxy)-1,1,1 -trifluorohex-3 -yn-2-one (88). Data:
colourless liquid, lH NMR (270 MHz, CDC13) 1.06 (9H, s, /-Bu), 2.72 (2H, t, 
J=  6.3 Hz, CH2O C ), 3 85 (2H, t, J=  6.3 Hz, CH20), 7.35 (10H, 2 x Ph); l9F 
NMR (376 MHz, CDC13) -78.63 (s); MS (Cl) 405.1498 (MT + H) 
(C22H24F30 2Si requires 405.1498).
6-Phenylmethoxy-l,l,l-trifluorohex-3-yn-2-one (89) w-Butyl lithium (2.5 
M in hexanes, 18 ml, 45.0 mmol) was added to 4-phenylmethoxybut-l-yne 
(87) (7.20 g, 45.0 mmol) in THF (100 ml) at -78°C and the mixture was stirred 
at this temperature for 30 min 2,2,2-Trifluoroethyl trifluoroacetate (9.70 g,
50.0 mmol) in THF (70 ml) was added, followed immediately by boron 
trifluoride diethyl etherate (8.50 g, 60.0 mmol) and the mixture was stirred at 
-78°C for 90 min. Saturated aqueous ammonium chloride (30 ml) was added 
and the mixture was allowed to warm to ambient temperature. The solvent was 
evaporated and the residue, in dichloromethane (200 ml), was washed with 
water (50 ml) and with brine (2 x 50 ml) and was dried (MgS04). Evaporation 
of the solvent gave 11.1 g (97%) of 6-phenylmethoxy-1,1,1-trifluorohex-3-yn-
2-one (89) Data: pale yellow oil; *H NMR (270 MHz, CDC13) 2.80 (2H, t, J  =
7.30-7.35 (5H, m, Ph); 19F NMR (376 MHz, CDC13) -78.65 (s), MS (Cl)
O
6 6 Hz, CH2C=C), 3 69 (2H, t, J=  6.6 Hz, OOfcCHJ, 4 58 (2H, s, PhCH20),
185




pyrazole (90). 6-(( 1,1 -Dimethylethyl)diphenylsilyloxy)-1,1,1 -trifluorohex-3- 
yn-2-one (88) (0.38 g, 0.93 mmol) was boiled under reflux with hydrazine 
hydrate (0.07 g, 0.93 mmol) in ethanol (2.2 ml) for 90 min. The evaporation 
residue, in DCM (20 ml), was dried (MgS0 4 ) and the solvent was evaporated 
to give 0.39 g (99%) of 3-(2-((l,l-dimethylethyl)diphenylsilyloxy)ethyl)-5- 
trifluoromethylpyrazole (90). Data: colourless oil; NMR (270 MHz, CDCI3) 
1 06 (9H, s, /-Bu), 2 88 (2H, t, J  = 5.7 Hz, pyrazole-CH2), 3.89 (2H, J  = 5.7 
Hz, CH20), 6.33 (1H, s, pyrazole 4-H), 7.3-7 7 (10H, m, 2 x Ph), 19F NMR 
(376 MHz, CDC13) -62.31 (s); 13C NMR (100 MHz, CDC13) 19.01 (CMe3),
26.74 (3 x CH3), 28 44 (pyrazole-CH2), 62.53 (CH20), 102.69 (pyrazole 4-C), 
121.44 (q, Jc.F = 268 Hz, CF3), 127.80 (2 x Ph 3,5-C2), 129.89 (2 x Ph 4-C), 
132.83 (2 x Ph 1-C), 134.81 (CH), 135.41 (2 x Ph 2,6-C2), 142.87 (q, J  =




3-(2-PhenylmethoxyethyI)-5-trifluoromethylpyrazole (91). 6-Phenyl- 
methoxy-l,l,l-trifluorohex-3-yn-2-one (89) (0.50 g, 1.95 mmol) was boiled 
under reflux with hydrazine hydrate (0.15 g, 1.95 mmol) in ethanol (4.6 ml) for 
1 h The evaporation residue, in DCM (50 ml), was dried (MgSC>4 ) and the
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solvent was evaporated to give 0.48 g (91%) of 3-(2-phenylmethoxyethyl)-5- 
trifluoromethylpyrazole (91). Data: pale yellow oil: JH NMR (270 MHz, 
CDC13) 2.91 (2H, t, J  = 5.9 Hz, pyrazole-CH2), 3.68 (2H, t, J  = 5.9 Hz, 
OCH2 CH2 ), 4.51 (2H, s, PhO^O), 6.33 (1H, s, pyrazole 4-H), 7 2-7 4 (5H, 
m, Ph); 19F NMR (376 MHz, CDC13) -62.35 (s); 13C NMR (100 MHz, CDC13) 
25.96 (pyrazole-CH2), 68.31 (OCH2), 73.21 (OCH2), 102.33 (pyrazole 4-C), 
121.46 (q, Jc.F = 268 Hz, CF3), 127.75 (Ph 2,6-C2), 127.91 (Ph 4-C), 128.48 
(Ph 3,5-C2), 137.44 (Ph 1-C), 142.66 (q, JC-y = 39.0 Hz, pyrazole 5-C), 143.02 
(pyrazole 3-C); MS (Cl) 271.1058 (M+ + H) (Ci3H 14F3N20  requires 
271.1058).
2-(5-Trifluoromethylpyrazol-3-yl)ethanol (92). To a solution of 3-(2- 
phenylmethoxyethyl)-5-trifluoromethylpyrazole (91) (0.32 g, 1.18 mmol) in 
methanol (4 ml) and perchloric acid (60% in water, 0.01 ml) was added a 
slurry of 10% palladium on activated carbon (0.1 g) in THF (1 ml). The 
suspension was evacuated and charged with hydrogen (x3) before being stirred 
in a hydrogen atmosphere for 70 min. The flask was evacuated, the suspension 
filtered through a pad of Celite® and the solvent evaporated to give a pale
brown oil which was crystallised (CHCI3 / CH3CH2OH) to yield 0.20 g (94%) 
of 2-(5-trifluoromethylpyrazol-3-yl)ethanol (92) Data: white solid; mp 85- 
8 6 °C; (270 MHz, (CD3 )2CO) 2.98 (2H, dt, J =  0.5, 5.7 Hz, pyrazole-CH2), 
4.12 (2H, t, J =  5.7 Hz, CH20), 6.40 (1H, br s, pyrazole 4-H); 19F NMR (376 









5-Fluoro-2-(trif1uoromethyl)benzimidazole (94). 4-Fluorobenzene-1,2- 
diamine (1.00 g, 7.93 mmol) was dissolved in TFA (10 ml) and the solution 
was heated under reflux for 5 d The excess TFA was removed by evaporation 
and the residue was subjected to heating at 200°C before sublimation at 200°C 
/ 12 mmHg (Kugelrohr) to yield 1.56 g (95%) of 5-fluoro-2-(trifluoromethyl)- 
benzimidazole (94). Data: peach solid; mp 174-175°C (literature157 219- 
220°C); lH  NMR (400 MHz, (CD3)2SO) 7 28 (1H, dt, J =  9.2, 2.1 Hz, 6-H), 
7.56 (1H, br d, J  = 8 9 Hz, 7-H), 7.79 (1H, m, 4-H), 14.2 (1H, br, NH); 13C 
NMR (100 MHz, (CD3)2SO) 112.74 - 112.98 (m, C-H), 118.82 (q, J c.F = 271 
Hz, CF3), 141.20 (q, J c.f  = 41 Hz, CCF3), 159.56 (d, J C-f  = 239 Hz, CF), 19F 
NMR (376 MHz, (CD3)2SO) -63.20 (s, CF3), -116.79 (br m, 5-F); MS (El) 
204.0321 (Mf', 100) (C8H4F4N2 requires 204.0311); Anal. Calcd for C g R d ^ :  




2,5-Bis(trifluoromethyl)benziinidazole (95). 3,4-Diaminobenzotrifluoride 
(1.00 g, 5.68 mmol) was dissolved in TFA (10 ml) and the solution was heated 
under reflux for 5 d 20 h The excess TFA was removed by evaporation and 
the residue was subjected to heating at 200°C before sublimation at 150 °C / 
10 mmHg (Kugelrohr) to yield 1.24 g (89%) of 2,5-
bis(trifluoromethyl)benzimidazole (95). Data: white solid, mp 159-161°C 
(literature192 198-199°C), ‘H NMR (270 MHz, (CD3)2SO) 7.72 (1H, dd, ./ = 
8.8, 1.8 Hz, 6-H), 7.95 (1H, d, J =  8.4 Hz, 7-H), 8 16 (1H, br s, 4-H), 14.3 
(1H, br, NH); 19F NMR (376 MHz, (CD3)2SO) -63.44 (s, 2-CF3), -59.72 (br s,
188
5-CF3); MS (El) 254.0254 (M*', 100) (C9H4F6N2 requires 254.0279), Anal. 
Calcd for C9H4F6N2: C, 42.54; H, 1.59; N, 11.02. Found: C, 42.60, H, 1.55; N,
11 . 10 .
CF
(96)
2-(Trif1uoromethyI)imidazo[4,5-6]pyridine (96). 2,3-Diaminopyridine (1.00 
g, 9.16 mmol) was dissolved in TFA (10 ml) and the resulting brown solution 
was heated under reflux for 2 d. The excess TFA was removed by evaporation 
and NMR of the remaining residue showed a mixture of intermediates. The 
residue was subjected to heating at 200°C before sublimation at 200 °C / 0.1 
mmHg (Kugelrohr) to yield 1.67 g (98%) of 2-(trifluoromethyl)imidazo[4,5- 
6]pyridine (96). Data: yellow solid, mp 240-241°C; ‘H NMR (270 MHz, 
(CD3)2SO) 7 48 (1H, dd, J = 8 4, 4 8 Hz, 6-H), 8.29 (1H, br d, J  = 8.1 Hz, 7- 
H), 8.59 (1H, dd, J =  4 .8 , 1.5 Hz, 5-H), 14.6 (1H, br, NH); 13C NMR (68 
MHz, (CD3)2SO) 119.07 (q, Jc.F = 271 Hz, CF3), 119.59 (br, 6,7-C2), 142.73 
(q, Jc.F * 44 Hz, CCF3), 145.76 (5-C), 19F NMR (376 MHz, (CD3)2SO) -63.65 
(s), MS (El) 187.0353 (M+>, 100) (C7H4F3N3 requires 187.0357).
H
(97)
2-(Trifluoromethyl)iinidazo[4,5-c]pyridine (97) 3,4-Diaminopyridine (1.00 
g, 9.16 mmol) was dissolved in TFA (10 ml) and the resulting brown solution 
was heated under reflux for 3 d. The excess TFA was removed by evaporation 
and NMR of the remaining residue showed a mixture of intermediates. The 
residue was subjected to heating at 200°C before sublimation at 250 °C / 1 
mmHg (Kugelrohr) to yield 1.71 g (98%) of 2-(trifluoromethyl)imidazo[4,5- 
cjpyridine (97). Data: white solid; mp 159-161 °C (literature193 290-291°C); JH
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NMR (270 MHz, (CD3)2SO) 7.98 (1H, d, = 6.6 Hz, 7-H), 8.27 (1H, d, =
6.6 Hz, 6-H), 9.25 (1H, s, 4-H), 14.2 (1H, br, NH); ,3C NMR (68 MHz, 
(CD3)2SO) 114.32 (7-C), 120 91 (q, J C-f = 270 Hz, CF3), 129 42 (m, CCF3), 
133.35 (6-C), 142.15(4-0, 154.02 (br, Cq); 19F NMR (376 MHz, (CD3)2SO) - 
63.60 (s); MS (El) 187.0364 (M‘ , 100) (C7H,F3N3 requires 187 0357), Anal 






(100) was synthesised by a procedure based on that discribed by Reitz's 
group160. A suspension of anhydrous potassium carbonate (10 g) and ethyl 
trifluoroacetate (9.95 g, 70.0 mmol) in ethanol (40 ml) was cooled to -10°C 
and treated dropwise over a 40 min period with hydrazine hydrate (1.70 ml,
35.0 mmol). The reaction mixture was allowed to warm to ambient 
temperature and stirring was continued for 16 h. After the mixture had been 
concentrated by evaporation, TFA (5 ml) was added, followed by the dropwise 
addition of TFAA (11.8 g, 56.0 mmol) over a 2 h period. The suspension was 
heated gently until it became a clear solution and reflux began. The solution 
was left for 16 h, after which colourless crystals were filtered off and placed 
over KOH in a desiccator for 16 h. Ether (200 ml) was added to the crystals 
and the resulting suspension was stirred for 20 min and the remaining solid was 
removed by filtration. The solvent of the filtrate was removed by evaporation 
to yield 7.37 g (94%) of l,2-bis(trifluoroacetyl)hydrazine (100). Data: 
colourless crystals; mp < 25°C (literature160 bp 65°C); 19F NMR (84 MHz, 






1,3,4-oxadiazole (101) was synthesised by a procedure based on that described 
by Reitz's group160. l,2-Bis(trifluoroacetyl)hydrazine (100) (6.0 g, 26.8 mmol) 
was thoroughly mixed with phosphorus pentoxide (15 g) and covered with 
additional phosphorous pentoxide (10 g). The mixture was slowly heated to 
300°C under a static nitrogen atmosphere. The crude product was distilled off 
and trapped at -78°C and then was redistilled (Kugelrohr) from calcium 
hydride to yield 4 01 g (73%) of 2,5-bis(trifluoromethyl)-l,3,4-oxadiazole
(101). Data: colourless liquid, bp 65°C (literature160 bp 65°C); 19F NMR (84 
MHz, CDC13) -65.34 (s).
N-(2-(2-Hydroxyethoxy)ethyl)-2,2,2-trifluoroacetaniide (104). N-(2-(2-
Hydroxyethoxy)ethyl)-2,2,2-trifluoroacetamide (104) was synthesised by an 
attempted synthesis of 3,5-bis(trifluoromethyl)-4-(2-hydroxyethoxyethyl)-4//-
1,2,4-triazole (103) using the method described by Reitz's group160. A solution 
of 2,5-bis(trifluoromethyl)-l,3,4-oxadiazole (101) (4.01 g, 22.5 mmol) in 
methanol (25 ml) was cooled to 0°C and treated dropwise with 2-(2- 
aminoethoxy)ethanol (2.37 g, 22.5 mmol). The mixture was stirred at ambient 
temperature for 16 h. The solvent was evaporated and the crude material was 
distilled (Kugelrohr) to yield 4.32 g (96%) of N-(2-(2-hydroxyethoxy)ethyl)-
2,2,2-trifluoroacetamide (104). Data: colourless liquid, bp20 195-200°C; 
NMR (270 MHz, CDC13) 3.35 (2H, t, J=  6.0 Hz, NCH2 CH2O), 3.43 (2H, m, 
OCH2CH2N), 3.45 (2H, m, OCH2 CH2OH), 3.51 (2H, m, CH2CH2OH), 4.59 





67.85 (RCH20), 72.11 (RCH2OH), 116.29 (q, J C-f  = 288.6 Hz, CF3), 156.44 
(q, Jc.f = 35.2 Hz, COCF3); 19F NMR (84 MHz, CDC13) -74.01; IR (film) 3750 
(br), 1715 (s), 1175 (s); MS (Cl) 202.0691 (M* + H, 100) (C6H10F3NO3 
requires 202.0691), 140 (90).
N-(3-(Phenylmethoxy)propyI)-2,2,2-trifluoroacetaiiiide (105) To a stirred 
solution of trifluoroacetamide (0.78 g, 6.87 mmol) in THF (20 ml) was added 
potassium /^/-butoxide (0.77 g, 6.87 mmol) portion-wise. Following 
dissolution, 3-(phenylmethoxy)propyl-4-methylbenzenesulphonate (20) (2.0 g, 
6.24 mmol) and sodium iodide (ca. 50 mg) were added slowly. The solution 
was stirred at ambient temperature and reaction monitored by t.l.c.. After 4 h, 
the mixture was cooled with an ice bath to 0°C and ether (20 ml) and water 
(10 ml) were added Following acidification to pH 1-2 the ether layer was 
washed with water (2 x 10 ml) and brine (10 ml), and dried (MgS04). 
Evaporation of the solvent gave 1.67 g (97%) of N-(3-(phenylmethoxy)- 
propyl)-2,2,2-trifluoroacetamide (105). Data: pale yellow oil ; *H NMR (400 
MHz, CDC13) 1.87 (2H, m, CH2CH2CH2), 3.50 (2H, m, CH^fLNCO), 3.66 
(2H, t, J  = 5 4 Hz, BnO-CH2CH2), 4 45 (2H, s, PhC^O ), 7 34 (5H, m, 
PhCH20); 19F NMR (84 MHz, CDC13) -76.71 (s), IR (film) 3650 (br), 1715 
(s), 1170 (s).
3-(PhenyImethoxy)propylamine (106). Sodium hydroxide (1.00 g, 50.0 
mmol) was dissolved in methanol (40 ml) and added to N-(3- 
(phenylmethoxy)propyl)-2,2,2-trifluoroacetamide (105) (1.60 g, 5.80 mmol).
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The mixture was stirred and heated under reflux for 4 h. The solvent was 
evaporated and the residue dissolved in ether (100 ml) and was washed with 
saturated sodium hydrogen carbonate solution. The organic layer was dried 
(MgS04), the solvent was evaporated and the residue was distilled (Kugelrohr) 
to yield 0.63 g (66%) of 3-(phenylmethoxy)propylamine (106). Data: 
colourless liquid, bp0.6 85-90°C (literature194 bpo.75 93.5°C); NMR (270 
MHz, CDCI3) 1.43 (2H, br, NH2), 1.75 (2H, qu, J  = 6.2 Hz, CH2CH2CH2), 
2 82 (2H, t, J = 6 8 Hz, CH2CH2NH2), 3.55 (2H, t ,J=6.2  Hz, B n O C ^C ^),





(107) was synthesised by a procedure based on that described by Reitz’s 
group69. A solution of 3-(phenylmethoxy)propylamine (106) (0.30 g, 1.80 
mmol) in methanol (0.6 ml) was cooled to 0°C and treated dropwise with 2,5- 
bis(trifluoromethyl)-l,3,4-oxadiazole (101) (0.37 g, 1.80 mmol) The solution 
was boiled under reflux for 9 d. After cooling, the solvent was evaporated to 
yield 0.27 g (42%) of 3,5-bis(trifluoromethyl)-4-[3-(phenylmethoxy)propyl]- 
4//-l,2,4-triazole (107) following distillation (Kugelrohr). Data: colourless 
liquid; bp06 150-155°C; lU NMR (400 MHz, CDC13) 2.12 (2H, m, 
CH2 CH2 CH2 ), 3.57 (2H, t, J=  5.5 Hz, B n O C ^C ^), 4.38 (2H, t, J=  8.2 Hz, 
R ^C F L C ^); 4.51 (2H, s, PhCHsO), 7.30 (5H, m, PhCH20); 19F NMR (376 
MHz, CDCI3) -62.80 (s); MS (Cl, iso-butane) 354.1041 (M+ + H, 100) 
(C14H14F6N30  requires 354.1041), 91 (26).
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3,5-Bis(trifluoromethyl)-4-(3-hydroxypropyI)-4//-l,2,4-triazole (108) To a 
solution of 3,5-bis(trifluoromethyl)-4-[3 -(phenylmethoxy)propyl]-4//-1,2,4- 
triazole (107) (0.20 g, 0.57 mmol) in ethanol (2 ml) was added a slurry of 10% 
palladium on activated carbon (0.03 g) and ethanol (0.5 ml). The suspension 
was evacuated and charged with hydrogen (x3) before being stirred in a 
hydrogen atmosphere. After 24 h perchloric acid (60% in water, 0.01 ml) was 
added and the mixture was stirred for a further 5 h in the presence of 
hydrogen. The flask was evacuated, and the suspension was filtered through a 
pad of Celite®, which was thoroughly washed with ethanol (15 ml). NaHCC>3 
(1 g) was added to the filtrate and the suspension was stirred for 1 h, filtered 
and the solvent evaporated to yield 0.14 g (94%) of 3,5-bis(trifluoromethyl)-4- 
(3-hydroxypropyl)-4//-l,2,4-triazole (108). Data: white crystals, mp <25°C; 
'H NMR (400 MHz, D20 ) 2 14 (2H, m, CH^HjCHj), 3.74 (2H, 7.9 Hz,
CHzCTfcOH), 4 48 (2H, t, J  = 5 8 Hz, RjNCTfcCHj); l9F NMR (376 MHz, 
D20 ) -63 49 (s); MS (El) 264 (M" + H, 1), MS (Cl, iso-butane) 264 0720 (M' 
+ H, 100) (C7H8F6N30  requires 264,0720), 206 (5),
Trifluoroacetylhydrazine (109). Anhydrous hydrazine (3.09 ml, 98.5 mmol) 
was added dropwise to a solution of ethyl trifluoroacetate (10.0 g, 70.4 mmol) 
in ethanol (80 ml) at -10°C over a 45 min period The reaction mixture was 
allowed to warm to ambient temperature and stirred for 16 h. The solvent and 
excess reagent were removed by evaporation to yield 9.02 g (100%) of 








Z-1,2,4-Tris(benzamido)but-1 -ene (113), Z-1,2,4-Tris(benzamido)but-1 -ene 
(113) was synthesised by Bamberger fragmentation as generally described by 
Windaus's group166. To a solution of imidazole-4-ethanamine hydrochloride 
(1.00 g, 5.40 mmol) in water (20 ml) at 0°C was added sodium hydroxide 
(1.08 g, 27.0 mmol) and benzyl chloride (1.94 ml, 16.7 mmol) in alternating 
portions, followed by water (15 ml). The temperature of the reaction mixture 
was maintained at 0°C and stirred for 3 h. After standing for 16 h, the 
suspension was filtered and the solid was washed with cold water to yield
6.52 g (73%) of Z-l,2,4-tris(benzamido)but-l-ene (113). Data: white solid; mp 
189°C (literature166 mp 191°C), XH NMR (270 MHz, (CD3)2SO) 2.70 (2H, t, J  
= 6 6 Hz, C=C-CH2), 3 42 (2H, m, CH2N), 6.60 (1H, d, J =  9.2 Hz, C=CH), 
7 4 - 8 0 (15H, m, 3 x NHCOPh), 8.47 (1H, t, J  = 5 4 Hz, CH2NHCOPh), 






(115). Z-l,2,4-Tris(benzamido)but-l-ene (113) (0.39 g, 0.91 mmol) was boiled 
under reflux with trifluoroacetic anhydride (4 ml) for 16 h. The excess reagent 
was evaporated and the residue was boiled under reflux in methanol (5 ml) for 
1 h. The solid was collected by filtration from the cooled mixture to give 0.08
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g (18%) of Z-4-(l,3-bis(benzamido)prop-l-enyl)-2-phenyl-5-trifluoromethyl- 
oxazole (115). Data: white solid, mp 216-217°C, NMR (400 MHz, 
(CD3)2SO) 4.19 (2H, br t, J  = 5.0 Hz, CH2), 6.29 (1H, br t, J  = 5.0 Hz, 
C=CH), 7.58-7.68 (9H, m, 3 x Ar 3,4,5-H3), 7 99 (2H, d, J=  6.7 Hz, 2,6-H2 
of oxazole-2-Ph), 8.15 (4H, m, 2 x benzamide 2,6-HO, 9.08 (1H, br t, 
NHCH2), 10.50 (1H, s, NH); 13C NMR (100 MHz, (CD3)2SO) 36.59, 119.07 
(q, Jc-F = 268 Hz, CF3), 124.87, 126.00, 126.48, 126.53, 129.90, 127.17, 
127.94, 128.11, 128.98, 130.96, 131.38, 131.73, 132.53 (q, J C- f  = 44 Hz, C- 
CF3), 133.43, 133.83, 140.54, 160.38, 164.96, 166.62, 19F NMR (376 MHz, 
(CD3)2SO) -58 89 (s); MS (Cl) 492.1535 (M+ + H, 55) (C27H21F3N30 3 requires 
492.1535).
(122)
l-Bromo-3,3,3-trif1uoropropan-2-one oxime (122). l-Bromo-3,3,3-
trifluoropropan-2-one oxime (122) was synthesised essentially by the method 
described by ReiBig's group176. To a solution of l-bromo-3,3,3- 
trifluoropropanone (10.0 g, 52.4 mmol) in acid-free chloroform (50 ml) was 
added hydroxylamine hydrochloride (5.46 g, 78.6 mmol) in water (10 ml). The 
mixture was boiled under reflux for 24 h. After cooling, the aqueous layer was 
extracted with chloroform (3 x 20 ml) and the combined organic extracts were 
dried (MgS04). The solvent was removed and the crude material was purified 
by distillation (Kugelrohr) to yield 6.45 g (60%) of l-bromo-3,3,3-trifluoro- 
propan-2-one oxime (122) as a 1 : 1 mixture of E  and Z geometrical isomers. 
Data: colourless liquid; bp20 80°C (literature176 bp8 5 80-90°C), !H NMR (400 
MHz, (CD3)2SO) 4.33 (1H, s, CH2), 4.42 (1H, s, CH2), 10 1 (1H, br, OH); 19F 





(124). l-Bromo-3,3,3-trifluoropropan-2-one oxime (122) (0.57 g, 2.75 mmol) 
was dissolved in anhydrous methyl ter/-butyl ether (110 ml) and sodium 
carbonate (1.75 g, 16.5 mmol) was added, followed immediately by 3,4- 
dihydro-2/7-pyran (5.02 g, 55.0 mmol). The suspension was stirred in a 
nitrogen atmosphere in the dark for 5 d. The suspension was filtered through a 
Celite® pad and the solvent of the filtrate was evaporated to give a yellow oil 
which was distilled (Kugelrohr) to yield 0.50 g (87%) of 4,4a,5,6,7,8a- 
hexahydro-3-(trifluoromethyl)pyrano[4,5-e]-1,2-oxazine (124). Data: 
colourless liquid; bp3 125°C (literature176 bp5 75°C); lH NMR (270 MHz, 
CDC13) 1.5-1.8 (4H, m, 5-H, 6-H), 2.21 (1H, m, 4a-H), 2.30 (1H, dd, J  = 
18.7, 4 4 Hz, 4-Heq), 2.52 (1H, dd, J=  18 9, 6 8 Hz, 4-H*), 3.75 (1H, ddd,7 =
1.3, 7.2, 11.5 Hz, 7-Hax), 3.95-4.05 (1H, m, 7-H*,), 5.22 (1H, d, J =  2.7 Hz, 




2-Iodoxybenzoic Acid (134) 2-Iodoxybenzoic acid (134) was synthesised by 
the method described by Dess and Martin . To a mixture of 2-iodosobenzoic 
acid (20.0 g, 73.5 mmol) and 0.73 M sulphuric acid solution (157 ml) was 
added potassium bromate (16.2 g, 97.3 mmol) over a 1 h period, during which 
the temperature was kept below 50°C. The mixture was warmed to 65°C and
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stirred for 4 h. The orange solution and white suspension of the reaction 
mixture were cooled to 0°C and filtered. The solid was washed with cold water 
(700 ml) and cold ethanol (30 ml) to yield 21.75 g (88%) of 2-iodoxybenzoic 
acid (134). Data: white solid
3,3,3-T riacetoxy-3-iodaisobenzofuran-1 -one (135). 3,3,3 -T riacetoxy-3 -
iodaisobenzofuran-l-one (135) was synthesised by the method described by 
Dess and Martin182. A stirred slurry of 2-iodoxybenzoic acid (134) (19.15 g, 
64.7 mmol) in acetic anhydride (56.9 ml, 603 mmol) and acetic acid (54 ml) 
was heated to 100°C for 40 min. After cooling to ambient temperature, most 
of the solvent was evaporated at 29°C / 1 mmHg (The Dess-Martin reagent 
has been reported to explode upon heating under confinement183). The white 
slurry was cooled and filtered in a nitrogen atmosphere and the solid was 
washed with cold ether (150 ml) to yield 17.48 g (61%) of 3,3,3-triacetoxy-3- 
iodaisobenzofuran-l-one (135) Data white solid; mp 121-122°C (literature182 
124-126°C).
OH
£-l,l,l-Trifluoro-6-(phenylmethoxy)hex-3-en-2-ol (136). A suspension of 
lithium aluminium hydride (2.50 g, 62.0 mmol) was prepared by the 
introduction of the solid in small portions to anhydrous THF (70 ml). The 
suspension was cooled to 0°C and 6-phenylmethoxy-1,1,1-trifluorohex-3-yn-2- 
one (89) (10.0 g, 39.0 mmol) was added dropwise as a solution in THF (20
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ml). After stirring for 30 min, the temperature of the reaction mixture was 
allowed to rise to ambient temperature before gentle boiling under reflux for 15 
h. The mixture was cooled to 0°C and water (3.27 ml), 5M sodium hydroxide 
solution (3 .27 ml) and water (9.81 ml) were added in succession with vigorous 
stirring. The suspension was allowed to warm to ambient temperature and 
stirred for 30 min. The precipitate was removed by filtration and the filtrate 
was extracted with ether (5 x 50 ml). The combined organic extracts were 
washed with saturated ammonium chloride solution (50 ml), water (50 ml) and 
brine (2 x 50 ml). The solvent was evaporated and DCM (150 ml) was added 
The solution was dried (MgS04) and the solvent was evaporated to yield 8.13 
g (80%) of £-l,l,l-trifluoro-6-(phenylmethoxy)hex-3-en-2-ol (136). Data: 
yellow liquid; lH NMR (270MHz, CDC13) 2.41 (2H, br q, J  = 6.4 Hz, 
CH2CH2CH=CH), 2 98 (1H, br s, OH), 3.55 (2H, t, J = 6 4 Hz, BnOC&CHz), 
5 52 (1H, m, CH=CHCH(OH)CF3), 4.51 (2H, s, PhC&O), 5 59 (1H, dd, J  = 
15.6, 6 8 Hz trans, CH=CHCH(OH)CF3), 5 98 (1H, dt, J=  15.6, 6.8 Hz trans, 
CH2CH=CHCH(OH)CF3), 7.33 (5H, m, Ph),19F NMR (376 MHz, CDC13) 




£ -l,l,l-T  rifluoro-6-(pheny Imethoxy )hexan-3-en-2-one (137). £-1,1,1-
Trifluoro-6-(phenylmethoxy)hex-3-en-2-ol (136) (2.00 g, 7.68 mmol) in 
anhydrous DCM (10 ml) was added dropwise to a stirred solution of 3,3,3- 
triacetoxy-3-iodaisobenzofuran-l-one (135) (12.5 g, 28.4 mmol) in DCM (150 
ml) over a period of 10 min. The reaction mixture was stirred at ambient 
temperature under a nitrogen atmosphere for 2.5 h. Ether (110 ml) and 1.3 M 
sodium hydroxide solution (220 ml) were added and the mixture stirred for 45 
min The layers were separated and the aqueous phase was extracted with
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ether (3 x 50 ml). The combined organic extracts were washed with saturated 
ammonium chloride solution (100 ml), water (100 ml) and brine (100 ml). The 
solvent was evaporated and the residue was dissolved in DCM (100 ml). The 
solution was dried (MgS04) and the solvent was evaporated to yield 1.47 g 
(74%) of £-l,l,l-trifluoro-6-(phenylmethoxy)hex-3-en-2-one (137). Data: 
yellow liquid; 'H NMR (400MHz, CDC13) 2.63 (2H, dq, J  = 6.1, 1.5 Hz, 
CH2CH2CH=CH), 3.64 (2H, t, J  = 6.1 Hz, BnOCHjCHa), 4.52 (2H, s, 
PhCHjO), 6.49 (1H, d, J  = 15.9 Hz trans, CH=CHCOCF3), 7.33 (6 H, m, 
PhCH2OCH2CH2CH2CH=CHCOCF3);19F NMR (376 MHz, CDCI3) -77.99 (s); 
IR (film) 1733 (s), 1632 (s); MS (Cl) 259.0946 (M* + H, 29) (C,3Hi4F30 2 
requires 259.0946), 91 (100).
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APPENDIX
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
5.31 -61.8479 -61.8448 -61.8479
6.01 -61.7987 -61.7987 -61.7987
6.48 -61.7034 -61.7127 -61.7096
6.95 -61.5498 -61.5590 -61.5590
7.18 -61.3808 -61.3962 -61.3870
7.42 -61.2118 -61.2118 -61.2026
7.78 -60.9107 -60.9107 -60.9107
7.91 -60.8032 -60.8032 -60.8032
841 -60.5543 -60.5574 -60.5604
9.12 -60.4283 -60.4283 -60.4314
9.87 -60.3976 -60.3976 -60.3945
10.29 -60.3822 -60.3822 -60.3792
Table 8 Data for 3,5-bis(trifluoromethyl)pyrazole (2).
212
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
8.37 -61.2702 -61.2702 -61.2733
9.10 -61.2733 -61.2733 -61.2733
10.05 -61.2549 -61.2579 -61.2579
10.78 -61.1565 -61.1565 -61.1596
11.24 -60.9630 -60.9660 -60.9660
11.92 -60.3239 -60.3362 -60.3454
12.32 -59.7739 -59.7800 -59.7862
12.79 -59.3468 -59.3468 -59.3529
13.06 -59.1778 -59.1747 -59.1809
13.43 -59.0610 -59.0580 -59.0610
Table 9. Data for 3-(trifluoromethyl)pyrazole-4-propanol (79).
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
8.56 -61.1135 -61.1135 -61.1135
9.54 -61.1166 -61.1166 -61.1135
10.11 -61.1043 -61.1074 -61.1043
10.64 -61.0060 -61.0060 -61.0090
10.91 -60.9199 -60.9199 -60.9199
11.56 -60.4498 -60.4468 -60.4529
12.17 -59.7493 -59.7616 -59.7647
12.77 -59.2085 -59.2147 -59.2116
13.02 -59.1041 -59.1010 -59.1010
13.26 -59.0242 -59.0242 -59.0211
Table 10 Data for 2-(3-trifluoromethylpyrazol-4-yl)ethanol (83).
213
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
7.95 -62.4992 -62.4962 -62.4962
8.78 -62.5023 -62.4992 -62.4992
9.59 -62.4747 -62.4777 -62.4747
10.04 -62.4839 -62.4777 -62.4747
10.55 -62.3886 -62.3856 -62.3856
11.03 -62.1582 -62.1582 -62.1582
11.50 -61.6666 -61.6696 -61.6666
12.02 -60.9660 -60.9660 -60.9691
12.76 -60.3638 -60.3638 -60.3669
13.05 -60.2716 -60.2716 -60.2716
13.35 -60.1733 -60.1733 -60.1702
Table 11. Data for 2-(5-trifluoromethylpyrazol-3-yl)ethanol (91).
214
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
5.45 -59.9676 -59.9676 -59.9676
6.04 -59.9461 -59.9430 -59.9430
6.96 -59.9830 -59.9830 -59.9860
7.92 -59.9246 -59.9246 -59.9246
9.07 -59.3807 -59.3838 -59.3869
9.49 -58.9536 -58.9506 -58.9567
10.24 -58.1609 -58.1671 -58.1609
10.72 -57.9766 -57.9735 -57.9735
11.08 -57.9366 -57.9366 -57.9397
11.54 -57.9213 -57.9213 -57.9213
12.26 -57.9151 -57.9120 -57.9090
13.12 -57.9274 -57.9243 -57.9274
Table 12. Data for 3-(pyridin-4-yl)-5-(trifluoromethyl)pyrazole
215
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
0.90 -65.1755 -65.1785 -65.1755
1.91 -65.1123 -65.1095 -65.1123
3.17 -64.9604 -64.9604 -64.9604
4.10 -64.9512 -64.9512 -64.9481
5.38 -64.8928 -64.8928 -64.8897
6.48 -64.7453 -64.7453 -64.7392
7.11 -64.5860 -64.5886 -64.5917
7.71 -64.4811 -64.4811 -64.4780
8.28 -64.3950 -64.3981 -64.3981
9.59 -64.3889 -64.3858 -64.3858
12.00 -64.4042 -64.3981 -64.4012
Table 13 Data for 2-(trifluoromethyl)imidazo[4,5-£]pyridine (95)
216
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
2.12 -65.2960 -65.2707 -65.2738
3.22 -65.2277 -65.2277 -65.2246
4.25 -65.1570 -65.1570 -65.1540
5.37 -65.1202 -65.1171 -65.1202
6.54 -65.0894 -65.0864 -65.0894
7.01 -65.1447 -65.1447 -65.1447
7.55 -65.0925 -65.0925 -65.0925
8.58 -64.7177 -64.7177 -64.7177
9.77 -64.3260 -64.3260 -64.3229
10.25 -64.2922 -64.2953 -64.2953
11.48 -64.2721 -64.2691 -64.2691
12.02 -64.2783 -64.2783 -64.2752
Table 14. Data for 2-(trifluoromethyl)imidazo[4,5-c]pyridine (96).
217
pH Chemical Shift (ppm)
Series 1 Series 2 Series 3
0.48 -63.9065 -63.9065 -63.9065
1.06 -63.8880 -63.8850 -63.8880
1.54 -63.8481 -63.8481 -63.8481
1.93 -63.7744 -63.7744 -63.7774
2.52 -63.6054 -63.6084 -63.6115
3.02 -63.0677 -63.0615 -63.0646
3.55 -62.9724 -62.9693 -62.9693
4.23 -62.9263 -62.9263 -62.9233
4.95 -62.9110 -62.9110 -62.9110
5.39 -62.9048 -62.9048 -62.9048
6.06 -62.9048 -62.9048 -62.9048
6.52 -62.9048 -62.9048 -62.9110
Table 15. Data for 3-(trifluoromethyl)pyridine.









Table 16 Data for 3,5-bis(trifluoromethyl)-4-(3-hydroxypropyl)-4//-l,2,4- 
triazole (107).
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